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I N T R O D U C T I O N
1.1 characterizing the genetic basis of human language
1.1.1 Human language and language disorders
Language is arguably the trait that most clearly distinguishes humans from
other species. While other species do communicate and some of them do so
using vocalizations, their communication systems are far simpler than human
language (Levinson & Holler, 2014). Human language goes beyond transmit-
ting simple and practical information about essential aspects of our lives, such
as food or imminent danger, it also enables us to share our thoughts, express
our feelings, and talk about even the most abstract matters we can imagine.
Language allows us to exchange an unlimited number of ideas using a finite set
of mental tools, thus it is not surprising that the mental processes underlying
this trait are complex (Graham et al. , 2015). Yet, language comes naturally to
us, and it is remarkable that, given the adequate environment, any normal child
becomes a proficient speaker in their native language without consciously mak-
ing any effort or needing formal tuition (Kuhl, 2004). Language is not only a
uniquely human trait, but it also appears to be universal to all human beings
(Fisher & Vernes, 2015). No human society that lacks complex language has yet
been discovered (Hammarström, 2016). Moreover, language has been crucial to
human cultural evolution, as it has enabled humans to cooperate and to share
knowledge that has been transmitted over many generations (Smith & Kirby,
2008).
Our linguistic environment clearly plays a role in developing and shaping
our language capacity, but there is also an innate component to these capabili-
ties, as evident from heritability studies in twins (Bishop et al. , 1995; Lewis &
Thompson, 1992). The first clues about the molecular basis of language came
from looking at the genetic make-up of individuals with speech and language
impairments. Individuals with speech and/or language impairment do not de-
velop adequate skills in this area even if they are raised in a language-rich en-
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vironment and receive appropriate input. Often in individuals with a general-
ized neurodevelopmental disorder, language is impaired as a secondary conse-
quence of other cognitive deficits, but in some other cases the only cognitive
aspect affected in that person is language itself, and those cases are defined as a
specific language disorder (Graham & Fisher, 2015). There are several different
kinds of developmental disorders that affect speech, language and/or reading
(Table 1.1), all of which usually manifest in early childhood and continue into
adulthood, affecting many aspects of life, such as educational achievement or
social and job opportunities. Because language deficits are often a core feature
of neuropsychiatric disorders such as autism-spectrum disorder (ASD) or in-
tellectual disability (ID) (Bishop, 2010; Pal, 2011), these neurodevelopmental
disorders are also useful conditions to investigate in order to disentangle the
genetic basis of speech and language.
1.1.2 The discovery of FOXP2-related language disorder
The fact that language-related disorders typically cluster in families provided
early indirect evidence that genetic factors may contribute to language (Neils &
Aram, 1986; Tomblin, 1989; Barry et al. , 2007; Lewis et al. , 2007). Moreover,
twin studies showed that monozygotic twins presented higher rates of concor-
dance for language traits and disorders than dizygotic twins (Lewis & Thomp-
son, 1992; Bishop et al. , 1995; Bishop & Hayiou-Thomas, 2008), highlighting
the genetic contribution to linguistic abilities. Towards the end of the 1990s,
with the rise of molecular genetic techniques, specific regions in the genome
were identified to be involved in the etiology of language impairment by linkage
studies (Fisher et al. , 2003), and followed up by targeted association studies of
the specific linked regions and mutation screens of candidate genes (Newbury
& Monaco, 2002).
A major breakthrough occurred in 2001, when geneticists identified the tran-
scription factor FOXP2 as the first gene implicated in a language disorder, thr-
ough investigation of a large multigenerational family (the KE family) with se-
vere communication problems (Lai et al. , 2001). Half of the members in the
KE family suffer from a rare form of speech and language impairment char-
acterized by difficulties in coordinating the orofacial movements required for
speech (childhood apraxia of speech, CAS; also known as developmental ver-
bal dyspraxia DVD). In addition to core deficits in orofacial motor control and
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Table 1.1: Disorders of speech, language and/or reading mentioned in this thesis
Disorder Definition
Childhood apraxia of
speech (CAS)
Deficits in planning and coordination of speech and sound
sequences necessary for fluid speech. Also known as devel-
opmental verbal dyspraxia (DVD)
Dysarthria Speech that may be abnormally slow, fast, weak or impre-
cise caused by affections to muscles and nerves that control
speech
Dyslexia A difficulty with reading and spelling that cannot be ex-
plained by other causes such as low IQ, physical impairment
or lack of opportunity to learn
Specific language im-
pairment (SLI)
Unexplained impairment in acquisition of spoken language,
affecting one or more of morphology, syntax, semantics and
pragmatics. Also known as developmental language disor-
der (DLD)
Expressive language
impairment
Type of SLI. Impaired ability to formulate ideas and mes-
sages using words and
Receptive language
impairment
Type of SLI. Impaired ability to understand messages en-
coded in words and sentences
Stuttering Involuntary repetitions, prolongations of syllables, and
pauses during speech
spoken language production, verbal fluency and language comprehension were
also impaired in the affected individuals (Vargha-Khadem et al. , 2005). The
pedigree of the KE family suggested a simple autosomal dominant inheritance;
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and linkage analysis identified a genomic region on chromosome 7 (7q31) that
segregated with the disorder in the family (Fisher et al. , 1998). It was an inde-
pendent clinical case with a similar phenotype to the KE family and a chromo-
somal translocation within the linked region that led researchers to the FOXP2
gene (Lai et al. , 2000). Sequencing of FOXP2 in the KE family revealed that
a missense mutation affecting this gene (p.R553H) was present in the affected
members of the family but not in the unaffected members, providing robust
evidence for the implication of a single gene in a speech and language disor-
der (Lai et al. , 2001). Follow-up studies on the function of this transcription
factor demonstrated that the p.R553H mutation severely disrupted the ability
of the FOXP2 protein to bind to DNA and regulate gene expression, as well as
affecting its subcellular localization (Vernes et al. , 2006). Since then, disrup-
tions affecting FOXP2 have been found in multiple additional cases of CAS (for
further details see section 1.2.3.) (MacDermot et al. , 2005; Turner et al. , 2013;
Laffin et al. , 2012; Shriberg et al. , 2006; Feuk et al. , 2006; Zeesman et al. ,
2006; Reuter et al. , 2016). This gene has thus become a fundamental starting
point to expand our knowledge on the genetic and biological basis of language
impairment, by studying its function and molecular networks in the context of
brain development. Note that throughout this dissertation symbols for genes
are italicized (e.g., FOXP2), whereas symbols for proteins are not italicized (e.g.,
FOXP2); human protein and gene symbols are written all in uppercase letters;
whereas when referring to murine orthologues only the first letter is uppercase
and the rest are all lowercase (e.g., Foxp2); and orthologues in other species are
written with the first and the last letters in uppercase and the rest in lowercase
(e.g., FoxP2).
1.1.3 The search for further language-related genes
The discovery of FOXP2 mutations causing a rare speech and language disorder
was an exceptional finding, as it is very rare to find a well-defined behavioural
phenotype with such a straightforward inheritance pattern. Identifying addi-
tional language-related genes remains challenging despite the technological ad-
vances that have emerged during the past decade. Language involves a highly
complex set of skills, with a complex underlying genetic architecture, which
is likely to be grounded in small contributions exerted by myriads of different
genes. That is probably the main reason why it has been difficult to pinpoint
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and disentangle the contributing genetic factors that shape this trait. Neverthe-
less, some notable progress has been made towards determining more of the
genetic risk factors underpinning language and language-related disorders.
Several linkage studies have been carried out aiming at identifying more chro-
mosomal regions co-inherited by individuals with a language disorder within
a particular family (Newbury & Monaco, 2010; Kang & Drayna, 2011; Reader
et al. , 2014; Graham & Fisher, 2015). However, none of these has yet led to the
discovery of another simple monogenic form of impairment, like CAS in the
KE family (Graham & Fisher, 2015). On the contrary, most of these studies have
found linkage of multiple genomic regions to the language impairment, suggest-
ing a heterogeneous genetic basis for these disorders. Follow-up genetic associa-
tion studies focused on the identified linkage intervals and provided a number
of candidate risk genes for different language impairments, all of which rep-
resented common variants with small effect sizes. Examples of this are CMIP1
and ATP2C2, single nucleotide polymorphisms (SNPs) in which were associ-
ated with specific language impairment (SLI) risk; or KIAA0319, DCDC2 and
MRPL19\C2ORF3, associated with dyslexia (Anthoni et al. , 2007; Francks et al.
, 2004; Meng et al. , 2005; Newbury et al. , 2009). DYX1C1 and ROBO1 are
other candidate susceptibility genes for dyslexia, which were also identified by
screening of mapped linkage regions (Hannula-Jouppi et al. , 2005; Taipale et al.
, 2003). Like dyslexia, stuttering is also a very well-defined condition and anal-
yses of a linkage region (12q) identified by studying various consanguineous
families led to the discovery of a coding variant in the gene GNPTAB that im-
perfectly co-segregated with stuttering in one family (Kang et al. , 2010). The
putative risk variant altered a conserved residue of the protein and was identi-
fied in a number of other cases, at a higher frequency than controls. Moreover,
follow-up investigations screening for variants of GNPTAB as well as for closely
related genes of the same pathway (GNPTG and NAGPA) in case-control stud-
ies identified several different rare coding variants in these genes that may be
associated with stuttering (Kang et al. , 2010).
In the last few years the first genome-wide association studies (GWAS) for
language-related disorders and language-related abilities in the general popu-
lation have been carried out (Graham & Fisher, 2015). So far, this methodology
has yielded only two genome-wide significant effects: one associated with so-
cial abilities near the SCN11A gene, and one associated with infant expressive
vocabulary near the ROBO2 gene (St Pourcain et al. , 2014a,b). The latter is
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particularly intriguing given the association of its close paralogue ROBO1 with
dyslexia and the well-established functions of ROBO proteins in brain devel-
opment (St Pourcain et al. , 2014a). However, in most language-related GWAS
studies, no variant has reached the threshold for genome-wide significance,
probably because these efforts have been relatively underpowered. Larger-scale
GWASs and meta-analyses are promising strategies to circumvent this issue and
they may be able to provide genome-wide significant hits in the future (Reader
et al. , 2014; Graham & Fisher, 2015).
The development of cheaper, more efficient and faster next generation se-
quencing (NGS) technologies has enabled large-scale whole-exome sequencing
(WES) and whole-genome sequencing (WGS), and consequently the genome-
wide study of mutations has in recent years been extended to single-base res-
olution (Stranneheim & Wedell, 2016). This has had a revolutionary impact
on the discovery of genes underlying developmental disorders, for which hun-
dreds of causal variants have been discovered by focusing on rare de novo vari-
ants in severe, sporadic cases (Stranneheim & Wedell, 2016). Given that sub-
jects with neurodevelopmental disorders typically present severe phenotypes
in which the reproductive fitness is greatly reduced, it was long hypothesized
that de novo variants might be particularly prevalent in this type of condition.
That is unlikely to be the case for language-related disorders, which do not
affect reproductive fitness as much as neurodevelopmental disorders such as
severe autism or ID (Graham & Fisher, 2015). Thus, language-related disorders
are more likely to be caused by inherited variants rather than by de novo vari-
ants. Nevertheless, a de novo frameshift mutation disrupting the FOXP2 gene
has been reported in a child with CAS (Turner et al. , 2013) and a de novo
copy-number variant (CNV) affecting ATP2C2, previously associated with SLI,
was reported in a case of language delay and expressive language impairment
(Smith et al. , 2015).
WES and WGS have not only been useful to uncover de novo variation, but
have also facilitated the identification of rare genetic variants in specific popu-
lations and families. An interesting example is the case of the Robinson Crusoe
island, which has a population isolate in which the incidence of SLI is notably
high. Initial linkage analyses had indicated that multiple genomic regions were
implicated in the etiology of SLI in this population, but it was the use of exome
sequencing to study five members of the population that pinpointed the puta-
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tive transcription factor NFXL1 as a novel candidate gene for involvement in
SLI risk (Villanueva et al. , 2015).
In a recent study, WES of 43 unrelated individuals affected by severe SLI
identified several potentially pathogenic inherited and de novo variants in sev-
eral different genes (Chen et al. , 2017). They found variants in genes already
implicated language-related disorders, such as ERC1, GRIN2A, ATP2C2, CNT-
NAP2 or ROBO1 (see sections below) but also some others are novel candidate
genes for language-related disorders, such as OXR1, SCN9A and KMT2D (Chen
et al. , 2017).
1.2 monogenic language-related disorders as a window into the
molecular networks underlying speech and language
1.2.1 Insights into complex phenotypes from monogenic disorders
Neurodevelopmental conditions such as language disorders typically have a
highly complex genetic etiology that makes the understanding of their biol-
ogy challenging. Rare monogenic cases may offer the best opportunities to fur-
ther our insights into the molecular mechanisms underlying these disorders.
In monogenic conditions the causality of any particular gene is of higher confi-
dence than in oligogenic or polygenic phenotypes. The large effect that a genetic
variant has on a monogenic disorder provides the possibility to efficiently in-
vestigate the biological and molecular impact that the variant might have using
cell and animal models. This greatly helps to clarify the potential causal connec-
tions between mutation of that particular gene and the condition, strengthening
(or not) the link between genotype and phenotype. By further investigating the
functions of the gene of interest and its molecular networks, researchers can
expand the knowledge of the biological foundations of complex neurodevelop-
mental disorders.
The disruption of FOXP2 in CAS cases is a paradigm of a monogenic lan-
guage disorder. As discussed in the following sections, the investigation of the
function and dysfunction of FOXP2 in cell and animal models has provided
ample insights into the biology underlying speech and language. To date, only
a few other cases of monogenic language disorders have been described or sug-
gested. For instance, the ERC1 gene was found to be the smallest region of over-
lap in probands with deletions in the 12p13.33 locus that suffered from CAS
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(Thevenon et al. , 2013). But the link between ERC1 and language is not as clear
as the one with FOXP2, as more genes are affected in the deletions and no func-
tional studies have been performed to see the impact of the loss of function of
ERC1 in model systems.
Conversely, in other neurodevelopmental conditions such as ASD or ID, which
can take advantage of much larger cohorts, advances in sequencing technolo-
gies such as NGS and WES have allowed the identification of hundreds of novel
candidate variants (Vorstman et al. , 2017; Hoischen et al. , 2014). ASD genetic
studies provide proof that the investigation of monogenic conditions can greatly
help narrowing the neurobiological pathways underlying heterogenic neurode-
velopmental disorders. Genes implicated in ASD converge on various biologi-
cal processes such as chromatin remodeling and transcriptional regulation, cell
growth and proliferation, and neuronal processes such as synaptic activity and
organization, dendritic morphology and axonogenesis (Vorstman et al. , 2017).
Neurodevelopmental disorders frequently co-occur with speech and language
difficulties, which suggests an overlapping etiology that probably includes shared
genetic influences (Graham & Fisher, 2015). Therefore, investigating monogenic
neurodevelopmental disorders in which language is severely impaired can also
be of great help to unmask genetic factors underlying language impairment.
Multiple language-related genes have been identified through studies involv-
ing individuals that suffered from additional cognitive deficits other than just
language impairment. Relevant examples include mutations in GRIN2A, which
have been linked to an epilepsy-aphasia disorder that includes speech apraxia
and dysarthria (Turner et al. , 2015); and de novo mutations in TBR1, a transcrip-
tion factor recurrently mutated in sporadic ASD cases that include language dif-
ficulties (Deriziotis et al. , 2014a). Initiatives like the Deciphering Developmen-
tal Disorders (DDD) study (https://decipher.sanger.ac.uk/ddd#overview)
or the SFARI database (https://gene.sfari.org) are valuable resources of ge-
netic variants found in neurodevelopmental disorders and autism, respectively.
As of September 2017, more than 1500 genes have been implicated in devel-
opmental disorders by the DDD study and 900 genes have been implicated in
ASD and are reported in the SFARI database. Although the confidence for these
associations is variable since the mere occurrence of a rare mutation in a gene
does not inevitably imply causality, a large number of them are supported by
multiple and/or strong sources of evidence. As mentioned above, functional
characterization of the putative risk variants can further support the role of the
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variant in the disorder as well as reveal novel insights of the basic biology the
gene that may be relevant for the phenotype. For instance, the pathogenic role
of TBR1 variants in ASD was strongly confirmed with functional studies show-
ing that patient mutations impaired core aspects of the biology of the encoded
protein such as its transcriptional activity (Deriziotis et al. , 2014a). Moreover,
these findings led researchers to investigate the physical interaction between
the TBR1 and FOXP2 proteins, and to consequently discover that pathogenic
mutations in both transcription factors disrupted the interaction. These find-
ings revealed a relevant molecular link underlying distinct neurodevelopmen-
tal disorders that include impaired language ability, hence providing another
piece in the intricate puzzle of genetics of language and brain development
(Deriziotis et al. , 2014a).
Investigating the biology of language-related genes can uncover the networks
in which they participate and can potentially feed back into the interpretation
of NGS and GWAS studies. For instance, a number of FOXP2-related genes are
also implicated in cases of neurodevelopmental disorders. As aforementioned,
TBR1 mutations lead to ASD with language delay (Deriziotis et al. , 2014a).
FOXP1 is the closest paralogue of FOXP2 and the encoded proteins form het-
erodimers to regulate gene expression; rare disruptions of FOXP1 result in a
syndromic form of ID that includes language impairment (Bacon & Rappold,
2012; Sollis et al. , 2016). Various FOXP2 downstream target genes have also
been connected to neurodevelopmental conditions such as ASD, schizophrenia
or epilepsy (Song et al. , 2008; Roll et al. , 2006; Lambert et al. , 2014; Peng et al.
, 2013; Mukamel et al. , 2011; Walker et al. , 2012; Roll et al. , 2010).
Transcription-related genes have emerged as key determinants of the biologi-
cal processes that lead to neurodevelopmental disorders (De Rubeis et al. , 2014).
Several transcription-related genes have been found in monogenic cases that
presented an impaired language together with other cognitive deficits. Due to
their roles in regulating the expression of large networks of genes, the neurode-
velopmental conditions caused by mutations in transcription factors are often
dosage sensitive. For instance, haploinsufficiency of the transcription factors
FOXP1, TBR1, TCF4, FOXG1, SOX5 or SATB2 all lead to neurodevelopmental
disorders that include language difficulties (Sollis et al. , 2016; Zarate & Fish,
2016; Lamb et al. , 2012; Peter et al. , 2014; Ma et al. , 2016; Nesbitt et al. , 2015;
Lennertz et al. , 2011; Deriziotis et al. , 2014a). The way language is affected in
each of these monogenic disorders is variable; probands carrying FOXP1 vari-
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ants mostly show an affected expressive language, SOX5 and TBR1 mutations
cause prominent language delays, and SATB2, FOXG1 and TCF4 mutation cases
have absent or limited speech development.
The following sections will (1) outline how the investigation of FOXP2 func-
tion has opened up many paths into the molecular and neural basis of speech
and language, and (2) introduce BCL11A, a transcription factor potentially rel-
evant in neurodevelopmental language-related disorder.
1.2.2 The FOXP family of proteins
The forkhead (FOX) family of proteins includes over 40 members characterized
by the presence of a forkhead box (FOX) domain, a highly conserved sequence
that mediates binding of these proteins to DNA. FOX proteins play important
roles during embryonic development in the regulation of genes important for or-
chestrating organogenesis (Hannenhalli & Kaestner, 2009; Jackson et al. , 2010;
Golson & Kaestner, 2016). The FOX family is organized into 19 subfamilies
based on phylogenetic hierarchy and sequence homology (Hannenhalli & Kaest-
ner, 2009; Jackson et al. , 2010). FOXP2 belongs to the FOXP subfamily, which
comprises FOXP1, FOXP2, FOXP3 and FOXP4, all of which generally act as
transcriptional repressors (Golson & Kaestner, 2016; Li et al. , 2004; Shu et al.
, 2001). FOXP1, FOXP2 and FOXP4 play overlapping yet distinct functions in
neurodevelopment and cooperative roles in mouse lung and esophagus devel-
opment (Bowers & Konopka, 2012b; Li et al. , 2004). The involvement of Foxp2
and Foxp4 in spinal cord development (Rousso et al. , 2012) has also been de-
scribed. In contrast, FOXP3 is structurally and evolutionary divergent, and its
function and expression is restricted to the immune system, where it regulates
T-cell lymphocyte development (Fontenot et al. , 2003).
FOXP1, FOXP2 and FOXP4 are expressed in the brain, the heart and the lung
(Shu et al. , 2001; Teufel et al. , 2003). They are all expressed in the cerebral cor-
tex and in the striatum. FOXP1 and FOXP2 are also found in the thalamus and
hypothalamus, and FOXP1 and FOXP4 overlap in the hippocampus. FOXP2 and
FOXP4 are also specifically expressed in the Purkinje cells in the cerebellum. In
the cerebral cortex, FOXP1 expression is confined to layers III-V; FOXP2, to lay-
ers V-VI; and FOXP4 is expressed through all the cortical layers (Takahashi et al.
, 2003, 2008; Ferland et al. , 2003).
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Figure 1.1: The FOXP family of proteins Schematic representation of the FOXP family
of proteins. Known domains are shown: the glutamine-rich region (Q-rich) is shaded in
black and white dashes; the polyglutamine tracts are shaded black; the zinc finger (ZF),
in light blue; the leucine zipper (LZ), in green; the forkhead domain (FOX), in dark blue;
and the nuclear localization signals (NLS), in pink. The number of amino acid residues
is indicated to the right of the schematic
The FOXP proteins share a conserved leucine zipper domain, a zinc finger
motif, a long glutamine-rich region (not present in FOXP3), and the FOX DNA-
binding domain, which is the most evolutionary conserved part of all FOXP
members (Li et al. , 2004; Wang et al. , 2003) (Figure 1.1). The FOX domain
includes two nuclear localization signals (NLS) (Mizutani et al. , 2007; Vernes
et al. , 2007). The FOXP proteins bind to the specific nucleotide sequence in the
DNA 5’-TRTTKRY through the FOX domain, but sequence variation among the
family members is thought to confer specificity to each protein in the recogni-
tion of different targets (Vernes et al. , 2007; Stroud et al. , 2006; Wang et al. ,
2003). The crystal structure of the FOX domain of FOXP2 bound to DNA fur-
ther revealed key residues in the recognition helix (helix 3) that mediate this
interaction (Stroud et al. , 2006).
The leucine zipper mediates the homo- and hetero-dimerization of the FOXP
proteins, which is a unique characteristic of this subfamily. This property is
needed for them to bind DNA and regulate gene expression (Li et al. , 2004).
A mutation in the leucine zipper of FOXP3 that disrupts its dimerization abil-
ity results in an X-linked autoimmunity and allergic dysregulation syndrome
(IPEX) (Chatila et al. , 2000). This mutation involves the deletion of a conserved
glutamic amino acid in the leucine zipper (Chae et al. , 2006). When this con-
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served residue was deleted in FOXP1, FOXP2 or FOXP4, it also impaired their
ability to homo- and hetero-dimerize (Li et al. , 2004). FOXP family hetero-
dimerization may offer another level of DNA site recognition, elegantly con-
trolled by the expression or availability of different FoxP partners.
All members of the FOXP subfamily also have a C2H2 zinc finger domain. In
some proteins this kind of domain is involved in binding DNA (Wolfe et al. ,
2003), but it may also mediate protein-RNA and protein-protein interactions.
The function of the zinc finger domain in FOXP proteins has not been deter-
mined yet. All FOXP proteins (except FOXP3) have a glutamine-rich region.
FOXP2 has two polyglutamine tracts (polyQ) of 40 and 10 glutamines, neither
of which are present in human FOXP1 or FOXP4 (Estruch et al. , 2016a). Rare
polymorphisms of the polyQ tract have been identified in FOXP2 in individuals
with neurodevelopmental disorders; for instance, an addition of 4 glutamines
was found in a case of CAS (MacDermot et al. , 2005). However, the causal
role of these variants in the disorder is unclear, as variations in the number of
glutamines in FOXP2 are also found in the general population (Exome Aggre-
gation Consortium (ExAC), Cambridge, MA (http://exac.broadinstitute.
org)). Unlike polyQs in triplet repeat diseases such as Huntington disease which
are encoded by long CAG repeats, FOXP2 polyQ tracts are encoded by a mixture
of CAAs and CAGs, which probably makes them more stable and less prone to
expansion (Butland et al. , 2007; Bruce & Margolis, 2002). One study suggested
a role in transcriptional repression for this region of the FOXP proteins, based
on the finding that mouse Foxp1 isoforms lacking the glutamine-rich region
showed stronger repression than the isoforms that have it (Wang et al. , 2003).
However, an effect of this kind was not observed in studies of FOXP2, which
found that the protein repressed transcription at similar levels, regardless of
presence or absence of the polyQ tract (Estruch et al. , 2016a).
1.2.3 FOXP2 mutations in childhood apraxia of speech
As introduced in section 1.1.2, heterozygous disruptions of the FOXP2 gene
cause a rare speech and language disorder, in which the most prominent fea-
ture is childhood apraxia of speech (CAS), which is a motor speech disorder
characterized by difficulties in coordinating and articulating the rapid orofacial
muscle movements necessary for fluent speech (Lai et al. , 2001). Together with
CAS, subjects with FOXP2 haploinsufficiency also present receptive and expres-
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sive language difficulties, IQ is usually (but not always) within the normal range
(Morgan et al. , 2016), and fine motor skills may be impaired but gross motor
skills are typically unaltered.
The first DNA sequence variant that was implicated in this speech and lan-
guage disorder was a missense mutation in one copy of the FOXP2 gene which
yields an arginine-to-histidine substitution (p.R553H) in the highly conserved
DNA-binding domain of the encoded transcription factor. The speech and mo-
tor deficits were accompanied by other expressive and receptive problems in
both oral and written language, as well as poor processing and production of
grammatical structures. Some of the affected KE family members also exhibited
lower IQ scores than unaffected members, but this did not entirely co-segregate
with the language disorder indicating that effects on non-verbal cognition were
unlikely to be central to the phenotype.
The underlying neuropathology of the disorder was studied using structural
magnetic resonance imaging (MRI) and functional MRI (fMRI) techniques. To-
gether, these approaches revealed that the affected KE family members pre-
sented bilateral structural and functional abnormalities in several motor-related
regions of the brain (Vargha-Khadem et al. , 1998; Watkins et al. , 2002; Liégeois
et al. , 2003, 2011). Affected KE family members exhibited significant bilateral
reductions in grey matter density in the caudate nucleus of the basal ganglia,
the ventral cerebellum and the inferior frontal gyrus of the cortex, which con-
tains Broca’s area. Conversely, the putamen of the basal ganglia and several
other cortical regions including the Wernicke’s area presented increased levels
of grey matter. Interestingly, the caudate nucleus was smaller in individuals
with CAS and its volume correlated significantly with the performance on a
test of oral praxis (Vargha-Khadem et al. , 1998; Watkins et al. , 2002; Belton
et al. , 2003). Consistent with the morphological findings, fMRI during the per-
formance of semantic language tasks revealed an under-activation of Broca’s
area and the putamen in the affected family KE members (Liégeois et al. , 2003,
2011). All these data indicate that the frontostriatal and frontocerebellar net-
works involved in learning, planning and execution of speech motor sequences
could be key circuits affected in impaired KE family members and FOXP2 might
play an important role in the development of such circuits.
Since the discoveries of the mutation in the KE family and the translocation
affecting FOXP2 in a child with CAS, several etiological inherited and de novo
FOXP2 variants in CAS have been identified, although overall disruption of this
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gene remains a rare cause of language disorder. Various large 7q31 deletions
that span FOXP2 have also been reported in individuals with CAS (Feuk et al. ,
2006; Lennon et al. , 2007; Palka et al. , 2012; Rice et al. , 2012; Zeesman et al. ,
2006; Zilina et al. , 2012). The deletions encompassed several genes other than
FOXP2, such that the phenotype of some these individuals is broader and more
severe than that of the KE family, but it is likely that disruption of FOXP2 is the
cause of the speech and language problems of these individuals. Chromosomal
rearrangements directly disrupting the FOXP2 gene in subjects with CAS fur-
ther support its involvement in the etiology of the disorder (Feuk et al. , 2006;
Lai et al. , 2000, 2001; Shriberg et al. , 2006; Tomblin et al. , 2009).
Most interestingly, several intragenic FOXP2 mutations affecting the amino-
acid sequence of the encoded protein have been reported in cases of speech-
related disorders (Figure 1.2). Based on the inheritance patterns, some of the
variants are clearly pathogenic, such as the variant of the KE family, p.R553H
(Lai et al. , 2001). Other likely pathogenic variants include the nonsense vari-
ants p.R328*, identified in two independent families with CAS, and p.R478*,
found de novo in one proband with delayed speech development and also to
co-segregate in another family with speech delay (MacDermot et al. , 2005;
Reuter et al. , 2016). Mutations that are predicted to truncate FOXP2 protein,
such as nonsense and frameshift variants, are usually etiological since they usu-
ally lead to a complete loss of protein function. Examples of this are FOXP2
variants p.R328* and p.R478* or de novo variants identified in a proband with
CAS (p.Q390Vfs*7) and in individuals with mild ASD and speech impairment
(p.R564* and p.F538Vfs*28) (Turner et al. , 2013; Reuter et al. , 2016). Of note,
inherited and de novo intragenic mutations in FOXP2, which include some of
the above described (p.R478* and p.F538Vfs*28), have been recently identified
in 14 individuals from eight unrelated families. The subjects present variable
degrees and types of speech and language impairment and most of them also
exhibited mild cognitive deficits, broadening the phenotypical and clinical spec-
trum associated with FOXP2 disruptions (Reuter et al. , 2016).
Several reported missense variants of FOXP2 are of uncertain significance,
since they either do not fully segregate with the typical disease phenotype in
the respective families in which they were reported or their inheritance pattern
is unknown (Graham & Fisher, 2015). For example, variant p.Q17L was identi-
fied in a subject with CAS but not in his affected sibling, and variant p.M406T
was carried by a proband that suffered from epilepsy-aphasia spectrum disorder
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Figure 1.2: FOXP2 causal variants Schematic representation of FOXP2 variants proba-
bly pathogenic identified in cases of speech impairment. Known domains are shown: the
glutamine-rich region (Q-rich) is shaded in black and white dashes; the polyglutamine
tracts are shaded black; the zinc finger (ZF), in light blue; the leucine zipper (LZ), in
green; the forkhead domain (FOX), in dark blue; and the nuclear localization signals
(NLS), in pink. Variants that have been functionally characterized in cell models are in
red.
but also by his unaffected siblings and father (MacDermot et al. , 2005; Roll et al.
, 2010). Variant p.N597H was identified in a proband with CAS but the parental
genotypes were not determined (Laffin et al. , 2012) and variant p.R536P, found
in a child with severe speech delay and autistic traits, was inherited from his
unaffected father, who probably presented mosaicism for this variant, but the
affected brother was not sequenced (Reuter et al. , 2016). In the cases where the
information on the pedigree is incomplete or where the variant does not clearly
co-segregate with the phenotype it is essential to determine with experimen-
tal methods whether the variant has an impact on protein function in order to
clarify putative causality. Bioinformatics algorithms, which are based on known
information on protein sequence and evolutionary history, can predict whether
an amino acid change may be damaging, but often provide false positives or
negatives. Functional characterization assays have proven to be fundamental in
determining the causality of FOXP2 variants in the disorder (Vernes et al. , 2006;
Estruch et al. , 2016a). These have been done extensively for the mutation of
the KE family p.R553H, which causes abnormal subcellular localization of the
FOXP2 protein and, most notably, impairs its ability to bind DNA and regulate
gene expression (Vernes et al. , 2006; Estruch et al. , 2016a). Similarly, p.R328*
and p.Q390Vfs*7 mutations impair subcellular localization and transcriptional
activity of FOXP2, which is expected since these mutations result in a truncated
form of the protein that lacks the DNA-binding domain as well as the NLSs
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(Vernes et al. , 2006; Estruch et al. , 2016a). In both cases, the functional assays
provided further support for the pathogenic role of the variants in the etiology
of CAS. Conversely, the FOXP2 missense variants p.Q17L and p.M406T, which
did not co-segregate with disorder in the respective families but were predicted
to be damaging variants, displayed normal nuclear localization and DNA bind-
ing, which suggests that they are incidental to the phenotype (Estruch et al. ,
2016a). Similarly, FOXP2 variant p.N597H, for which the genotype of the par-
ents of the affected proband was unknown, did not exhibit any altered protein
function in cellular assays (Estruch et al. , 2016a). These are examples that show
how functional characterization studies are critical to ascertain the significance
of FOXP2 variants for speech and language disorder.
1.2.4 FOXP1 variants in neurodevelopmental disorders
FOXP1 is the closest paraloguous protein to FOXP2, sharing 68% amino acid
identity. The expression of FOXP1 significantly overlaps with FOXP2 in several
brain structures (Teramitsu et al. , 2004; Ferland et al. , 2003). Moreover, the
two proteins are known to functionally interact by forming hetero-dimers to
cooperatively regulate shared downstream target genes (Li et al. , 2004; Shu et al.
, 2001). The close relationship of FOXP1 with FOXP2 suggested that mutations
affecting FOXP1 might also be related to speech and language disorders.
The first evidence implicating FOXP1 in speech and language impairment
came from patients that presented large deletions of chromosome 3p, which
spanned this gene, as well as other genes (Petek et al. , 2003; Pariani et al. ,
2009). Although the phenotypes were understandably varied probably due to
involvement of multiple genes, most of the subjects presented language difficul-
ties. Subsequent studies of individuals with ID reported missense and truncat-
ing variants or smaller deletions encompassing FOXP1, demonstrating that the
disruption of a single copy of the gene was sufficient to cause a neurodevelop-
mental disorder characterized by global developmental delay and ID together
with moderate to severe speech impairment (Hamdan et al. , 2010; O’Roak et al.
, 2011; Srivastava et al. , 2014; Lozano et al. , 2015; Sollis et al. , 2016; Carr et al.
, 2010; Le Fevre et al. , 2013; Siper et al. , 2017; Meerschaut et al. , 2017). Autis-
tic behaviours frequently accompany the FOXP1-related disorder (Siper et al.
, 2017; Meerschaut et al. , 2017). Recent large-scale exome sequencing efforts
have identified FOXP1 as a gene with recurrent de novo mutations associated
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with ASD (Iossifov et al. , 2014). Also, distinctive facial features such as a high
broad forehead and a short nose are associated with FOXP1 mutations (Siper
et al. , 2017; Meerschaut et al. , 2017). The language impairment seen in pa-
tients with FOXP1 mutations consistently affects expressive skills more severely
than receptive skills. Although articulation problems were reported for a large
number of cases, formal diagnoses of CAS have not been described (Bacon &
Rappold, 2012). Moreover, no causative FOXP1 mutations were identified in an
early study that screened a cohort of 49 patients with CAS, which is perhaps
not surprising given that it is now known that the phenotype resulting from
haploinsufficiency of this gene is typically more severe than that due to FOXP2
mutations (Vernes et al. , 2009).
Notably, all of the causative FOXP1 mutations reported to date in which the
inheritance could be determined have occurred de novo, consistent with the fact
that this type of mutation represents the major genetic cause of severe forms of
sporadic neurodevelopmental disorders, such as ID, epilepsy and autism (Siper
et al. , 2017; Veltman & Brunner, 2012). The disrupting effect of missense and
truncating variants on FOXP1 protein function was demonstrated in cell mod-
els, which showed that etiological mutations disrupt nuclear subcellular local-
ization and transcriptional repression activity (Sollis et al. , 2016). Interestingly,
whilst most of the assessed variants showed impaired dimerization with FOXP1
or FOXP2, some others retained the interaction, suggesting the possibility of a
dominant-negative effect, for example by preventing wild-type FOXP protein
from binding to DNA and regulating gene expression (Sollis et al. , 2016).
Given that the phenotype caused by FOXP1 mutations is more severe than
that due to FOXP2 mutations, it may be that the former gene has broader effects
on neurodevelopment than the latter. All patients carrying heterozygous FOXP1
mutations present with problems in the language domain, but it is not known
to what extent these language deficits share molecular pathophysiology with
FOXP2-related language disorder. It is interesting to speculate that the speech
and language deficits in some of the reported FOXP1 mutation cases could be
exacerbated through a potential dominant-negative effect on wild-type FOXP2
protein (Bacon & Rappold, 2012; Sollis et al. , 2016).
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1.2.5 Functions of FOXP2 in the developing and adult brain
The discovery of FOXP2 mutations in speech and language disorder put this
transcription factor in the spotlight and promoted many investigations to ex-
plore its functions in the brain. FOXP2 is expressed in several brain areas, in-
cluding the basal ganglia, the deep cortical layers, the thalamus and the cere-
bellum (Lai et al. , 2003), sites in which structural and functional abnormalities
have been reported in the KE family (Vargha-Khadem et al. , 1998; Watkins et al.
, 2002; Liégeois et al. , 2003, 2011), as described in section 1.2.3. The involve-
ment of these FOXP2-expressing regions in neural processes such as learning,
planning and executing movement sequences suggests a role for this gene in
the circuitry underlying speech and language.
Animal models, including knockouts as well as cell lines carrying etiological
variants, have been essential to further the knowledge on FOXP2 functions in
the developing brain. Human FOXP2 and mouse Foxp2 are expressed in the
same brain regions, including the cerebral cortex, the striatum and the cerebel-
lum (French & Fisher, 2014). Homozygous disruption of murine Foxp2 results
in mice with smaller cerebellums that die 3 to 4 weeks after birth (French &
Fisher, 2014). Heterozygous knockouts of Foxp2 in mice have also been stud-
ied to model the haploinsufficiency of humans with FOXP2-related CAS. Some
studies report that Foxp2 haploinsufficiency leads to striatal and cerebellar
structural defects together with motor impairments (Shu et al. , 2005). Like ho-
mozygous knockouts, mice carrying two copies of Foxp2 p.R552H, the mouse
variant analogous to the mutation found in the KE family, die soon after birth
and have a cerebellum of reduced size with decreased foliation (Groszer et al. ,
2008). Foxp2 p.R552H heterozygote mice (matching the heterozygous status
observed in humans with CAS) are viable and healthy. Despite exhibiting a
normal baseline motor performance, experiments using a voluntary running-
wheel system and accelerating rotarods showed that these heterozygous mice
have impaired motor-skill learning (Groszer et al. , 2008). For example, Foxp2
p.R552H heterozygotes had significant delays in learning the necessary motor
skills to use the wheel (Groszer et al. , 2008). This is in line with the problems
in fine motor control observed in some subjects with FOXP2 disruptions; such
underlying difficulties might be particularly apparent for learning the motor
sequences that are crucial for speech articulation (Alcock et al. , 2000; Palka
et al. , 2012; Turner et al. , 2013). Furthermore, electrophysiology experiments
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revealed abnormal synaptic plasticity for Foxp2 p.R552H heterozygous mice in
the striatum and cerebellum, brain regions implicated in motor learning and
control (Groszer et al. , 2008).
FOXP2 is among the most conserved genes in humans. Aside from variation
in polyQ tracts, the mouse and human proteins differ in only three amino acids
and show conserved expression patterns. Two of the relevant substitutions oc-
curred on the human lineage after splitting from chimpanzees. Researchers in-
serted these two human substitutions into the endogenous Foxp2 gene in mice,
creating a partially humanized version of the protein, and observed that stri-
atal, cortical and thalamic neurons had significantly longer dendrites and in-
creased synaptic plasticity (Enard et al. , 2009; Reimers-Kipping et al. , 2011).
Notably, mice carrying one copy of the Foxp2 p.R552H mutation showed the
opposite effects (Groszer et al. , 2008; Enard et al. , 2009). All together, this
points towards an important role for Foxp2 in cortico-striatal circuits that reg-
ulate motor-skill learning and function, and also suggests that this particular
function might have been important for the evolution of speech and language
in humans (Enard et al. , 2009; Reimers-Kipping et al. , 2011). Further investiga-
tions indicated that Foxp2 controls the development of cortico-striatal circuits
through directly repressing the expression of Mef2c, which is a regulator of
cortico-striatal synapse formation and striatal spinogenesis (Chen et al. , 2016b).
Independent investigations of downstream target genes of FOXP2 both in cul-
tured neurons and human fetal brain further highlighted its role in regulating
multiple aspects of neural plasticity. FOXP2 directly regulates genes involved in
synaptic plasticity, neurite outgrowth and axon guidance (Spiteri et al. , 2007;
Vernes et al. , 2007). Follow-up functional experiments demonstrated that in
the developing brain the KE mutation significantly impaired normal neurite
outgrowth and branching of medium spiny neurons, a type of neuron that
represent 85% of all striatal neurons (Vernes et al. , 2011). Gain- and loss-of-
function experiments indicated that FOXP2 promotes neuronal differentiation
in neuronal-like cell lines and medium spiny neurons (Devanna et al. , 2014;
Chiu et al. , 2014). Interestingly, this effect seems to be mediated by interaction
of FOXP2 with retinoic acid signaling pathways, some members of which are
regulated by FOXP2 (Devanna et al. , 2014).
Animal models have also been used to investigate the role of this transcrip-
tion factor in the production of vocalizations. Wild-type mouse pups generate
ultrasonic vocalizations when separated from their mother, known as isolation
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calls. These vocalizations are absent in Foxp2 complete knockouts and reduced
in the heterozygote knockouts (Shu et al. , 2005). However, pups carrying Foxp2
p.R552H heterozygotes produce similar numbers of isolation calls to wild-type
littermates (Groszer et al. , 2008). Ultrasonic vocalizations of mouse pups are
entirely innate and cannot be considered a proxy to human speech or language.
Conversely, the vocalizations of zebra finches have to be learned from an adult
tutor. Juvenile male zebra finches learn complex vocalizations by imitation,
which makes this animal a valuable model to study roles of FoxP2 in vocal
learning. Additionally, the neural circuits that underlie vocal motor learning in
songbirds show interesting parallels to the ones in humans (Fisher & Scharff,
2009). In zebra finches, FoxP2 is expressed in a striatal brain structure of the
song system called Area X (Teramitsu et al. , 2004). Interestingly, the expression
of FoxP2 in Area X is increased during the period of song learning. Moreover,
viral knockdown of FoxP2 in this structure results in an incomplete and inac-
curate vocal imitation, which alters the ability of juvenile birds to learn songs
from other individuals (Murugan et al. , 2013; Haesler et al. , 2007). Follow-up
studies found that knocking down FoxP2 affected the signaling between area X
and the connected cortical structures, in part through a decrease of dopamine
levels in these circuits (Murugan et al. , 2013). Together with the fact that overex-
pression of FoxP2 in this area also results in inaccurate song imitation (Haesler
et al. , 2007), these studies indicate that a tightly regulated FoxP2 dosage is key
for normal vocal learning in zebra finches.
1.2.6 Functions of FOXP1 in the developing brain
It has been known for many years that FoxP1 is expressed in the developing
brain (Shu et al. , 2001; Ferland et al. , 2003) but its specific roles there were not
explored until several independent studies consistently implicated this gene
in neurodevelopmental disorder (Hamdan et al. , 2010; O’Roak et al. , 2011;
Srivastava et al. , 2014; Lozano et al. , 2015; Sollis et al. , 2016; Carr et al. , 2010;
Le Fevre et al. , 2013).
FOXP1 is widely expressed in human and murine tissues and is involved in
the development of multiple organs, such as brain, heart, lung, esophagus and
the immune system (Shu et al. , 2001; Shi et al. , 2004; Wang et al. , 2004; Shu
et al. , 2007; Hu et al. , 2006). Within the central nervous system, key sites of ex-
pression include the cerebral cortex, striatum, the hippocampus and the spinal
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cord (Shu et al. , 2001; Morikawa et al. , 2009; Ferland et al. , 2003; Teramitsu
et al. , 2004). During development, it regulates cortical migration, midbrain
dopamine neuron differentiation and also plays a role in the development of
the striatum (Palmesino et al. , 2010; Konstantoulas et al. , 2010; Araujo et al. ,
2015; Bacon et al. , 2015; Precious et al. , 2016).
Foxp1 knockout mice die at embryonic day 14.5 (E14.5) due to cardiac de-
fects, which indicates that this gene is also important for non-neural develop-
mental processes (Wang et al. , 2004; Shu et al. , 2007). Mice with conditional
brain-specific loss of Foxp1 show altered hippocampal electrophysiology and
striatal morphology (Bacon et al. , 2015). These animals also exhibited memory
deficits, repetitive behaviours as well as reduced social interests (Bacon et al. ,
2015). It has also been shown that Foxp1 knockdown specifically in the mouse
cerebral cortex leads to an abnormal neuronal migration (Li et al. , 2015b).
Like Foxp2, FoxP1 is also involved in the development and function of stri-
atal medium spiny neurons. Reduction of Foxp1 levels results in abnormalities
in the excitability and differentiation of medium spiny neurons (Araujo et al.
, 2015). Also, it has been suggested that Foxp1 regulates pathways involved
in striatal development and function both in mice and human neuronal cell
models (Araujo et al. , 2015). The implication of this gene in striatal and cor-
tical development indicates that, similarly to Foxp2, it may also be important
for cortico-striatal circuits that underlie motor function. Furthermore, Foxp1 is
also expressed in the motor neuronal region of the spinal cord (Tamura et al. ,
2003; Shu et al. , 2001), where it plays a critical role regulating the formation
and connection of motor neurons to target muscles by acting as a downstream
effector of Hox gene pathways (Rousso et al. , 2012; Arber, 2008; Dasen et al.
, 2008). So far, findings from mouse models are in line with the phenotypes
observed in patients with FOXP1 mutations and therefore shed light on the
molecular mechanisms that may be involved in the etiology of related neurode-
velopmental disorders.
1.2.7 FOXP4
FOXP4 is the least studied of the FOXP subfamily members. FOXP4 expression
has been reported in several tissues including brain, lung, heart, spleen, liver,
testes and kidney (Teufel et al. , 2003; Lu et al. , 2002). While heterozygous
Foxp4 knockout mice do not exhibit any obvious defects, homozygous knock-
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outs die at E12.5 due to cardiac malformations, similarly to Foxp1 knockout
mice. Further examination of Foxp4 mutant mice revealed the development of
two complete hearts (Li et al. , 2004). A neural role for Foxp4 has been reported
in the mouse cerebellum (Tam et al. , 2011). FoxP4 is expressed in Purkinje cells
of the cerebellum from embryonic stages to adulthood. Knocking down the ex-
pression of Foxp4 at postnatal day 10 (P10), but not at P5, resulted in defects of
Purkinje cell dendritic arborization (Tam et al. , 2011).
The only FOXP4 disruption reported in humans is a homozygous frameshift
mutation found in a child with neurodevelopmental delay and malformations
of the larynx and the heart (Charng et al. , 2016). Given the known expres-
sion pattern and data from mouse knockouts, it is plausible that this phenotype
might be due to FOXP4 mutation; however further observations of disruptions
of the gene are necessary to confirm the existence of a FOXP4-related syndrome.
Although FOXP4 was the strongest candidate gene in this case, variants in two
other genes were also found in a homozygous state in the child and heterozy-
gous state in the parents (Charng et al. , 2016).
1.2.8 FOXP protein-protein interactions
The fine control that the FOXP proteins exert spatially and temporally in the
regulation of gene expression appears to be crucial for the development of the
language and motor circuitry. Transcription factors, such as the FOXPs, are pre-
cisely regulated via their associations with other proteins (Smith & Matthews,
2016). Identifying the proteins that interact with the FOXP proteins can shed
light on their functions in normal brain development, and also help to explain
the different phenotypes resulting from mutations affecting these proteins. More-
over, finding proteins that bind these transcription factors can provide new can-
didate genes that can be examined for variants in patient cohorts. Studies of the
key interactions can facilitate interpretation of the biological relevance of rare
variants identified by exome/genome sequencing and of associations found in
genome-wide association studies of language impairment. Understanding the
FOXP interactome will extend our knowledge of the roles of these transcription
factors in the brain and consequently, help further elucidate the genetic basis
of speech and language.
Two prominent experimental approaches that are typically used to screen
for protein-protein interactions are yeast two-hybrid screens (Y2H) and affinity
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purification followed by mass spectrometry-based proteomics (AP/MS). Both
these approaches have been used to try identifying putative FOXP interactors.
In the Y2H assay, the two proteins of interest are fused to the DNA binding do-
main (DBD) and the transcriptional activation domain (AD) of a transcription
factor, respectively. The protein fused to the DBD is known as the bait, and the
protein fused to the AD as the prey. Both fusion proteins are expressed together
in a genetically modified yeast strain in which the specific DNA binding site of
the DBD is upstream of a reporter gene. Upon interaction between the bait and
the prey, the DBD and AD are brought in close proximity and a functional tran-
scription factor is reconstituted, consequently activating the expression of the
reporter gene. This leads to a specific phenotype that can be selected usually
by growing the yeast in selective media for that phenotype. For instance, the re-
porter gene may be an essential amino acid (e.g. leucine) that will allow only the
yeast cells that express it to grow in plates lacking that specific amino acid. To
perform a genome-wide Y2H screen for interactors of a given bait, a library of
cDNAs fused to ADs is used as the prey. In an AP/MS screen, a protein usually
fused to an epitope-tag is either purified by affinity columns recognizing the tag
or immuno-precipitated using a specific antibody. This results in the purifica-
tion of multi-protein complexes containing the tagged protein. The complexes
are digested and the masses of the resulting peptides are subsequently analyzed
with MS to identify the different proteins that were present in the pulled-down
complex.
Screening techniques are highly sensitive but can be susceptible to false posi-
tives. In AP/MS, common false positives include molecules that are difficult to
remove with the washing steps, such as abundant proteins (e.g. actin, tubulin or
ribosomal proteins), proteins that bind unfolded peptides (heat-shock proteins)
and proteins that bind non-specifically to the affinity matrix. In Y2H, false pos-
itives may be of diverse origins. For instance, unfolded peptides can show non-
specific interactions, while proteins that activate the expression of the reporter
proteins or proteins that interfere with the selection method can also result in
false positive signals. Thus, to fully ensure the veracity of an interaction found
with these techniques, it is imperative to confirm the results obtained with a
different method.
Pull-downs are a standard commonly used strategy for validating interac-
tions, but it can be challenging to develop reliable and efficient assays, since
the conditions have to be optimized for each protein pair. Techniques such as
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Bioluminescence Resonance Energy Transfer (BRET) or Mammalian two-hybrid
(M2H) are advantageous alternatives because they are performed in living mam-
malian cells and can therefore better mimic real in vivo interactions. In con-
trast to pull-down strategies, BRET and M2H methods do not require cell lysis,
which can disrupt interactions, and additionally they offer a higher throughput.
However, techniques like these don’t have the power to detect all kinds of in-
teractions. A certain technique might be well suited for one type of interaction,
but not appropriate to detect a different one. It is very difficult to predict which
method will work best for detecting any particular interaction; therefore it is
ideal to assess and confirm protein interactions using several complementary
approaches.
A number of putative FOXP-interacting proteins have been identified in large-
scale high-throughput protein-protein interaction screening surveys (Coromi-
nas et al. , 2014; Sakai et al. , 2011; Li et al. , 2015a; Ravasi et al. , 2010). Most
of these have not yet been confirmed with an alternative method, but a small
number have been validated and further characterized (Figure 1.3). The FOXP
proteins homo and hetero-dimerize with each other through their leucine zip-
per. (Li et al. , 2004; Deriziotis et al. , 2014b; Estruch et al. , 2016a). As explained
above, the dimerization ability of these proteins is needed for them to bind
DNA and regulate transcription, and it may play a role in modulating their
DNA-binding specificity (Sin et al. , 2015; Li et al. , 2004).
The most well described FOXP interactors are the C-terminal binding pro-
teins (CTBP) 1 and 2, which function as co-repressors for several transcription
factors (Li et al. , 2004; Estruch et al. , 2016a). CTBP1 was identified in a Y2H
screen using a fragment of FOXP2 encompassing residues 269 to 500 as bait.
The interaction was validated with coIPs in HEK293 cells, which also showed
that CTBP1 was able to interact with FOXP1 and FOXP2 but not with FOXP4.
Accordingly, in luciferase assays CTBP1 enhanced the transcriptional repres-
sion activity of FOXP1 and FOXP2 but not FOXP4. A putative CTBP1 binding
site (PLNLV) is conserved in FOXP1 and FOXP2 (Li et al. , 2004). FOXP2 trun-
cations lacking the PLNLV site led to a loss of repression, however mutations
of the CTBP1 binding site in both FOXP1 and FOXP2 did not significantly alter
their ability to repress transcription. These findings suggest that CTBP1 may be
important but is not essential for transcriptional repression mediated by FOXP1
and FOXP2. Evidence of the interaction between CTBP2 and FOXP2 has come
from multiple independent Y2H screens (Sakai et al. , 2011; Rolland et al. , 2014;
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Corominas et al. , 2014). Recently, a study by our group confirmed FOXP2 in-
teraction with CTBP1 and CTBP2 using a BRET assay (Estruch et al. , 2016a).
In line with the previously reported findings for CTBP1, CTBP2 also interacted
with FOXP1 but not with FOXP4 (Estruch et al. , 2016a). However, two etiolog-
ical FOXP2 truncations that lack the putative CTBP binding site proposed by
Li and colleagues (Li et al. , 2004) partially retained the interaction with the
CTBPs, suggesting that the PLNLV motif in FOXP2 is not essential for the in-
teraction. Using a series of FOXP2 C-terminal truncations, the minimal CTBP
binding region was narrowed down to residues 259 to 329. This region includes
both of the amino acid substitutions that occurred in FOXP2 since the diver-
gence of the human and the chimpanzee lineages, but these substitutions did
not affect the CTBP interaction (Estruch et al. , 2016a).
Another co-factor that has been shown to interact with FOXP1, FOXP2 and
FOXP4 is GATAD2B, a component of the NuRD chromatin- remodeling com-
plex (Chokas et al. , 2010). This interaction was also identified using a Y2H
screen using a FOXP2 fragment containing residues 250 to 500 as bait, which
includes the leucine zipper and the zinc finger domains. The interaction was
validated for FOXP1, FOXP2 and FOXP4 using coIP assays. To assess whether
GATAD2B acted as a co-repressor of the FOXPs, a luciferase assay was carried
out in cultured lung cells using a construct containing the lung-specific PDPN
(also known as T1-alpha) promoter. Overexpression of GATAD2B with FOXP1
or FOXP4 significantly reduced the expression of the luciferase gene, suggesting
that GATAD2B cooperates with FOXP1 and FOXP4 to repress the PDPN pro-
moter. This effect was not observed for GATAD2B and FOXP2. Additional exper-
iments corroborated the ability of FOXP1 and GATAD2B to synergistically re-
press expression of the PDPN endogenous gene. Further interactions with other
components of the NuRD complex were shown for FOXP1 and FOXP4; MTA1
interacted with FOXP1 and HDAC1/2 interacted with FOXP1 and FOXP4. Strik-
ingly, by cooperatively regulating lung-specific gene expression, HDAC2 and
FOXP1 interaction was shown to play a role in the modulation of lung epithe-
lium immunological responses to injury (Chokas et al. , 2010). Interestingly,
GATAD2B mutations have been associated with ID (Willemsen et al. , 2013),
but the relevance of the FOXP-GATAD2B interaction in the brain has not been
studied.
FOXP1 also interacts with the co-repressor NCOR2 (Jepsen et al. , 2008). This
interaction was first hypothesized based on the fact that knockout mice of NCOR2
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Figure 1.3: FOXP interacting-proteins. Network diagram of FOXP protein-protein in-
teractions at least confirmed with two different experimental approaches. Lines indicate
protein-protein interactions. A pink border indicates that the genes encoding for these
proteins have been associated with neurodevelopmental disorders. Shaded in light blue
are the members of the NuRD complex.
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or FOXP1 exhibit similar cardiac malformation phenotypes. NCOR2-FOXP1 in-
teraction was detected by co-IP experiments performed in HEK293 cells overex-
pressing FOXP1 and NCOR2, and also in dissected mice hearts, which express
both proteins endogenously. Furthermore, it was demonstrated that FOXP1 and
NCOR2 cooperatively repress the expression of common target genes to pro-
mote cardiac growth and regulate macrophage differentiation (Jepsen et al. ,
2008).
An association between FOXP2 and POT1, a nuclear protein involved in telom-
ere maintenance and DNA repair mechanisms has also been reported (Tanabe
et al. , 2011). POT1 was identified in a Y2H screen using the C-terminal part
of FOXP2 (484-715) as bait. Further Y2H assays narrowed down the POT1-
interacting region in FOXP2 to residues 484-598, which include the FOX DNA-
binding domain. It was observed that POT1 localized in the cytoplasm when
transfected alone, but co-transfection with FOXP2 promoted its translocation
to the cell nucleus. The etiological variant FOXP2 p.R553H did not change the
subcellular localization of POT1. These findings contradict other studies that
report that POT1 protein is localized in the cell nucleus, specifically in the
telomeric foci (Calvete et al. , 2015; Ramsay et al. , 2013). Although this poten-
tial interaction is intriguing since it could reveal an additional non-canonical
function for FOXP2, further evidence will be needed to support these findings.
In addition to the co-repressors described above, a few transcription factors
have also been shown to interact with FOXP2. NKX2-1 is a transcription factor
with important roles in lung, brain and thyroid development (Kimura, 2003;
Sussel et al. , 1999). Nkx2-1 interaction with Foxp2 was identified in mouse
lung cell lines using a mammalian two-hybrid assay and confirmed with CoIP
experiments (Zhou et al. , 2008). In vitro GST pull-down assays revealed the
Nkx2-1 DNA-binding domain mediated the interaction with Foxp2, which sug-
gested that this interaction might prevent Nxk2-1 from binding to DNA. Sub-
sequently, this was confirmed by competitive EMSA assays, in which increasing
amounts of FOXP2 inhibited the formation of NKX2-1-DNA complexes in a
dose-dependent manner. In line with this finding, Foxp2 inhibited Nkx2-1 abil-
ity to regulate the transcription of the lung-specific gene SP-C. Taken together,
these data indicate that the interaction between Foxp2 and NKx2-1 acts to pre-
vent Nkx2-1 from binding DNA and regulating lung-specific target genes (Zhou
et al. , 2008).
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Another transcription factor known to interact with FOXP2 is NFATC2. This
was discovered in a study in which the FOXP2 forkhead domain was co-crys-
alized with NFATC2 to investigate the interaction between FOXP3 and NFATC2
(Wu et al. , 2006). Chemical crosslinking of the FOX domain of FOXP2 and
NFATC2 revealed that they only form stable complexes in the presence of a spe-
cific DNA sequence. NFATC2 is expressed in several organs including the brain
(Vihma et al. , 2016), hence it is possible that it interacts with the FOXPs in
neural sites of co-expression to regulate brain development. However, to date
the functional consequences of the interaction FOXP-NFATC2 have only been
studied for FOXP3 in the context of the immune system (Wu et al. , 2006).
A large-scale Y2H screen first suggested the neuron-specific transcription fac-
tor TBR1 as a putative interactor of FOXP2 (Sakai et al. , 2011). Interaction of
TBR1 with FOXP2 interaction was later confirmed using a BRET assay (Derizi-
otis et al. , 2014a). The interaction involves the FOXP2 region encompassing
amino acid residues 122-258, and the DNA-binding domain (T-box) of TBR1
(Deriziotis et al. , 2014a). Interestingly, de novo heterozygous mutations in TBR1
have been found in subjects that exhibit ASD together with language delay. Eti-
ological mutations in both FOXP2 and TBR1 disrupted the interaction between
these transcription factors (Deriziotis et al. , 2014a), pointing towards a role for
this interaction in the pathophysiology of the distinct yet overlapping neurode-
velopmental disorders caused by mutations in these different genes. Together
with the fact that the two encoded proteins are expressed in overlapping areas
of the brain, these findings suggest that the interaction FOXP2-TBR1 may be
important for brain development.
A large Y2H screen identified several interactors of murine FoxP1: Tle6, Tcf3,
Phf2, Per2, Per1, Smad4 (Ravasi et al. , 2010). These are all proteins involved in
transcriptional regulation, however the biological or physiological function of
these putative interactions remains to be explored.
Most of the known FOXP-interacting proteins are transcription-related pro-
teins such as members of the chromatin remodeling complex NuRD or the tran-
scription factors TBR1, NKX2-1, and NFATC2 (Chokas et al. , 2010; Zhou et al.
, 2008; Wu et al. , 2006; Deriziotis et al. , 2014a). But over their lifespan the
FOXPs also have to interact with other classes of proteins, such as chaperones
to be properly folded, or nuclear import proteins. Another class of proteins that
are likely to interact with the FOXPs are post-translational modification (PTM)
enzymes. PTMs tightly regulate many aspects of transcription factor function,
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such as protein stability, subcellular localization, transcriptional activity, DNA-
binding, and protein-interactions (Filtz et al. , 2014). Interestingly, large high-
throughput screens identified MAPK3 and PIAS3, phosphorylation and sumoy-
lation enzymes, respectively, as FOXP2 interacting-proteins (Corominas et al. ,
2014; Sakai et al. , 2011). However, at the start of this PhD project, these interac-
tions had not been confirmed and their functional roles had not been character-
ized. Thus, the post-translational mechanisms that may regulate FOXP function
remained elusive.
1.2.9 Transcriptional regulatory networks of FOXP1 and FOXP2
Mutations in FOXP1 and FOXP2 lead to monogenic rare language-related dis-
orders. However, the genetic factors underlying speech and language are multi-
ple and probably interconnected forming complex molecular networks of genes.
Therefore, exploring upstream and downstream molecular pathways that regu-
late and are regulated by these transcription factors, together with their protein-
protein interactions provides a sensible entry point to uncover the neuroge-
netic networks that may contribute to the formation of brain circuits that shape
speech and language. Figures 1.4 and 1.5 depict FOXP2 and FOXP1 known
molecular networks, respectively.
There have been multiple genome-wide studies of FOXP2 transcriptional tar-
gets, which have revealed a large number of potential candidate target genes
(Vernes et al. , 2007, 2011; Spiteri et al. , 2007; Nelson et al. , 2013). Many of the
genes regulated by FOXP2 belong to networks implicated in neuronal-specific
processes such as neurite outgrowth and synaptic plasticity (Vernes et al. , 2011;
Spiteri et al. , 2007), but for most transcriptional targets the physiological rele-
vance is unclear and only a subset have been further confirmed and character-
ized.
Perhaps the most well-established FOXP2 target gene reported to date is CNT-
NAP2, which encodes a transmembrane protein expressed in the brain that
mediates cell-cell interactions, with important roles in the regulation of the
strength and plasticity of synapses (Rodenas-Cuadrado et al. , 2014). Multiple
heterozygous mutations in CNTNAP2 have been reported in patients with a
range of complex phenotypes including ID, autism and schizophrenia, which
can include language difficulties (Poot, 2015; Rodenas-Cuadrado et al. , 2014).
However, numerous heterozygous genetic disruptions in CNTNAP2 are also
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Figure 1.4: FOXP2 molecular networks. Diagram depicting upstream FOXP2 regula-
tors (top part), FOXP2 protein interactors (middle part), and downstream FOXP2 target
genes and biological processes in which they are involved (bottom part). Genes in pink
or circled in pink have been associated with language-related or neurodevelopmental
disorders.
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found in the normal population and, therefore, it is not clear whether haploin-
sufficiency of this gene confers an increased risk for neurodevelopmental disor-
ders. In contrast, homozygous mutations of CNTNAP2 have been identified in
a few sporadic cases of neurodevelopmental disorders that present more severe
phenotypes such as cortical dysplasia, focal epilepsy, language regression and
severe cognitive impairment (Rodenas-Cuadrado et al. , 2016). Further molecu-
lar studies of CNTNAP2 gene function both in humans and mice have indicated
that it is involved in neural processes such as synaptic transmission, dendritic
arborization or neuronal migration, suggesting important roles in cortical de-
velopment (Anderson et al. , 2012; Peñagarikano et al. , 2011).
Other FOXP2 candidate target genes have also been linked to neurodevelop-
mental disorders, such as SRPX2, uPAR, MET and DISC1 (Mukamel et al. , 2011;
Roll et al. , 2010; Walker et al. , 2012). It would be interesting to further confirm
these as FOXP2 target genes and explore whether they may be relevant in the
etiology of FOXP2-related CAS cases. Most of the investigations of FOXP1 tar-
get genes have focused on non-neuronal tissues. FOXP1 directly regulates the
transcription of genes involved in B cell development, monocyte differentiation
and macrophage function (Shi et al. , 2004, 2008; Hu et al. , 2006; Jepsen et al. ,
2008). In lung tissue, FoxP1 and FoxP2 regulate PDPN as well as SCGB1A1 gene
expression (Shi et al. , 2004; Shu et al. , 2007). FoxP1 also functions as a tran-
scriptional repressor of Nkx2-5, a key regulator of cardiomyocyte proliferation
during cardiac development (Zhang et al. , 2010).
In the brain, FoxP1 regulates Pitx3, a transcription factor required for mid-
brain dopaminergic neuron differentiation and survival during development
(Konstantoulas et al. , 2010). Araujo and colleagues performed a broad charac-
terization of FOXP1 downstream target neuronal pathways by coupling RNA-
seq and ChIP-seq methodologies using both mice striatal tissue and human neu-
ronal progenitor cells. They found that FOXP1 target genes significantly over-
lapped with FOXP2-regulated genes in the striatum and, notably, that they were
enriched for ASD-related genes (Araujo et al. , 2015).
Investigations of factors that regulate FOXP2 and FOXP1 expression and func-
tion are scarce. In the zebra fish, FoxP2 expression is regulated by the transcrip-
tion factors pax6 (Coutinho et al. , 2011) and lef1, which is involved in the
Wnt signaling pathway (Bonkowsky et al. , 2008). Also, manipulation of the
Wnt signaling pathway in embryonic chicken retinas affected the expression
of FoxP2 (Trimarchi et al. , 2009). Another study showed that the neural tran-
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Figure 1.5: FOXP1 molecular networks. Diagram depicting upstream FOXP1 regulators
(top part), FOXP1 protein interactors (middle part), and information on downstream
FOXP1 target genes (bottom part). Genes in pink or circled in pink have been associated
with language-related or neurodevelopmental disorders.
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scription factor POU3F2 regulates FOXP2 in human cell lines (Maricic et al. ,
2013). Interestingly, the binding site of POU3F2 is affected by a substitution
shared by nearly all humans but absent or polymorphic in Neanderthals (Mari-
cic et al. , 2013). The amount of FOXP2 protein can also be regulated by post-
transcriptional mechanisms. A study by Clovis et al. found that the microRNAs
miR-9 and miR-132 repressed the expression of Foxp2 protein by targeting its
3’UTR region. Furthermore, removing the 3’UTR of Foxp2, which includes reg-
ulatory elements, resulted in an ectopic expression of Foxp2 and led to a signifi-
cant delay of neurite outgrowth (Clovis et al. , 2012). Although all these studies
are interesting and potentially relevant to understanding how FOXP2 is regu-
lated, additional replication studies and further investigations are needed to
confidently confirm the findings.
1.2.10 BCL11A mutations in neurodevelopmental disorder
As noted above during the last two decades researchers have been successfully
exploiting FOXP2 and its molecular networks to gain insights into the molec-
ular basis of speech and language. The vast majority of this knowledge has
come from studying the functions of this gene in cellular and animal models.
With the rise of next generation sequencing technologies, more monogenic cases
of language-related disorders are being uncovered, providing novel candidate
genes that, like FOXP2, can be further investigated to provide fresh perspectives
into the biology of speech and language.
One novel putative language-related gene is BCL11A. A microdeletion that
solely affects this gene was reported in a child with CAS, the same phenotype
that is caused by mutations in FOXP2 (Peter et al. , 2014). In this case, though,
the proband also presented additional signs such as mild cognitive deficits
and hypotonia. BCL11A had previously been associated with neurodevelop-
mental disorder in multiple cases of individuals suffering from the 2p15p16.1
microdeletion syndrome (OMIM #612513), a rare genetic neurodevelopmental
syndrome characterized by ID, dysmorphic features and microcephaly (Balci
et al. , 2015; Peter et al. , 2014; Rajcan-Separovic et al. , 2007; Chabchoub et al. ,
2008; de Leeuw et al. , 2008; Fannemel et al. , 2014; Félix et al. , 2010; Florisson
et al. , 2013; Hancarova et al. , 2013; Hucthagowder et al. , 2012; Liang et al. ,
2009; Piccione et al. , 2012; Prontera et al. , 2011; Basak et al. , 2015). Patients
with the 2p16.1-p15 microdeletion syndrome present varying degrees of neu-
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rodevelopmental delay and ID together with motor delay, growth retardation,
microcephaly and other cranial and skeletal anomalies. Of note, the majority
of the patients with this syndrome also show delays in the acquisition of lan-
guage abilities. BCL11A is a reasonable candidate for contributing to the key
features of this syndrome because it is a transcription factor expressed in the
brain, but the contribution of other genes within the deleted genomic region
cannot be discarded. Moreover, there are two non-overlapping critical regions
for this syndrome and only one includes BCL11A (Lévy et al. , 2017).
BCL11A, also known as CTIP1, encodes a C2H2 zinc finger transcription fac-
tor expressed both in the blood and in the brain, with several splicing isoforms
(Satterwhite et al. , 2001; Kuo & Hsueh, 2007; Liu et al. , 2006), which are de-
scribed in chapter 5. Its functions in the hematopoietic system have been exten-
sively studied, where it plays a central role in hematopoiesis and in regulating
the switch from fetal to adult hemoglobin by acting as a transcriptional repres-
sor of fetal hemoglobin (HbF) (Satterwhite et al. , 2001; Sankaran et al. , 2010).
The presence of chromosomal microdeletions at 2p15-p16.1 encompassing the
gene in individuals with speech sound disorder and with more severe ID, as
well as the fact that it has been suggested as a recurrently mutated gene in ASD
(Peter et al. , 2014; Iossifov et al. , 2014; De Rubeis et al. , 2014; Balci et al. , 2015),
indicate that this protein can also have a crucial role in the brain.
However, BCL11A functions in the brain have not been as thoroughly inves-
tigated as its role as a key hematopoietic transcription factor. BCL11A is ex-
pressed in the cortex and the hippocampus of mouse and rat brain (Kuo &
Hsueh, 2007; Leid et al. , 2004). BCL11A molecular links are depicted in Fig-
ure 1.6. This protein interacts and acts as a co-repressor with the neural nuclear
receptors: NR2F1, NR2F2 and NR2E1; but it can also independently bind DNA
as a transcription factor through its C2H2 zinc finger domains (Avram et al. ,
2000; Estruch et al. , 2012; Chan et al. , 2013). At the cellular level, BCL11A
is known to regulate dendrite outgrowth and axon branching in cultured hip-
pocampal neurons (Kuo et al. , 2009), which is controlled in part by its physical
interaction with the ID-related transcription factor CASK (Kuo et al. , 2010). In
the cortex, BCL11A helps orchestrate the migration and specification of cortical
projection neurons by regulating the expression of SEMA3C and TBR1 (Wood-
worth et al. , 2016; Cánovas et al. , 2015; Wiegreffe et al. , 2015). Moreover,
BCL11A directs the acquisition of sensory areas in the developing neocortex
and represses motor area identity (Greig et al. , 2016).
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Clearly, BCL11A is an intriguing language-related gene with important roles
in the cerebral cortex and therefore has the potential to provide fresh insights
into the biology of speech and language.
1.3 aims and scope of the thesis
Language is a complex trait with heterogeneous multifactorial genetic founda-
tions; hence it is challenging to unravel the individual contributions of each
single gene to its development and functions. A sensible entry point to start dis-
secting the crucial molecular pathways is to look at monogenic language-related
disorders.
In this dissertation, my main aim was to shed light on the molecular biol-
ogy underlying language by investigating the molecular functions of transcrip-
tion factors that have been implicated in monogenic language-related disorders.
To do so, I use two main approaches: (1) The identification and investigation
of FOXP protein interaction partners and (2) the functional characterization
of BCL11A mutations found in cases of neurodevelopmental disorders that in-
clude language impairments.
Deciphering the protein-protein interactions of a particular protein helps un-
derstand the molecular and physiological function of that protein and at the
same time, uncovers the molecular networks underlying particular biological
aspects that involve that protein. The major part of this thesis is concerned with
finding and characterizing protein-protein interactions of three FOXP proteins:
FOXP1, FOXP2 and FOXP4, with a special focus on FOXP2. In Chapter 2, I val-
idate the interaction between FOXP2 and the post-translational enzyme PIAS1,
which was identified in multiple prior independent Y2H screens but never fur-
ther investigated. The investigation of this interaction leads to the discovery
that FOXP2 is subject to SUMOylation, the post-translational modification of
proteins with small ubiquitin-like modifiers (SUMO), which regulates many as-
pects of protein function. I find that PIAS1, as well as other members of the
PIAS family, promotes FOXP2 SUMOylation. Moreover, I show that the most
well-studied etiological FOXP2 mutation implicated in speech and language
disorder leads to substantially reduced SUMOylation of the encoded protein.
In Chapter 3, I seek to validate SFPQ and NONO as interaction partners of
FOXP2. These proteins were identified in mass spectrometry screens for FOXP2
interactors previously performed in our group. I find that the interaction of
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FOXP2 with SFPQ and NONO is consistently not validated in all the different
complementary protein-protein interaction methods employed, suggesting that
these putative interactors were false positives in the initial mass spectrometry
screens.
The results obtained in Chapter 3 indicate the need for new mass spectrome-
try screens to search for novel FOXP protein interaction partners. Therefore, in
Chapter 4, I use affinity purification of FOXP1, FOXP2 and FOXP4 complexes
followed by mass spectrometry analysis to generate a list of several new puta-
tive FOXP-interacting proteins. I use validation methods to confirm seven FOXP-
interacting transcription factors from this screen: SOX5, NR2F1, NR2F2, SATB1,
SATB2, YY1 and ZMYM2. I also map the binding regions of these co-factors
within FOXP2. Strikingly, most of the newly identified FOXP-interacting part-
ners have well-established roles in brain development and/or are implicated
in neurodevelopmental disorders with symptoms that overlap with those re-
sulting from mutations in FOXP1 and/or FOXP2. I confirm that the majority of
these transcription factors are co-expressed with FOXP2 in neuronal subpopula-
tions, suggesting that the interactions may occur in vivo and have physiological
relevance. Furthermore, I find that these interactions are disrupted by etiologi-
cal mutations of FOXP1 and FOXP2. Thus, the findings in this chapter expand
the FOXP interactome, revealing that these proteins are part of a broader tran-
scription factor network that underlies brain development and neurodevelop-
mental disorders.
The functional characterization of gene variants identified in people with a
certain disorder is crucial to confidently determine the etiological role of that
particular gene. Additionally, it provides new insights into the function of that
gene in both health and disease. In Chapter 5, I perform functional charac-
terization of several de novo missense mutations in BCL11A that were found
in individuals with neurodevelopmental delay and impaired language func-
tion. By using a wide range of molecular assays, I assess the impact of these
mutations on protein function in cellular models and find that they all lead
to a loss of protein function thus confirming their causal role in the disorder
and contributing to the delineation of a novel monogenic ID syndrome. The re-
sults in this chapter also highlight the importance of the N-terminus region of
BCL11A in core protein functions such as protein-protein interactions and gene
transcription and suggest that transcriptional dysregulation underlies BCL11A-
associated syndrome.
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Finally, in Chapter 6 I summarize the work of the thesis, discussing how the
findings from the four experimental chapters have increased our understanding
of the molecular and genetic basis of language-related disorders, and consider-
ing the future of this growing field.
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T H E L A N G UAG E - R E L AT E D T R A N S C R I P T I O N FAC T O R
F OX P 2 I S P O S T-T R A N S L AT I O N A L LY M O D I F I E D W I T H
S M A L L U B I Q U I T I N - L I K E M O D I F I E R S 1
Abstract: Mutations affecting the transcription factor FOXP2 cause a rare form of
severe speech and language disorder. Although it is clear that sufficient FOXP2 ex-
pression is crucial for normal brain development, little is known about how this
transcription factor is regulated. To investigate post-translational mechanisms for
FOXP2 regulation, we searched for protein interaction partners of FOXP2, and iden-
tified members of the PIAS family as novel FOXP2 interactors. PIAS proteins mediate
post-translational modification of a range of target proteins with small ubiquitin-like
modifiers (SUMOs). We found that FOXP2 can be modified with all three human
SUMO proteins and that PIAS1 promotes this process. An aetiological FOXP2 muta-
tion found in a family with speech and language disorder markedly reduced FOXP2
SUMOylation. We demonstrate that FOXP2 is SUMOylated at a single major site,
which is conserved in all FOXP2 vertebrate orthologues and in the paralogues FOXP1
and FOXP4. Abolishing this site did not lead to detectable changes in FOXP2 sub-
cellular localization, stability, dimerization or transcriptional repression in cellular
assays, but the conservation of this site suggests a potential role for SUMOylation in
regulating FOXP2 activity in vivo.
1 This chapter has been published as: Estruch, S.B., Graham S.A., Deriziotis P., Fisher S.E. (2016). The
language-related transcription factor FOXP2 is post-translationally modified with small ubiquitin-
like modifiers. Scientific reports, 6:20911. 10.1038/srep20911.
49
250 the language-related transcription factor foxp2 is sumoylated
2.1 introduction
Heterozygous disruption of the FOXP2 gene, which encodes a member of the
forkhead box (FOX) family of transcription factors, leads to a rare and severe
form of speech and language disorder (MIM 605317 (gene), 602081 (disorder)).
This developmental disorder was first described in a three-generation pedigree
(the KE family), in which half of the family members have difficulties with learn-
ing to make coordinated orofacial movements underlying speech (childhood
apraxia of speech), together with wide-ranging impairments in comprehension
and production of spoken and written language, but without serious impact
on other aspects of cognitive functioning (Lai et al. , 2001). All affected mem-
bers of the KE family carry a missense mutation (R553H) within the FOX DNA-
binding domain, which abolishes DNA binding and transcriptional repression
by FOXP2 (Lai et al. , 2001; Nelson et al. , 2013; Vernes et al. , 2006). Around
twenty further cases of speech/language disorder resulting from FOXP2 hap-
loinsufficiency have since been reported, including nonsense and frameshift
point mutations, as well as chromosomal rearrangements disturbing the locus
(Adegbola et al. , 2015; Nazaryan et al. , 2014; Turner et al. , 2013; Utine et al. ,
2014). Thus, adequate FOXP2 expression appears to be essential for normal de-
velopment of language-related brain circuits, presumably in order to establish
correct expression levels of crucial downstream target genes involved in pro-
cesses such as neurite outgrowth and synaptic plasticity (Groszer et al. , 2008;
Vernes et al. , 2011).
FOXP2 shows evolutionarily-conserved expression in brain structures includ-
ing the cortex, basal ganglia, thalamus and cerebellum (Ferland et al. , 2003; Lai
et al. , 2003). Studies in animal models further support the notion that precisely
controlled levels of FOXP2 are necessary for normal brain development (as re-
viewed in (Fisher & Scharff, 2009; French & Fisher, 2014)). Mice in which both
copies of the Foxp2 gene have been disrupted show severe motor impairments
and developmental delay, and die 3-4 weeks after birth (French & Fisher, 2014;
Groszer et al. , 2008) (Note that the murine orthologue of FOXP2 is designated as
Foxp2 and orthologues in other species as FoxP2). When mice are heterozygous
for a Foxp2 mutation equivalent to that found in the KE family, they are overtly
normal, but exhibit deficits in motor skill learning and abnormal electrophysiol-
ogy within cortico-striatal circuits (French & Fisher, 2014; Groszer et al. , 2008;
French et al. , 2012). Transient manipulation of Foxp2 levels also has deleterious
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consequences in the developing mouse brain: both knock-down and overexpres-
sion of Foxp2 have been reported to affect neurogenesis, neuronal morphology
and migration (Garcia-Calero et al. , 2016; Tsui et al. , 2013). The effect of ma-
nipulating FoxP2 levels has also been investigated in the zebra finch, a species
which, like humans, has the unusual ability to learn vocalizations from other
individuals (Fisher & Scharff, 2009). Both knock-down and overexpression of
FoxP2 in key parts of the brains of juvenile zebra finches disrupts the normal
process of song learning (Haesler et al. , 2007; Heston & White, 2015), indicat-
ing that precise control of FoxP2 levels is necessary for normal vocal learning
behaviour in this species.
Studies in songbirds indicate that, in addition to the spatial regulation of
expression, dynamic temporal regulation of activity of this transcription factor
is important for its functions in the developing and adult brain. Zebra finch
FoxP2 expression is elevated in a specific song-related brain region (Area X)
during the critical period in which juvenile birds learn their song (Haesler et al.
, 2007; Rochefort et al. , 2007). Furthermore, in adult birds, FoxP2 levels in
Area X decrease when males practice songs alone, but not during performance
of songs to females, which may contribute to the increased variability in song
output during solo practice compared to female-directed singing (Miller et al. ,
2008; Murugan et al. , 2013; Teramitsu & White, 2006; Thompson et al. , 2013).
Similar dynamic regulation of the human orthologue could potentially play a
role in vocal learning during speech acquisition.
While several studies have examined patterns of FOXP2 protein expression
in the brains of different species (Ferland et al. , 2003; Lai et al. , 2003; Men-
doza et al. , 2015), few investigations have addressed potential mechanisms for
regulation of FOXP2 activity (Fu et al. , 2014). Transcription factor activity is of-
ten regulated via interaction with other transcription factors, co-repressors/co-
activators, chromatin-modifiers, and post-translational modification enzymes.
Such interactions can alter protein turnover, increase or decrease transcriptional
activation/repression activity, or influence selection of downstream targets. A
small number of FOXP2-interacting proteins have been described, notably the
paralogues FOXP1 and FOXP4, the transcription factor TBR1, and the co-re-
pressor CtBP1 (Deriziotis et al. , 2014b,a; Li et al. , 2004; Lozano et al. , 2015). To
uncover additional mechanisms for regulation of FOXP2 activity we sought to
identify novel protein interaction partners. We found that members of the PIAS
family of proteins interact with FOXP2, and also with the paralogue FOXP1.
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PIAS proteins mediate post-translational modification of nuclear proteins with
small ubiquitin-like modifiers (SUMOs) (Meulmeester & Melchior, 2008; Ry-
tinki et al. , 2009). SUMOs are ubiquitously-expressed polypeptides that are
reversibly coupled to many different proteins with a variety of functional out-
comes. We show that FOXP2 is modified with SUMOs at a single major evo-
lutionarily-conserved site, and that PIAS1 promotes this modification. SUMOy-
lation of FOXP2 is an excellent candidate mechanism for dynamic regulation of
FOXP2 activity in vivo.
2.2 material and methods
2.2.1 Yeast two-hybrid assay
The yeast two-hybrid assay was performed by Dualsystems Biotech AG (Switzer-
land). The bait construct was produced by fusing the coding sequence of full-
length human FOXP2 (Uniprot accession O15409) to the DNA-binding domain
of the bacterial transcription factor LexA. Preys consisted of a human foetal
brain cDNA library fused to the activation domain of yeast Gal4. LacZ was used
as the reporter gene and interactions identified by the presence of blue colour. It
was confirmed that transfection of the FOXP2 bait construct alone did not acti-
vate transcription of the reporter gene. False positive interactors were removed
using the bait dependency test to identify prey constructs which activated tran-
scription without co-transfection with the FOXP2 bait construct.
2.2.2 DNA constructs
The coding sequences of PIAS1 (NM_016166.1), PIAS2 (NM_004671.3), PIAS3
(NM_006099.3), PIAS4 (NM_015897.1), SUMO1 (NM_003352.4), SUMO2 (NM_
006937.3), and SUMO3 (NM_001286416.1), and a 1146 bp region of the pro-
moter of SRPX2, were amplified from human foetal brain cDNA using the
primers listed in Supplementary Table S2.1. The cloning of wild-type FOXP2,
FOXP1 and CtBP1, and of synthetic truncated forms of FOXP2, has been de-
scribed previously (Deriziotis et al. , 2014a,b; Lozano et al. , 2015). For ex-
pression of fusion proteins with Renilla luciferase, YFP and mCherry, cDNAs
were subcloned into the pLuc, pYFP and pmCherry expression vectors, respec-
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tively, which have been described previously (Deriziotis et al. , 2014b,a). For ex-
pression of proteins with three tandem N-terminal Myc tags or an N-terminal
V5 tag, cDNAs were subcloned into vectors which were created by modifica-
tion of the vector pEGFP-C2 (Clontech), and have an identical backbone to the
pLuc, pYFP and pmCherry vectors, with the exception of the N-terminal tag
and polylinker. To generate the FOXP2-UBC9 fusion protein, the UBC9 cod-
ing sequence (NM_194260.2) plus 58 upstream nucleotides were fused to the 3’
end of the FOXP2 coding sequence in the V5-tag vector, removing the FOXP2
stop codon. The FOXP2 K674R and R553H mutants, PIAS1 C350S mutant, and
SUMO alanine mutants were generated by site-directed mutagenesis using the
Quick-Change Site-Directed Mutagenesis kit (Stratagene) following the manu-
facturers protocol. Primers used in site-directed mutagenesis are listed in Sup-
plementary Table S2.2. The SRPX2 luciferase reporter plasmid was generated
by subcloning a 1146 bp region of the SRPX2 promoter into the promoter-
less firefly luciferase vector pGL4.23 (Promega). All constructs were verified
by Sanger sequencing. Plasmid sequences are available upon request.
2.2.3 Cell culture and transfection
HEK293 were obtained from ECACC (cat. no. 85120602) and cultured in DMEM
supplemented with 10% foetal bovine serum. HeLa-SUMO3 cells, which stably
express SUMO3 with an N-terminal hexahistidine tag (Tatham et al. , 2009),
and the parental HeLa cell line, were kindly provided by Professor Ronald
Hay and Dr Michael Tatham, and were cultured in DMEM supplemented with
10% foetal bovine serum (with the addition of 5 µ M puromycin for the HeLa-
SUMO3 cell line). Transfections were performed using GeneJuice (Merck-Milli-
pore) according to the manufacturer’s instructions.
2.2.4 BRET assay
BRET assays were performed as described (Deriziotis et al. , 2014b).
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2.2.5 Fluorescence microscopy
HEK293 cells were seeded on coverslips coated with poly-L-lysine. Cells were
cultured for 30 h post-transfection, and then fixed with methanol and nuclei
were stained with Hoechst 33342. Fluorescence images were acquired using a
Zeiss LSM510 confocal microscope with LSM Image Software or a Zeiss Axio
Imager 2 upright fluorescence microscope with ApoTome.2 using ZEN Image
software.
2.2.6 Gel shift assay
HEK293 cells were transfected in 6-well plates and cultured for 48 h. Cells were
lysed in 300 µ L of Laemmli sample buffer containing 10% Tris(2-carboxyethyl)-
phosphine hydrochloride (TCEP) and incubated for 10 min at 95◦ C. Proteins
were resolved on 10% SDS-polyacrylamide gels and transferred to PVDF mem-
branes using a TransBlot Turbo Blotting apparatus (Bio-Rad). Membranes were
blocked in PBS containing 0.5% milk and 0.1% Tween-20 and incubated overnight
at 4◦ C with primary antibody. The following antibodies were used: anti-GFP
(Clontech cat. no. 632380, 1:8000, for YFP constructs); anti-mCherry (Novus
cat. no. NBP1-96751, 1:1000); anti-V5 tag (Genetex cat. no. GTX42525, 1:3000);
anti-Myc tag (Abcam cat. no. ab9106, 1:1000); anti-β -actin (Sigma cat. no. A5441,
1:10,000). After washing, membranes were incubated with horseradish peroxi-
dase-conjugated goat anti-mouse or anti-rabbit IgG for 45 min at room temper-
ature. Proteins were visualized using Novex ECL Chemiluminescent Substrate
Reagent Kit (Life Technologies) and a ChemiDoc XRS+ imaging system (Bio-
Rad). Densitometry was performed using the Chemidoc XRS+ System image
analysis software (Bio-Rad).
2.2.7 Pull-down assay
Purification of SUMO3 conjugates from HeLa cells stably expressing His-tagged
SUMO3 was performed as previously described (Tatham et al. , 2009). Briefly,
cells were seeded in 6-well plates and transfected with YFP-tagged FOXP2 vari-
ants or YFP alone. After 48 h cells were lysed in 6 M Guanidinium-HCl, 10
mM Tris, 100 mM Sodium phosphate buffer pH 8.0, 5 mM β -mercaptoethanol
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and 5 mM imidazole. An aliquot of the lysate (10% ) was retained as the in-
put sample and the remainder was incubated with His-tag Dynabeads (Life
Technologies) overnight at 4◦ C with rotation. Beads were washed with 8 M
Urea, 10 mM Tris pH 6.3, 100 mM sodium phosphate buffer, 0.1 % Triton x-
1000 and 5 mM β-mercaptoethanol. SUMO3 conjugates were eluted by incuba-
tion at room temperature for 20 minutes in 200 mM imidazole, 150 mM Tris
pH 8.0, 5% SDS, 30% glycerol, 720 mM β-mercaptoethanol and 0.0025% bro-
mophenol blue. Western blotting was performed as described above; His-tagged
SUMO3 conjugates were detected using an anti-His tag antibody (Abgent cat.
no. AM1010a, 1:1000).
2.2.8 Protein degradation assay
HEK293 cells were transfected in 6-well plates and cultured for 48 h. Cyclohex-
imide was added for the indicated times at a final concentration of 50 µ g/ml.
Cells were lysed for 10 min at 4◦ C with 100 mM Tris pH 7.5, 150 mM NaCl, 10
mM EDTA, 0.2% Triton X-100, 1% PMSF, and protease inhibitor cocktail. Cell
lysates were cleared by centrifugation at 10,000xg for 3 min at 4◦ C. Gel elec-
trophoresis, western blotting and densitometry were performed as described
above.
2.2.9 Fluorescence measures of protein expression levels
HEK293 cells were transfected with YFP-FOXP2 and mCherry in clear-bottomed
black 96-well plates in triplicate. Cells were cultured in a TECAN M200PRO
microplate reader at 37◦ C with 5% CO2. Fluorescence intensity measurements
were taken at multiple time points. For each well and time point, the background-
subtracted YFP intensity was divided by the background-subtracted mCherry
intensity. Triplicate conditions were averaged.
2.2.10 Luciferase assays
HEK293 cells were seeded in clear-bottomed white 96-well plates and trans-
fected in triplicate. For the SV40 assay, cells were transfected with 12 ng of
pGL3-promoter firefly luciferase reporter construct (Promega), 5 ng of pRL-TK
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Renilla luciferase normalization control (Promega), and 16 ng of YFP-FOXP2
(wild-type or K674R or R553H mutant) or YFP control construct. For the SRPX2
assay, cells were transfected with 4.3 ng of SRPX2 luciferase reporter construct,
5 ng of pGL4.74 Renilla luciferase normalization control (Promega), and 45 ng
of YFP-FOXP2 (wild-type or K674R or R553H mutant) or YFP control construct.
After 48 h, luciferase activity was measured in a TECAN F200PRO microplate
reader using the Dual-Luciferase Reporter Assay system (Promega).
2.3 results
2.3.1 FOXP2 interacts with members of the PIAS family of proteins
To identify candidate interaction partners of FOXP2, a screen of a human foetal
brain yeast two-hybrid library was conducted using the full-length human pro-
tein as bait. The most frequently observed prey in this screen was PIAS1 (Sup-
plementary Table S2.3). The vertebrate PIAS family includes four proteins with
conserved domain architecture and 45-60% sequence identity (Fi gure 2.1a).
Interestingly, PIAS3 was one of four proteins identified as candidate FOXP2
interactors in an independent screen of a human foetal brain yeast two-hybrid
library, also using full-length human FOXP2 as the bait (Sakai et al. , 2011).PIAS
proteins are known to interact with and modulate the activity of a range of tran-
scription factors (Kotaja et al. , 2002; Rytinki et al. , 2009). Members of the PIAS
family therefore appeared to be strong candidates for FOXP2 interaction part-
ners.
In order to confirm the interaction of FOXP2 with PIAS proteins, we used a Bi-
oluminescence Resonance Energy Transfer (BRET) assay, which allows protein-
protein interactions to be monitored in live mammalian cells in culture (Derizio-
tis et al. , 2014b). In the BRET assay, a protein of interest is expressed as a fusion
with Renilla luciferase (Luc) and a candidate interaction partner is expressed as
a fusion with yellow fluorescent protein (YFP). An interaction between the two
proteins brings the Luc and YFP moieties into sufficient proximity to allow res-
onance energy transfer to occur upon addition of a luciferase substrate, shifting
the wavelength of the emitted light from 480 nm to 530 nm. Using Luc-FOXP2
and YFP-PIAS fusion proteins, we confirmed that FOXP2 interacts with PIAS1
and PIAS3, and in addition demonstrated interaction with PIAS4, and a poten-
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Figure 2.1
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Figure 2.1: FOXP2 interacts with members of the PIAS family of SUMO E3 ligases(a)
Top: schematic representation of human PIAS proteins. Domains are shaded in dark
blue: SAP domain (SAP); PINIT domain (PINIT); SP-RING domain (SP-RING); acidic do-
main (AD); serine/threonine- rich domain (S/T). The number of amino acid residues
is shown to the right of the schematic. Bottom: identity matrix for PIAS proteins. (b)
BRET assay for interaction between FOXP2 and PIAS proteins. HEK293 cells were trans-
fected with luciferase-FOXP2 (donor) and YFP-PIAS (acceptor). The control donor pro-
tein is a nuclear-targeted luciferase. Values are mean corrected BRET ratios ± S.E.M. (n =
3) (c) Fluorescence micrographs of HEK293 cells transfected with mCherry-PIAS (red)
and YFP-FOXP2 (green). Nuclei were stained with Hoechst 33342 (blue). (d) Left panel:
Schematic representation of synthetic truncated forms of FOXP2. The number of amino
acid residues is shown on the left; 1-715 represents the full-length protein. Known do-
mains are shown in dark blue: glutamine-rich region (Q-rich); zinc finger (ZF); leucine
zipper (LZ); forkhead domain (FOX). A nuclear-targeting signal (shown in black) was ap-
pended to the C-terminus of variants 1-487, 1-329, and 1-258 because these variants lack
endogenous nuclear targeting signals. Centre panel: BRET assay for interaction between
synthetic FOXP2 truncations and wild-type FOXP2. HEK293 cells were transfected with
luciferase-FOXP2 truncations (donor) and YFP-FOXP2 (acceptor) Right panel: BRET as-
say for the interaction between synthetic FOXP2 truncations and PIAS1. HEK293 cells
were transfected with luciferase-FOXP2 truncations (donor) and YFP-PIAS1 (acceptor).
The control donor protein is a nuclear-targeted luciferase. Values are mean corrected
BRET ratios ± S.E.M. (n = 3).
tial weaker interaction with PIAS2 (Figure 2.1b). Note that all experiments were
performed using HEK293 cells, unless indicated otherwise.
We noted that PIAS proteins exhibited nuclear localization with a distinctive
speckled appearance, as has been reported previously (Kotaja et al. , 2002). We
therefore examined if co-expression of PIASs with FOXP2 would cause redistri-
bution of FOXP2, which normally exhibits a diffuse localization within nuclei.
Expression of PIAS1 together with FOXP2 caused a dramatic change, involving
extensive co-localization of FOXP2 with PIAS1 in nuclear speckles (Figure 2.1c).
A similar effect was observed upon expression of PIAS3 and PIAS4, consistent
with the interaction observed in the BRET assay. Upon overexpression of PIAS2,
FOXP2 retained a largely diffuse nuclear distribution, with little FOXP2 exhibit-
ing co-localization with PIAS2 within speckles, consistent with the lower level
of interaction observed between FOXP2 and PIAS2 in BRET experiments. The
interaction between FOXP2 and PIASs may therefore draw FOXP2 into nuclear
speckles.
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To try to identify the region of FOXP2 involved in binding to PIAS proteins,
we performed BRET assays using a series of synthetic, truncated versions of
FOXP2 (Deriziotis et al. , 2014a) (Figure 2.1d). These truncations appear to be
effective in mapping interaction sites because deletion of the region containing
residues 330-487, which contains the leucine zipper dimerization domain (Li
et al. , 2004), results in a substantial reduction in interaction with full-length
FOXP2 (Figure 2.1, centre). Notably, even the shortest FOXP2 truncation tested
(residues 1-258) retained the ability to interact with PIAS1, though perhaps to
a slightly lesser degree than the full-length protein (Figure 2.1d, right). These
results suggest that some key determinants of PIAS binding reside within the N-
terminal region of FOXP2. Apart from a polyglutamine tract, this region does
not contain any known domains, but it does include regions of polypeptide
that are highly conserved in FOXP1 and FOXP4, and has also been identified as
the region interacting with the autism-related transcription factor TBR1, sug-
gesting that this region may coordinate multiple protein-protein interactions
(Deriziotis et al. , 2014a).
2.3.2 FOXP2 is SUMOylated
PIAS proteins function as SUMO E3 ligases, promoting the transfer of SUMO
from the SUMO-conjugating enzyme UBC9 to an acceptor lysine residue in a
target protein, in a manner analogous to the transfer of ubiquitin to proteins
by ubiquitin E3 ligases (Meulmeester & Melchior, 2008; Rytinki et al. , 2009).
There are three SUMO proteins in vertebrates, SUMO1, SUMO2 and SUMO3,
all of which have a molecular weight of 11 kDa. SUMO2 and SUMO3 have
∼ 95% amino acid sequence identity and are thought to be functionally very
similar, whereas SUMO1 has only ∼ 50% amino acid sequence identity with
SUMO2/3 and is not functionally redundant with these proteins (Meulmeester
& Melchior, 2008) The SUMOylation of specific proteins is typically difficult to
detect due to the dynamic nature of the modification, which is readily removed
by SUMO-specific proteases of the SENP family, and the fact that only a minor
proportion of target protein molecules carry a SUMO moiety at any one time
(Meulmeester & Melchior, 2008; Rytinki et al. , 2009). To facilitate detection
of protein SUMOylation, the 18 kDa SUMO-conjugating enzyme UBC9 can be
fused to a target protein of interest (Jakobs et al. , 2007). We therefore generated
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a FOXP2-UBC9 fusion construct, which also carries a V5 epitope tag to enable
the fusion to be detected independently from endogenous FOXP2 (Figure 2.2a).
We transfected cells with FOXP2-UBC9 together with a YFP-fusion of SUMO1,
SUMO2 or SUMO3. The use of YFP-tagged SUMOs allows discrimination be-
tween proteins modified with endogenous and exogenous SUMO. Lysates of
transfected cells were probed by western blotting with anti-V5 antibody to de-
tect any shift in the migration of FOXP2-UBC9 resulting from SUMOylation
(Figure 2.2b). All samples contained a FOXP2-UBC9 species that migrated at ∼
110 kDa, representing unSUMOylated protein. Cells transfected with FOXP2-
UBC9 and a YFP-SUMO contained a ∼ 170 kDa FOXP2-UBC9 species that was
not present in control cells transfected with FOXP2-UBC9 and YFP, indicating
that FOXP2 can be SUMOylated with all three SUMOs (Figure 2.2b). To con-
firm that the ∼ 170 kDa species represents YFP-SUMO conjugated to FOXP2-
UBC9, we generated mutant forms of YFP-SUMO, in which the two C-terminal
glycine residues required for conjugation to target proteins (and to UBC9) were
mutated to alanine. As expected, cells transfected with FOXP2-UBC9 together
with an alanine mutant YFP-SUMO did not contain the ∼ 170 kDa species (Fig-
ure 2.2b). In cells transfected with FOXP2-UBC9 together with a mutant YFP-
SUMO or YFP alone, a ∼ 130 kDa FOXP2-UBC9 species was observed, which
may represent FOXP2-UBC9 modified with endogenous SUMO (Figure 2.2b).
Note that the observed molecular weights of the different FOXP2-UBC9 species
do not necessarily correspond with theoretical values because SUMOylated pro-
teins are branched polypeptides and exhibit anomalous migration.
In order to confirm the results of the gel shift assay, we also examined FOXP2
SUMOylation in a BRET assay using Luc-FOXP2 with YFP-SUMO fusion pro-
teins. Interaction of FOXP2 was observed with SUMO1, SUMO2 and SUMO3,
but not with their respective alanine mutants, in agreement with the gel shift
assay (Figure 2.2c). Notably, the BRET assay readily allows detection of FOXP2
SUMOylation without the need to fuse FOXP2 to UBC9, indicating that the tech-
nique is highly sensitive for monitoring SUMOylation. BRET has rarely been
used in studies of SUMOylation, but may be a widely applicable technique for
examining this modification, with the advantage that its use in live cells over-
comes the difficulties in maintaining protein SUMOylation encountered in most
experimental procedures.
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Figure 2.2
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Figure 2.2: FOXP2 can be SUMOylated with SUMO1, 2 and 3. (a) Schematic representa-
tion of the FOXP2-UBC9 fusion protein with an N-terminal V5 epitope tag. (b) Gel shift
assay for FOXP2 SUMOylation. FOXP2-UBC9 was expressed in HEK293 cells together
with a YFP-fusion of either wild-type SUMO (GG), or mutant SUMO in which the two
C-terminal glycine residues required for conjugation to the target protein were mutated
to alanine (AA), or with YFP alone (control). Top panel: western blot probed with anti-
V5 antibody to detect FOXP2-UBC9. The 110 kDa species is unmodified FOXP2-UBC9.
The 130 kDa species is FOXP2-UBC9 modified with endogenous SUMO. The 170 kDa
species is FOXP2-UBC9 modified with YFP-SUMO. Middle panel: western blot probed
with anti-YFP antibody. The asterisk indicates unconjugated YFP-SUMO. Higher molecu-
lar weight species are cellular proteins modified with YFP-SUMO. Bottom panel: western
blot probed with anti-β-actin to confirm equal loading. (c) BRET assay for interaction be-
tween FOXP2 and SUMO. HEK293 cells were transfected with luciferase-FOXP2 (donor)
and YFP-SUMO (acceptor), using either wild-type SUMO (GG) or alanine mutants (AA).
The control donor protein is a nuclear-targeted luciferase. Values are mean corrected
BRET ratios ± S.E.M. (n = 3).
2.3.3 PIAS1 promotes SUMOylation of FOXP2
To determine if PIAS proteins are involved in the SUMOylation of FOXP2, we
focused on PIAS1, the PIAS family member identified in the original yeast
two-hybrid screen. We tested if overexpression of PIAS1, together with SUMO,
would allow SUMOylation of FOXP2 to be detected in a gel shift assay with-
out the need to fuse FOXP2 to UBC9. Overexpression of myc-tagged PIAS1 to-
gether with any of the three SUMO proteins (fused to mCherry) gave rise to a
new FOXP2 species of ∼ 140 kDa, suggesting that PIAS1 is able to stimulate
SUMOylation of FOXP2 (Figure 2.3a). Importantly, the observation of a new
high molecular weight FOXP2 species in this experiment shows that FOXP2
can be SUMOylated without being fused to UBC9.
To confirm that the increase in SUMOylation was mediated directly by PIAS1,
we generated a catalytically inactive version of PIAS1 that has a point mutation
(C350S) within the SP-RING domain, which is involved in the recognition of
target proteins (Figure 2.3b) (Kahyo et al. , 2001; Rytinki et al. , 2009). The
C350S PIAS1 mutant was unable to interact with FOXP2 in a BRET assay, in-
dicating that the SP-RING domain may be involved in recognition of FOXP2
as a SUMOylation target (Figure 2.3b). The C350S mutant displayed a more
2results 63
Figure 2.3: PIAS1 promotes FOXP2 SUMOylation. (a) Gel shift assay for SUMOylation
of FOXP2. HEK293 cells were transfected with V5-tagged FOXP2 and mCherry-SUMO,
together with myc- tagged PIAS1 (+) or an empty vector (-). Top panel: western blot
probed with anti-V5 antibody. The 90 kDa species is unmodified FOXP2. The 140 kDa
species is FOXP2 modified with mCherry- SUMO. Second panel: western blot probed
with anti-mCherry. The asterisk indicates unconjugated mCherry-SUMO. Higher molec-
ular weight species are cellular proteins modified with mCherry- SUMO. Third panel:
western blot probed with anti-myc tag to detect PIAS1. Bottom panel: western blot
probed with anti-β-actin to confirm equal loading. (b) Top: schematic representation
of PIAS1 C350S mutant. Bottom: BRET assay for interaction of FOXP2 with PIAS1.
HEK293 cells were transfected with luciferase-FOXP2 (donor) and YFP-PIAS (wild-type
(WT) or C350S mutant, acceptor). The control donor protein is a nuclear-targeted lu-
ciferase. Values are mean corrected BRET ratios ± S.E.M. (n = 3).
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Figure 2.3: (Cont.)(c) Fluorescence micrographs of HEK293 cells transfected with
mCherry-tagged wild-type PIAS1 (WT) or C350S mutant (red) and YFP-FOXP2 (green).
Nuclei were stained with Hoechst 33342 (blue). (d) Gel shift assay for SUMOylation
of FOXP2. HEK293 cells were transfected with FOXP2-UBC9 together with mCherry-
SUMO or mCherry alone (control) and myc-tagged wild-type PIAS1 (+), C350S mu-
tant (M) or empty vector (-). Top panel: western blot probed with anti-V5 antibody
to detect FOXP2-UBC9. The 110 kDa species is unmodified FOXP2-UBC9. The 130
kDa species is FOXP2-UBC9 modified with endogenous SUMO. The 170 kDa species is
FOXP2-UBC9 modified with mCherry-SUMO. Second panel: western blot probed with
anti-mCherry antibody. The asterisk indicates unconjugated mCherry- SUMO. Higher
molecular weight species are cellular proteins modified with mCherry-SUMO. Third
panel: western blot probed with anti-myc to detect PIAS1. Fourth panel: western blot
probed with anti-β-actin to confirm equal loading. Bottom panel: densitometry analysis
of FOXP2-UBC9 species.
diffuse nuclear localization than wild-type PIAS1, suggesting that the localiza-
tion of PIAS1 within nuclear speckles is connected to its activity as a SUMO
E3 ligase (Figure 2.3c). Consistent with this, the C350S mutant did not induce
redistribution of FOXP2 into nuclear speckles (Figure 2.3c). In a gel shift as-
say, wild-type PIAS1 promoted the modification of FOXP2-UBC9 with both en-
dogenous SUMO (∼ 130 kDa species) and mCherry-tagged SUMO (∼ 170 kDa
species) (Figure 2.3d). The C350S mutant was unable to promote SUMOylation
of FOXP2-UBC9 (Figure 2.3d), indicating that the increase in FOXP2 SUMOyla-
tion observed upon PIAS1 overexpression is due to the SUMO E3 ligase activity
of PIAS1.
2.3.4 K674 is the major SUMOylation site in FOXP2
SUMOs are conjugated to target proteins via an isopeptide bond formed by the
C-terminal carboxyl group of SUMO and the amino group of a lysine side chain
in the target protein. Lysine residues that are subject to SUMOylation are of-
ten found within the consensus sequence Ψ KX(D/E), where Ψ is a hydropho-
bic amino acid and X is any amino acid, although many SUMOylation sites
do not conform to this pattern (Geiss-Friedlander & Melchior, 2007). We used
three prediction algorithms to identify potential SUMOylation sites in FOXP2:
SUMOplot (www.abgent.com/sumoplot), GPS-SUMO (sumosp.biocuckoo.org)
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(Zhao et al. , 2014), and JASSA (www.jassa.fr) (Beauclair et al. , 2015). All three
algorithms identified K674 as a high-confidence potential SUMOylation site
(Supplementary Table S2.4). No other lysine residues in FOXP2 were identified
as potential SUMOylation sites by more than one algorithm. Residue K674 lies
in the C-terminal region of FOXP2, which does not contain any previously de-
scribed functional domains, consistent with the typical localization of SUMOy-
lation sites within structurally disordered regions of polypeptide (Figure 2.4a)
(Diella et al. , 2008). This residue is within a VKEE sequence that matches the
consensus Ψ KX(D/E) motif (Figure 2.4b). In addition, the putative SUMOyla-
tion site at K674 belongs to a class of predicted SUMOylation sites termed KEPE
motifs, which have the consensus sequence Ψ KX(D/E)PXXX(D/E) (Diella et al.
, 2009). KEPE motifs are found in over 130 human proteins, and are enriched
among proteins involved in transcription (Diella et al. , 2009). The critical resi-
dues of the KEPE motif are conserved in vertebrate FOXP2 proteins, supporting
a functional role for the motif (Figure 2.4b).
To assess if K674 functions as a SUMOylation site, we mutated this residue to
arginine, thus removing the amino group required for SUMO conjugation but
preserving the positive charge at this position of the polypeptide. We performed
a gel shift assay using wild-type or mutant FOXP2-UBC9 co-transfected with
PIAS1 and each of the three SUMOs. In this assay, the ∼ 170 kDa SUMOylated
FOXP2-UBC9 species observed in cells transfected with wild-type FOXP2 was
not present in cells transfected with the K674R mutant (Figure 2.4c). Thus K674
is the major site in FOXP2 that is subject to modification by SUMO1, SUMO2
and SUMO3.
The dramatic reduction in SUMOylation resulting from mutation of residue
K674 suggests that this residue may be the most important SUMOylation site
in vivo. To detect if a proportion of FOXP2 might be SUMOylated at alterna-
tive sites, we employed a HeLa cell line stably expressing His-tagged SUMO3
(Tatham et al. , 2009). Using cobalt affinity purification under denaturing condi-
tions, SUMOylated species were purified from HeLa-SUMO3 cells transfected
with YFP-tagged wild-type FOXP2, YFP-tagged K674R mutant, or YFP alone
(Figure 2.4d). YFP-FOXP2 was detected in the affinity-purified protein fraction
from the HeLa-SUMO3 cells, confirming that FOXP2 can be SUMOylated with-
out being fused to UBC9 (Figure 2.4d). Note that in this key experiment we did
not detect an observable shift in the molecular weight of FOXP2 as a result of
SUMOylation, in contrast to the clear size shifts observed in our earlier exper-
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Figure 2.4
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Figure 2.4: (Cont.) K674 is the major SUMOylation site in FOXP2. (a) Schematic rep-
resentation of FOXP2 showing the predicted SUMOylation site. Known domains are
shown in dark blue: glutamine-rich region (Q-rich); zinc finger (ZF); leucine zipper (LZ);
forkhead domain (FOX). (b) Sequence alignment of the region surrounding the puta-
tive SUMOylation site in FOXP2 orthologues. Conserved residues are shown on a black
background. Critical residues of the KEPE-type SUMOylation site motif are shown in
turquoise. UniProt accession numbers: Homo sapiens O15409; Pan troglodytes Q8MJ98;
Mus musculus P58463; Gallus gallus Q5IHK1; Xenopus laevis Q4VYS1; Danio rerio
Q4JNX5. (c) Gel shift assay for FOXP2 SUMOylation. HEK293 cells were transfected
with FOXP2-UBC9 (wild-type (WT) or K674R mutant) together with YFP-SUMOs or
YFP alone (control). Top panel: western blot probed with anti-V5. The 110 kDa species is
unmodified FOXP2-UBC9. The 130 kDa species is FOXP2-UBC9 modified with endoge-
nous SUMO. The 170 kDa species is FOXP2-UBC9 modified with YFP-SUMO. Bottom
panel: western blot probed with anti-β-actin. (d) Pull-down assay for FOXP2 SUMOy-
lation. HeLa cells stably expressing His-tagged SUMO3, or the parental HeLa cell line
(control), were transfected with YFP-FOXP2 (wild-type (WT) or K674R mutant) or YFP
alone. His-tagged species were isolated under denaturing conditions using cobalt affin-
ity purification. Western blots of total lysate (input) and affinity-purified material (elu-
tion) were probed with anti-His tag antibody to visualize SUMO-conjugated proteins
(top panel). YFP and YFP-FOXP2 were visualized using anti-GFP antibody: FOXP2 is
indicated by an arrowhead and YFP with an asterisk (middle panel). Total protein was
visualized by Coomassie blue staining (bottom panel). (e) BRET assay for interaction of
FOXP2 with SUMO. HEK293 cells were transfected with luciferase-FOXP2 (wild-type
(WT) or K674R mutant, donor) and YFP-SUMO (wild-type (GG) or alanine mutant (AA),
acceptor). The control is a nuclear-targeted luciferase. Values are mean corrected BRET
ratios ± S.E.M. (n = 3). (f) BRET assay for interaction of FOXP2 and PIAS proteins. Cells
were transfected with luciferase-FOXP2 (wild-type (WT) or K674R mutant, donor) and
YFP-PIAS (acceptor). (g) Fluorescence micrographs of HEK293 cells transfected with
mCherry-PIAS (red) and YFP-FOXP2 K674R mutant (green). Nuclei were stained with
Hoechst 33342 (blue).
iments. One potential explanation of the discrepancy is that this experiment
employed His-tagged SUMO, with a molecular weight of only ∼ 10 kDa, com-
parable to that of endogenous SUMO, while our prior experiments used YFP-
and mCherry-tagged SUMO proteins, which have substantially higher molec-
ular weights of >35 kDa. Importantly, YFP-FOXP2 was not detectable among
proteins eluted from resin incubated with lysate from the parental HeLa cell
line, demonstrating that FOXP2 does not bind non-specifically to the affinity
resin (Figure 2.4d). Moreover, the YFP control protein was not detectable in the
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affinity-purified fraction from the HeLa-SUMO3 cells, demonstrating that only
SUMOylated proteins are purified using this procedure (Figure 2.4d).
The K674R mutant was also present in the affinity-purified material from the
HeLa-SUMO3 cell line, indicating that specific enrichment of SUMOylated pro-
teins allows detection of rarer forms of FOXP2 that are SUMOylated at one or
more alternative sites (Figure 2.4d). Different SUMOylation site prediction tools
variously identify potential additional SUMOylation sites at K74, K285, K417
and K560 (Supplementary Table S2.4). However, none of these predictions are
consistent across two or more prediction tools, and none lie within a typical
consensus SUMOylation motif. While it is possible that several additional sites
in FOXP2 may occasionally be SUMOylated, modification at these sites may not
serve a critical biological function.
In a BRET assay, the K647R mutant displayed consistently reduced, but not
abolished, interaction with wild-type SUMO1, SUMO2 and SUMO3, and no
interaction with the respective alanine mutants (Figure 2.4e). The residual in-
teraction between the K674R mutant and SUMOs in the BRET assay might be
accounted for by the presence of minor secondary SUMOylation sites. Given
that the reduction in the BRET signal resulting from the K674R mutation is
modest, there may also be a contribution to this signal from non-covalent as-
sociation of the mutant with SUMO. Low-affinity, non-covalent interactions be-
tween SUMOs and other proteins are mediated by SUMO-interaction motifs
(SIMs) (Meulmeester & Melchior, 2008). We employed the JASSA (Beauclair et
al., 2015) and GPS-SUMO (Zhao et al. , 2014) algorithms to identify potential
SIMs in FOXP2, but no high-confidence SIMs were found (Supplementary Table
S2.5).
SUMO may instead associate with the K674R mutant as part of a complex
with UBC9 and PIAS. In support of this model, the K674R mutant exhibited a
similar degree of interaction with PIASs as wild-type FOXP2 in a BRET assay
(Figure 2.4f). We also observed co-localization of the K674R mutant with PIASs
in nuclear speckles (Figure 2.4g). Therefore K674 is not required for interaction
of FOXP2 with PIAS proteins, consistent with the mapping of the PIAS binding
site to the N-terminal region of FOXP2 (Figure 2.1d). Furthermore, the relocal-
ization of FOXP2 to nuclear speckles that is observed upon overexpression of
PIASs appears to be due to the interaction between PIAS and FOXP2, and not
to the SUMOylation of FOXP2.
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2.3.5 Functional consequences of FOXP2 SUMOylation
SUMOylation can affect the function of transcription factors in several ways
(Meulmeester & Melchior, 2008). To identify potential effects of SUMOylation
on FOXP2 function, we assessed if the K647R SUMOylation site mutant dis-
played any altered properties in cellular assays. The mutant did not exhibit
any differences in subcellular localization, retaining a diffuse nuclear distribu-
tion (Figure 2.5a). To assess differences in protein expression level, we trans-
fected cells with YFP fusions of wild-type FOXP2 or the K674R mutant, and
measured fluorescence intensity over time, relative to the fluorescence inten-
sity of co-transfected mCherry. No differences were observed in the ultimate
expression level of the wild-type and mutant proteins, or in the time course of
induction of expression (Figure 2.5b). To test for differences in protein degra-
dation, cycloheximide was added to cells expressing wild-type FOXP2 or the
K674R mutant to arrest protein synthesis, and the decrease in FOXP2 protein
over time was monitored by western blotting. For both wild-type and mutant
FOXP2, the amount of protein had dropped to approximately 25% of starting
levels after 6 h incubation with cycloheximide, and no difference in the rate of
degradation was observed between the wild-type and mutant proteins (Figure
2.5c). Abolishing the major SUMOylation site therefore does not have a substan-
tial effect on FOXP2 turnover in cultured cells. It is possible that differences
in stability might be evident after longer incubations with cycloheximide, but
reliable quantification of FOXP2 is precluded by the low levels of remaining
protein.
To determine if SUMOylation might affect the transcriptional regulatory ac-
tivity of FOXP2, we employed a luciferase reporter assay in which luciferase
expression is driven by the SV40 viral promoter (Vernes et al. , 2006). As previ-
ously reported, wild-type FOXP2 repressed luciferase activity by around 60% ,
whereas the mutant FOXP2 found in the KE family (R553H), which is unable
to bind DNA, did not repress luciferase activity (Figure 2.5d) (Vernes et al. ,
2006). The K674R mutant did not differ significantly in its repressive capability
from the wild-type protein (Figure 2.5d). A luciferase assay was also performed
using the human SRPX2 promoter. It has previously been reported that FOXP2
represses transcription from this promoter (Roll et al. , 2010). In our assay, wild-
type FOXP2 substantially repressed luciferase activity, and the R553H mutant
showed loss of repression, but the K674R mutant again did not differ signifi-
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Figure 2.5: Abolishing the K674R SUMOylation site has no effect in cellular assays
of FOXP2 function. (a) Fluorescence micrographs of cells transfected with YFP-tagged
wild-type (WT) and K674R mutant forms of FOXP2. Nuclei were stained with Hoechst
33342 (blue). (b) Fluorescence- based measurement of FOXP2 expression level. HEK293
cells were transfected with YFP-FOXP2 (wild-type (WT) or K674R mutant), together
with mCherry for normalization. Fluorescence intensity was measured 24, 36 and 48
h post-transfection. Values are mean YFP/mCherry fluorescence ratios ± S.E.M. (n =
3), relative to the value for wild-type FOXP2 at 48 h.(c) Western blot assay for FOXP2
degradation. HEK293 cells were transfected with V5-tagged FOXP2 (wild- type (WT)
or K674R mutant). Cycloheximide (CHX) was added to cells 48 h after transfection for
varying amounts of time. Top: western blots of whole cell extracts probed with anti-
V5 and anti-β- actin antibodies. Bottom: densitometry quantification of FOXP2. Values
are normalized to β-actin and plotted relative to the 0 h time point. (d) Luciferase re-
porter assays for transcriptional regulatory activity of FOXP2. HEK293 cells were trans-
fected with a luciferase reporter vector containing the SV40 promoter (left) or the human
SRPX2 promoter (right), together with YFP- FOXP2 (wild-type (WT), K674R or R553H
mutants), or YFP alone (control). Values are mean relative luciferase activity ± S.E.M. (n
= 3),
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Figure 2.5: (Cont.) expressed relative to the control. Asterisks indicate significant differ-
ences compared to wild-type FOXP2 (p<0.05, one-tailed student’s t-test). NS, not signif-
icant. Exact p-values for the SV40 assay are 0.0043 for the control, 0.0048 for R553H,
0.1598 for K674R. Exact p-values for the SRPX2 assay are 0.0009 for the control, 0.0017
for R553H, and 0.2566 for K674R.(e) BRET assay for FOXP2 dimerization. HEK293 cells
were transfected with luciferase- FOXP2 (wild-type (WT) or K674R mutant, donor) and
YFP-FOXP2 (acceptor). The control is a nuclear-targeted luciferase. Values are mean cor-
rected BRET ratios ± S.E.M. (n = 3). (f) BRET assay for interaction of FOXP2 with CtBP1.
HEK293 cells were transfected with luciferase-FOXP2 (wild- type (WT) or K674R mu-
tant, donor) and YFP-CtBP1 (acceptor). The control is a nuclear-targeted luciferase. Val-
ues are mean corrected BRET ratios ± S.E.M. (n = 3)
cantly in its repressive capability from the wild-type protein (Figure 2.5d). Thus
the loss of the SUMOylation site does not have a generalized effect on the repres-
sive capability of FOXP2.
We then looked to see if abolishing the SUMOylation site affects the ability
of FOXP2 to form homodimers (Li et al. , 2004). The mutant displayed normal
dimerization ability in a BRET assay (Figure 2.5e), as might be expected given
that FOXP2 dimerization is mediated by the leucine zipper domain, which is
not located near to the SUMOylation site (Figure 2.4a) (Li et al. , 2004; Deriziotis
et al. , 2014b). Finally we employed a BRET assay to assess if the K674R mutant
differed in its ability to bind to the co-repressor CtBP1 (Li et al. , 2004; Deriziotis
et al. , 2014b). Again, no differences were observed between the wild-type and
mutant proteins (Figure 2.5f). Thus, in our cell-based assays, abolishing the
major SUMOylation site in FOXP2 does not have a substantial impact on the
behaviour of the protein.
2.3.6 A FOXP2 mutant that causes speech/language disorder shows reduced SUMO-
ylation
Members of the KE family who are affected by speech and language disorder
all carry a heterozygous mutation, R553H, within the DNA-binding domain of
FOXP2 (Figure 2.6a) (Lai et al. , 2001). This mutation affects a critical residue
within the DNA-recognition helix of the FOX domain and abolishes DNA bind-
ing (Lai et al. , 2001; Nelson et al. , 2013; Stroud et al. , 2006; Vernes et al. , 2006).
272 the language-related transcription factor foxp2 is sumoylated
Unexpectedly, a gel shift assay in which cells were transfected with wild-type
or mutant FOXP2, together with PIAS1 and SUMO, showed a clear reduction
in SUMOylation of the R553H mutant, though it was still modified to a greater
extent than the K674R mutant (Figure 2.6b). A BRET assay also showed a near
total loss of interaction between SUMOs and the R553H mutant in comparison
to wild-type FOXP2 (Figure 2.6c), in contrast to the partially retained interac-
tion between SUMOs and the K674R mutant (Figure 2.4d).
Given that the major SUMOylation site is intact in the R553H mutant, the re-
duction in SUMOylation may be a consequence of reduced interaction between
the mutant and components of the SUMOylation machinery, such as PIASs or
UBC9. Consistent with this possibility, the R553H mutant showed reduced or
abolished interaction with PIASs in a BRET assay (Figure 2.6d). The R553H
mutant continued to show some co-localization with PIASs in transfected cells,
however the tendency of this mutant to form aggregates makes it unclear if the
punctae containing both proteins are nuclear speckles or protein aggregates
(Figure 2.6e) (Vernes et al. , 2006). Decreased interaction with PIAS1 could ac-
count for the relatively higher level of R553H SUMOylation in the gel shift
assay compared to the BRET assay, because the overexpression of PIAS1 in the
gel shift assay might have a compensatory effect on SUMOylation. Interestingly,
the R553H mutant was SUMOylated to a similar extent as wild-type FOXP2
when these proteins were fused to UBC9 (Figure 2.6f), suggesting that fusion
to UBC9 might rescue a loss of interaction with the SUMOylation machinery in
the R553H mutant.
Thus in contrast to the K674R mutant, which is able to interact with PIASs
but cannot be SUMOylated, the R553H mutant has reduced interaction with
PIASs, but can still be SUMOylated by employing overexpression of PIAS or
fusion to UBC9. It is unexpected that the R553H mutation should reduce inter-
action with PIASs, because truncated forms of FOXP2 that lack the entire FOX
domain, and are thus also unable to bind DNA, are still able to interact with
PIAS1 (Figure 2.1d). The partial mislocalization and increased propensity for
protein aggregation resulting from the R553H mutation may contribute to the
reduction in interaction, although the majority of mutant protein still displays
a normal diffuse nuclear localization, and retains the ability to interact with
wild-type FOXP2, indicating that the mutation does not cause gross misfold-
ing of the entire population of molecules (Vernes et al. , 2006; Deriziotis et al.
, 2014a). Potentially the R553H mutation causes a conformational change that
2results 73
Figure 2.6: The R553H FOXP2 mutant which causes speech/language disorder ex-
hibits reduced SUMOylation. (a) Schematic representation of the FOXP2 R553H mu-
tant. Known domains are shown in dark blue: glutamine-rich region (Q-rich); zinc finger
(ZF); leucine zipper (LZ); forkhead domain (FOX).
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Figure 2.6: (Cont.) (b) Gel shift assay for FOXP2 SUMOylation. HEK293 cells were trans-
fected with V5-tagged FOXP2 (wild-type (WT), K674R or R553H mutant) together with
mCherry-SUMO and myc-tagged PIAS1. Top panel: western blot probed with anti-V5
antibody. The 90 kDa species is unmodified FOXP2. The 140 kDa species is FOXP2 mod-
ified with mCherry-SUMO. Second panel: western blot probed with anti-myc tag anti-
body to detect PIAS1. Third panel: western blot probed with anti-mCherry. The asterisk
indicates unconjugated mCherry-SUMO. Higher molecular weight species are cellular
proteins modified with mCherry-SUMO. Bottom panel: western blot probed with anti-
β-actin to confirm equal loading. (c) BRET assay for interaction of FOXP2 with SUMO.
HEK293 cells were transfected with luciferase-FOXP2 (wild-type (WT) or R553H mu-
tant, donor) and YFP-SUMO (wild-type (GG) or alanine mutant (AA), acceptor). The
control donor protein is a nuclear-targeted luciferase. Values are mean corrected BRET
ratios ± S.E.M. (n = 3). (d) BRET assay for interaction of FOXP2 with PIAS proteins.
HEK293 cells were transfected with luciferase-FOXP2 (wild-type (WT) or R553H mu-
tant, donor) and YFP-PIAS (acceptor). The control donor protein is a nuclear-targeted
luciferase. Values are mean corrected BRET ratios ± S.E.M. (n = 3). (e) Fluorescence mi-
crographs of HEK293 cells transfected with mCherry-PIAS (red) and YFP-FOXP2 R553H
mutant (green). Nuclei were stained with Hoechst 33342 (blue). (f) Gel shift assay
for FOXP2 SUMOylation. HEK293 cells were transfected with FOXP2-UBC9 (wild-type
(WT), K674R or R553H mutant) together with mCherry-SUMO3 and myc-tagged PIAS1.
Top panel: western blot probed with anti-V5. The 110 kDa species is unmodifed FOXP2-
UBC9. The 170 kDa species is FOXP2-UBC9 modified with mCherry-SUMO3. Second
panel: western blot probed with anti-myc tag antibody to detect PIAS1. Third panel:
western blot probed with anti-mCherry. The asterisk indicates unconjugated mCherry-
SUMO. Higher molecular weight species are cellular proteins modified with mCherry-
SUMO. Bottom panel: western blot probed with anti-β-actin to confirm equal loading.
blocks the PIAS binding site. Alternatively, the loss of DNA-binding capacity
and/or destabilization of the FOX domain resulting from the R553H mutation
may permit interactions with other cellular proteins, such as those involved
in protein degradation, that in turn interfere with PIAS binding. Although the
mechanism by which the R553H mutation reduces interaction with PIAS is un-
clear, it seems likely that a functional FOX domain is needed in addition to
the K674 SUMOylation site to permit normal levels of FOXP2 SUMOylation in
cells.
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2.3.7 SUMOylation of other FOXP proteins
FOXP2 has three mammalian paralogues, FOXP1, FOXP3 and FOXP4 (Figure
2.7a). FOXP1, FOXP2 and FOXP4 exhibit 55-65% sequence identity, are able to
form heterodimers, and are expressed in overlapping cell populations in the
brain and other organs, suggesting that they may co-operate in the regulation
of certain subsets of target genes (Ferland et al. , 2003; Li et al. , 2004; Lu et al. ,
2002). FOXP3 is structurally divergent, and its expression is restricted to regu-
latory T lymphocytes (Fontenot et al. , 2003). The critical residues of the KEPE
SUMOylation motif in FOXP2 are conserved in FOXP1 and FOXP4, which is
particularly striking because the C-terminal regions of these proteins generally
exhibit a low level of similarity (the region is absent in FOXP3) (Figure 2.7a,b).
This low level of sequence conservation in the C-terminal region of the FOXP
proteins is consistent with the polypeptide in this region being structurally dis-
ordered, in order to maintain accessibility of the SUMOylation site (Diella et al.
, 2008).
The conservation of the SUMOylation site in FOXP1 prompted us to assess
if this protein may also be subject to PIAS-mediated SUMOylation. The es-
sential role of FOXP1 in brain development has recently come to light since
it was discovered that haploinsufficiency of FOXP1 is associated with intellec-
tual disability, autistic features, expressive speech deficits and dysmorphic fea-
tures (Hamdan et al. , 2010; Horn et al. , 2010; Le Fevre et al. , 2013; Lozano
et al. , 2015; O’Roak et al. , 2011). The FOXP1-related disorder is more severe
than that resulting from haploinsufficiency of FOXP2, indicating that the two
proteins have non-redundant functions in human brain development (Bacon &
Rappold, 2012).Furthermore, and in contrast to aetiological FOXP2 variants, all
aetiological FOXP1 variants reported to date have occurred de novo (Le Fevre
et al. , 2013; Lozano et al. , 2015). In a BRET assay, FOXP1 and FOXP2 exhibited
similar levels of interaction with PIAS1, PIAS2 and PIAS4, but unlike FOXP2,
FOXP1 showed little or no interaction with PIAS3 (Fig 7c). BRET assays also
showed clear interaction of FOXP1 with all three SUMOs (Fig 7d). It is there-
fore likely that FOXP1 is also subject to modification by SUMO1, SUMO2 and
SUMO3, at an equivalent site to that in FOXP2 (K636), but that the members
of the PIAS family have differing levels of importance in the SUMOylation of
FOXP1 and FOXP2. Three proteome-wide studies of SUMOylation in human
cell lines have also identified FOXP1 and FOXP4 as substrates for SUMOyla-
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Figure 2.7: The FOXP2 paralogue FOXP1 is also SUMOylated. (a) Left: Schematic rep-
resentation of the FOXP family of proteins. Known domains are shown in dark blue:
glutamine-rich region (Q-rich); zinc finger (ZF); leucine zipper (LZ); forkhead domain
(FOX). The number of amino acid residues is indicated to the right of the schematic.
Right: identity matrix for FOXP proteins. (b) Sequence alignment of the region sur-
rounding the SUMOylation site in FOXP proteins. Conserved residues are shown on
a black background. Critical residues of the KEPE-type SUMOylation site motif are
shown in turquoise and the SUMO conjugation site is labeled. UniProt accession num-
bers: FOXP2 O15409; FOXP1 Q9H334; FOXP4 Q8IVH2. (c) BRET assay for interaction
of FOXP1 and FOXP2 with PIAS proteins. HEK 293 cells were transfected with luciferase-
FOXP1 or luciferase-FOXP2 (donor) and YFP-PIAS (acceptor). The control donor protein
is a nuclear-targeted luciferase. Values are mean corrected BRET ratios ± S.E.M. (n = 3).
(d) BRET assay for interaction of FOXP1 and FOXP2 with SUMO. HEK293 cells were
transfected with luciferase-FOXP1 or luciferase-FOXP2 (donor) and YFP-SUMO (wild-
type (GG) or alanine mutant (AA), acceptor). The control donor protein is a nuclear-
targeted luciferase. Values are mean corrected BRET ratios ± S.E.M. (n = 3).
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tion, supporting a conserved role for SUMOylation in the regulation of FOXP
transcription factors (Golebiowski et al. , 2009; Tatham et al. , 2011; Wen et al. ,
2014).
2.4 discussion
In this study we have shown that FOXP2 has a single major SUMOylation site
at K674, which can be modified by SUMO1, SUMO2 and SUMO3. This site is
fully conserved in orthologues of FOXP2, and lies within the C-terminal region
of the protein, which previously had no known function. We have demonstrated
that FOXP2 interacts with members of the PIAS family of E3 SUMO ligases, and
that this interaction probably involves the SP-RING domain of PIAS and the N-
terminal region of FOXP2. The interaction between FOXP2 and PIAS proteins
causes relocalization of FOXP2 to nuclear speckles, and promotes SUMOylation
of FOXP2. The FOXP2 paralogues FOXP1 and FOXP4 probably also undergo
PIAS-mediated SUMOylation at equivalent sites.
SUMOylation is believed to occur in all cell types and across all developmen-
tal stages, and thousands of nuclear proteins are thought to be modified in this
way (Meulmeester & Melchior, 2008). The essential role of SUMOylation in de-
velopment is evidenced by the early embryonic lethality resulting from Ubc9
knockout in mice (Nacerddine et al. , 2005). Global changes in SUMOylation
levels during brain development have been documented in mouse and rat, but
the functional impact of these changes is uncertain (Hasegawa et al. , 2014; Lo-
riol et al. , 2012). Effects of SUMOylation on several neural proteins have been
reported, with impacts on neuronal specification and dendritic and synaptic
morphogenesis, but for most proteins the function of SUMOylation remains
unclear (Gwizdek et al. , 2013; Meulmeester & Melchior, 2008).
In our cellular assays, abolishing the major SUMOylation site in FOXP2 did
not produce changes in subcellular localization, stability, transcriptional regu-
lation, dimerization with wild-type FOXP2, or interaction with the co-repressor
CtBP1. Abolition of the SUMOylation site may have effects on unknown protein
interactions, or on regulation of a particular subset of target genes. It would
therefore be of interest in future to perform proteomic and transcriptomic stud-
ies to search for protein-protein interactions and target genes that are affected
by loss of the FOXP2 SUMOylation site. At the same time, the failure to observe
differences between wild-type FOXP2 and the K647R mutant is not necessarily
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surprising given the small proportion of wild-type protein molecules modified
by SUMOylation at any one time. Like several other post-translational modifica-
tions, SUMOylation is a dynamic, reversible process which allows protein activ-
ity to be regulated on short time-scales in response to external signals that may
change over the course of development. The consequences of loss of SUMOyla-
tion in FOXP2 may therefore only be apparent in the context of a developing
organism, and SUMOylation of FOXP2 is potentially essential in vivo but not in
cultured cells. It would therefore be interesting to abolish the FOXP2 SUMOyla-
tion site in an animal model, in order to assess the effect of loss of SUMOylation
on developmental regulation of gene expression. There are still very few exam-
ples of animal models in which a SUMOylation site in a specific protein has
been ablated. However, abolishing the SUMOylation sites of the transcription
factor NR5A1 in the mouse resulted in aberrant regulation of target genes and
prominent endocrine abnormalities, without affecting protein stability or local-
ization (Lee et al. , 2011), consistent with the suggestion that the consequences
of loss of SUMOylation may only be apparent in an organismal context. To our
knowledge there has been no systematic survey of rare variants in human de-
velopmental disorders for changes likely to affect SUMOylation. Thus, the im-
portance of SUMOylation of specific proteins to normal development is not yet
fully appreciated.
The rapid and dynamic nature of SUMOylation makes it well suited as a
mechanism for modifying the activity of proteins such as FOXP2 in response to
activity within neural circuits. Such mechanisms may be important for support-
ing neural plasticity, a process in which FOXP2 orthologues have been shown
to play a role in animal models (French et al. , 2012; Groszer et al. , 2008; Mu-
rugan et al. , 2013). The absolute conservation of the SUMOylation site and sur-
rounding KEPE motif in FOXP2 orthologues and in the paralogues FOXP1 and
FOXP4 suggests that SUMOylation may be an evolutionarily ancient and con-
served mechanism for regulating the activity of these transcription factors in
the brain and elsewhere, both during development and in the adult organism.
The selection of target proteins for SUMOylation is mediated by SUMO E3
ligases, such as members of the PIAS family. Our results indicate that multiple
PIAS proteins may participate in FOXP SUMOylation in vivo, and that different
PIASs may be involved in the SUMOylation of different FOXPs. RNA expression
data from the Human Protein Atlas (www.proteinatlas.org) suggests that the
four PIAS proteins have ubiquitous expression, with PIAS1 and PIAS3 showing
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moderate expression levels across all tissues tested, whereas PIAS2 and PIAS4
have lower average expression levels with high expression in testis. However
the PIAS proteins are not functionally redundant, because Pias1 knockout mice
exhibit perinatal lethality, whereas Pias2 and Pias4 knockouts have no obvious
phenotype (Pias3 knockouts have not yet been reported) (Liu et al. , 2004; Santti
et al. , 2005; Wong et al. , 2004). There may be some temporal or spatial speci-
ficity in the interaction of PIASs with FOXPs, and we also do not exclude the
involvement of other kinds of SUMO E3 ligase in the SUMOylation of FOXPs.
The reduced level of SUMOylation of the R553H mutant, and the reduced in-
teraction of the mutant with PIAS proteins, indicate that mutations within the
FOX domain of FOXP2 can interfere with PIAS-mediated SUMOylation. Inter-
estingly, PIAS1-mediated SUMOylation has also been reported for FOXL2 and
FOXA2, which belong to different subfamilies of the FOX transcription factor
family (Belaguli et al. , 2012; Marongiu et al. , 2010). The different subfamilies
of FOX proteins show little similarity outside the FOX domain, raising the pos-
sibility that the FOX domain may act in concert with other subfamily-specific
protein regions to promote SUMOylation of FOX transcription factors. Aetio-
logical mutations have been reported in the FOX domains of several other FOX
transcription factors (Benayoun et al. , 2011), but the effects of these mutations
on protein SUMOylation have not been investigated. We predict that disorder-
related FOX domain mutations would disrupt SUMOylation of other FOX tran-
scription factors, including FOXP1.
Concurrently with the submission of this manuscript, SUMOylation of FOXP2
by SUMO1 and SUMO3 was reported by an independent research group (Mered-
ith et al. , 2015). In agreement with our findings, this report identified K674 as
the major SUMOylation site in FOXP2, and found that the R553H variant dis-
plays reduced SUMOylation. Furthermore, no effect on protein stability or lo-
calization was observed when mutating the SUMOylation site, in line with our
data. Some potential small effects on transcriptional regulation in luciferase
reporter assays were observed, including for SRPX2, using a similar reporter
construct to that employed in our experiments, emphasizing that the effects of
SUMOylation on FOXP2-mediated transcriptional regulation warrant further
investigation, ideally in a more biologically-relevant model, and that the effects
of SUMOylation may be promoter-dependent.
SUMOylation is currently the only confirmed post-translational modification
of FOXP2. A key part of the way SUMOylation affects protein function is through
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interaction with other post-translational modifications, for example by competi-
tion with ubiquitination and acetylation for modification of specific lysine side
chains. Our findings thus emphasize the need to investigate further the post-
translational modifications of FOXP2 in order to understand how the activity
of this transcription factor may be dynamically regulated in the developing and
adult brain.
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Supplementary Table S2.1: Cloning primer sequences
Restriction sites are underlined.
Gene Forward primer Site Reverse primer Site
PIAS1 AAGATCTCGGCGGACAGT
GCGGAACTAAAGC
BglII CGCTAGCTTAGTCCAATGA
AATAATGTCTGGT
NheI
PIAS2 GGATCCTGGCGGATTTCG
AAGAGTTG
BamHI TCTAGATTAGTCCAATGAG
ATGATGTCAGG
XbaI
PIAS3 AGATCTTGGCGGAGCTGG
GCGAATTAAA
BglII TCTAGATCAGTCCAGGGAA
ATGATGTC
XbaI
PIAS4 GGATCCTGGCGGCGGAG
CTGGTG
BamHI TCTAGATCAGCAGGCCGGC
ACCAGGCCCTT
XbaI
SUMO1GGATCCTGTCTGACCAGG
AGGCAAAACCTT
BamHI TCTAGACTAAACTGTTGAAT
GACCCCC
XbaI
SUMO2GGATCCTGGCCGACGAAA
AGCCCAAGGAAG
BamHI TCTAGATTAGTAGACACCT
CCCGTCTG
XbaI
SUMO3GGATCCTCTCCGAGGAGA
AGCCCAAGGAG
BamHI TCTAGACTAGAAACTGTGC
CCTGCCAG
XbaI
UBC9 AGATCTGGAACACCTGTC
CGCTACGCTC
BglII TCTAGATTATGAGGGCGCA
AACTTCTT
XbaI
SRPX2
pro-
moter
GGTACCCTCTGCCTCCTG
GGTTCAAG
KpnI AAGCTTGATGGGGGAGAAG
GAACACA
HindIII
Supplementary Table S2.2: Site-directed mutagenesis primer sequences
Mutant Primer 1 Primer 2
FOXP2
K674R
CATACATTCAATCCACGTC
AGGGAAGAGCCAGTGATTG
CAATCACTGGCTCTTCCCTGA
CGTGGATTGAATGTATG
PIAS1
C350S
ACATTGTAGATGAGAACTT
GTAAGGGCCCGACAC
GTGTCGGGCCCTTACAAGTTC
TCATCTACAATGT
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SUMO1
AA
AGACTAAACTGTTGAATGAGC
CGCCGTTTGTTCCTGATAAAC
GTTTATCAGGAACAAACGGC
GGCTCATTCAACAGTTTAGTCT
SUMO2
AA
TTCTAGATCAGTAGACAGCTGC
CGTCTGCTGTTGGAAC
GTTCCAACAGCAGACGGCAGCT
GTCTACTGATCTAGAA
SUMO3
AA
CTCTCCGGCACAGCTGCCGTCT
GCTGCT
AGCAGCAGACGGCAGCTGTG
CCGGAGAG
Supplementary Table S2.3: Summary of yeast two-hybrid results
DNA was isolated from positive colonies, the cDNAs of the prey constructs were se-
quenced, and BLAST search was used to identify the proteins encoded by positive clones.
Proteins represented by two or more clones are listed.
HGNC symbol Number of preys
PIAS1 7
CHD3 4
FXYD6 4
NREP 3
FKBP1A 2
NRGN 2
Supplementary Table S2.4: Prediction of putative FOXP2 SUMOylation sites
The table lists all the lysine residues in FOXP2 (Uniprot O15409). SUMOylation sites
were predicted using three web-based algorithms: Joined Advanced SUMOylation Site
and SIM Analyser (JASSA,www.jassa.fr), SUMOplot analysis Program (www.abgent.
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com/SUMOplot), and GPS-SUMO (SUMOsp.biocuckoo.org/). JASSA uses a scoring sys-
tem based on a Position Frequency Matrix derived from the alignment of experimental
SUMOylation sites. One of the two sites identified by JASSA corresponds to an inverted
consensus SUMOylation site D/E-X-K-ψ, where ψ = A/F/I/L/M/P/V/W; X = any amino
acid. The second is a standard consensus SUMOylation site in the context of a negatively
charged amino acid-dependent SUMOylation motif (NDSM): ψ-K-X-D/E-X-α, where 2
out of 6 α must be D/E. SUMOplot predicts the probability (0-1) for the major SUMO
canonical consensus sequence ψ-K-X-D/E where ψ =I/L/V. The GPS-SUMO score is
based on 983 SUMOylation sites in 545 proteins collected from the literature.
Residue Sequence context JASSA SUMOplot GPS-
SUMO
K74 LLLQQQTSGLKSPKSSDKQRP 0.80
K77 QQQTSGLKSPKSSDKQRPLQV
K81 SGLKSPKSSDKQRPLQVPVSV
K140 LQQQQLQEFYKKQQEQLHLQL
K141 QQQQLQEFYKKQQEQLHLQLL
K195 QQQQQQQHPGKQAKEQQQQQQ
K198 QQQQHPGKQAKEQQQQQQQQQ
K271 LSPAEIQQLWKEVTGVHSMED
K285 GVHSMEDNGIKHGGLDLTTNN 0.77
K306 SSSTTSSNTSKASPPITHHSI
K349 SHTLYGHGVCKWPGCESICED
K365 SICEDFGQFLKHLNNEHALDD
K397 VVQQLEIQLSKERERLQAMMT
K417 THLHMRPSEPKPSPKPLNLVS High (In-
verted)
K421 MRPSEPKPSPKPLNLVSSVTM
K433 LNLVSSVTMSKNMLETSPQSL
K482 VGAIRRRHSDKYNIPMSSEIA
K499 SEIAPNYEFYKNADVRPPFTY
K549 AYFRRNAATWKNAVRHNLSLH
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K560 NAVRHNLSLHKCFVRVENVKG 0.17
K569 HKCFVRVENVKGAVWTVDEVE
K582 VWTVDEVEYQKRRSQKITGSP
K587 EVEYQKRRSQKITGSPTLVKN
K596 QKITGSPTLVKNIPTSLGYGA
K674 PQPHIHSIHVKEEPVIAEDED High
(NDSM)
0.93 24.943
Supplementary Table S2.5: Prediction of putative FOXP2 SUMO-interacting motifs
(SIMs)
SUMO-interacting motifs (SIMs) were predicted using two web-based algorithms: Joined
Advanced SUMOylation Site and SIM Analyser (JASSA, www.jassa.fr/), and GPS-SUMO
(SUMOsp.biocuckoo.org/). JASSA uses a scoring system based on a Position Frequency
Matrix derived from the alignment of experimental SIMs and the maximum predictive
score is 38. The GPS-SUMO score is based on 151 SIMs in 80 proteins collected from
the literature. In both cases, putative SIMs were only identifiable by using the lowest
possible detection threshold. Potential SIMs are indicated in bold type.
Residues Sequence context JASSA GPS-SUMO
47-50 DTSSEVSTVELLHLQQQQAL 0.275
49-52 SSEVSTVELLHLQQQQALQA 0
63-66 QQALQAARQLLLQQQTSGLK 0
148-151 KKQQEQLHLQLLQQQQQQQQ 0.053
233-236 QQLQQQQHLLSLQRQGLISI 0.018
241-244 LLSLQRQGLISIPPGQAALP 0.097 28.42
423-426 EPKPSPKPLNLVSSVTMSKN 0.01
618-624 QAALAESSLPLLSNPGLINN 0.036
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A S S E S S M E N T O F F OX P 2 - C A N D I DAT E P R O T E I N
I N T E R AC T I O N S I D E N T I F I E D I N P R E V I O U S M A S S
S P E C T R O M E T RY S C R E E N S
Abstract: Heterozygous disruptions in the FOXP2 gene cause a rare speech and lan-
guage disorder characterized by difficulty in coordinating the oral motor sequences
necessary for fluent speech. The FOXP2 gene encodes a transcription factor that is
expressed in a subset of brain structures such as the cortex, striatum and cerebel-
lum, where it regulates aspects of neural development and function. The activity
of transcription factors is dependent on and regulated by multiple protein-protein
interactions. Therefore, determining which co-factors FOXP2 interacts with can pro-
vide insights into the molecular functions of this protein in the context of speech
and language development. Although a number of studies have investigated roles of
FOXP2 in the brain and sought to identify downstream target genes, knowledge re-
garding its protein-protein interactions remains scarce. Prior research in our group
sought to identify FOXP2-interacting proteins by means of immunoprecipitation fol-
lowed by mass spectrometry. In this study, I re-evaluated the dataset from this earlier
screen, selecting two promising candidate FOXP2 interactors, NONO and SFPQ, for
targeted investigation. I aimed to validate these interactions using multiple comple-
mentary methods: bioluminescence resonance energy transfer assay, cobalt-affinity
purification, and mammalian two-hybrid assay. The interaction between FOXP2
and NONO/SFPQ failed to validate using any of these techniques, suggesting that
these proteins are unlikely to be physiological interaction partners. Consequently,
the methodology used in the previous mass spectrometry screen may have been vul-
nerable to false positive results, indicating the need for new screens that search for
FOXP2-interacting proteins.
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3.1 introduction
The transcription factor FOXP2 was the first gene to be conclusively linked
with speech and language development (Lai et al. , 2001). In particular, a het-
erozygous etiological mutation in this gene was identified in a large, multi-
generational family (the KE family) in which half of the members suffered from
childhood apraxia of speech (CAS), a disorder characterized by difficulties coor-
dinating the precise oral motor sequences required for speech production. This
mutation yields a substitution in the DNA-binding domain of the FOXP2 pro-
tein and abolishes its ability to bind its usual target sequences and regulate
gene expression (Stroud et al. , 2006; Vernes et al. , 2006). Since then, a number
of other alterations affecting the gene have been found in individuals with sim-
ilar speech and language deficits (Laffin et al. , 2012; MacDermot et al. , 2005;
Reuter et al. , 2016; Turner et al. , 2013), firmly establishing FOXP2 as a critical
genetic factor underlying language development and function.
FOXP2 belongs to the FOXP family of transcription factors, which also in-
cludes FOXP1, FOXP3 and FOXP4. FOXP2, FOXP1 and FOXP4 are expressed
in the brain where they play overlapping but distinct roles in its development
(Bowers & Konopka, 2012a; Shu et al. , 2001). These three proteins share the
same domain organization: a glutamine-rich region, a zinc finger domain, a
leucine zipper and a forkhead DNA-binding domain. FOXP3 is divergent from
the other FOXPs in sequence and structure, and its expression is restricted to the
immune system (Fontenot et al. , 2003). FOXP2 DNA-binding sites and target
genes have been characterized in several studies, which show that FOXP2 regu-
lates genes implicated in neuronal processes such as synaptic plasticity and neu-
rite outgrowth (Spiteri et al. , 2007; Vernes et al. , 2011, 2007). In contrast, knowl-
edge of FOXP2 protein interactions remains scarce. In order to regulate gene
expression, transcription factors need to physically interact with transcription-
related proteins, such as chromatin remodelling enzymes or other transcription
factors (Smith & Matthews, 2016). Protein-protein interactions regulate numer-
ous aspects of a transcription factor function, such as DNA-binding affinity
and specificity, transcriptional activation/repression activity, subcellular local-
ization, and protein turnover.
FOXP2 forms homo-dimers and also hetero-dimerizes with FOXP1 and FOXP4
through the leucine zipper domain (Li et al. , 2004). This dimerization is essen-
tial for transcriptional regulatory activity, and heterodimerization among FOXP
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proteins may generate a repertoire of dimers with different DNA-binding speci-
ficities (Sin et al. , 2015).
A small number of other proteins have also been reported to interact with
FOXP2, including the transcriptional co-repressors CTBP1, CTBP2 and GATAD2B
(Chokas et al. , 2010; Estruch et al. , 2016a). Large-scale yeast two-hybrid (Y2H)
screens have provided only a small number of candidate FOXP2 interactors
(Corominas et al. , 2014; Rolland et al. , 2014; Sakai et al. , 2011). Most of
the candidates identified in these screens have not been confirmed, but pre-
vious studies from our group have successfully validated and further inves-
tigated two of these proteins, namely, the transcription factor TBR1 and the
post-translational modification enzyme PIAS1 (Estruch et al. , 2016b; Derizi-
otis et al. , 2014a). Rare mutations in TBR1 cause autism spectrum disorder
(ASD) together with language deficits (Deriziotis et al. , 2014a). Strikingly, in
cellular assays the interaction between FOXP2 and TBR1 could be disrupted by
known mutations in either transcription factor, suggesting a shared molecular
etiology for distinct neurodevelopmental disorders that include language im-
pairment (Deriziotis et al. , 2014a). As described in Chapter 2, investigations of
the interaction between FOXP2 and PIAS1 led to the discovery that FOXP2 is
SUMOylated (Estruch et al. , 2016b). Evidence of FOXP2 SUMOylation has also
been found in two independent studies which additionally suggested that this
post-translational modification is involved in regulating FOXP2 activity in the
cerebellum, where it may help modulate motor function and vocal communi-
cation (Meredith et al. , 2015; Usui et al. , 2016). These studies represent clear
examples of how identifying and understanding FOXP2 physical interactions
with other proteins can reveal valuable knowledge about the transcription fac-
tor and its roles in brain development.
Further characterizing the FOXP2 interactome is critical to fully comprehend
its molecular functions. In this chapter I aimed to expand the known FOXP2
interactome by validating putative binding partners suggested by mass spec-
trometry analysis of immunoprecipitated FOXP2 complexes in a previous un-
published investigation by our group. From this dataset I selected the transcrip-
tional regulators SFPQ and NONO as promising candidates, and attempted to
validate their interaction with FOXP2 using a range of complementary protein-
protein interaction techniques. The results consistently demonstrate a lack of in-
teraction between FOXP2 and NONO/SFPQ with all methods employed, which
suggests that these proteins are not physiological interaction partners. I con-
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clude that the experimental and/or analytical methods used in the previous
mass spectrometry study to create a list of candidate FOXP2-interacting pro-
teins were likely suboptimal and vulnerable to false positives. This chapter
thus highlights the need for fresh mass spectrometry screens using improved
methodology to deliver further insights into the FOXP2 interactome.
3.2 material and methods
DNA constructs
The cloning of human FOXP2 (NM_014491) has been described previously (Es-
truch et al., 2016b). The coding sequences of NONO (NM_007363) and SFPQ
(NM_005066) were amplified from human foetal brain cDNA using the primers
listed in Table 1 and then cloned into pCR2.1-TOPO (Invitrogen). For expres-
sion of fusion proteins with Renilla luciferase, yellow fluorescent protein (YFP),
mCherry, HisV5 and myc tags, the coding sequences of FOXP2, NONO and
SFPQ were subcloned into the pLuc, pYFP, pmCherry, pHisV5 and pMyc ex-
pression vectors, respectively, which have been described previously (Estruch
et al. , 2016b).
Table 3.1: Cloning primers for NONO and SFPQ.
∗ BclI generates sticky ends that are complementary to BamHI.
Forward primer Reverse primer Restriction sites
NONO AGGATCCAGAGTA
ATAAAACTTTTAA
CTTGG
CTCTAGATTAGTATCG
GCGACGTTTGTTTGGG
BamHI + XbaI
SFPQ GATGATCAGCTCTCG
GGATCGGTTCCG
GAGTC
CGCTAGCCTAAAAT
CGGGGTTTTTTGT
TTGGG
BclI* + XbaI
For the mammalian two-hybrid assay, modified versions of the vectors pBIND
and pACT (Promega) were created. The pBIND and pACT vectors contain the
yeast GAL4 DNA-binding domain and the herpes simplex virus VP16 activa-
tion domain, respectively, upstream of a multiple cloning region. The Renilla lu-
ciferase gene was removed from pBIND, together with its promoter and polyA
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signal, by excising a ClaI fragment and religating the backbone, creating the
modified construct pBIND2 (Supplementary Figure S2.1). The construct pACT2
was generated by inserting the functional region of the original pACT vector
into the pBIND2 backbone using the NdeI and XbaI sites (Supplementary Fig-
ure S2.2). The cDNAs of FOXP2, NONO and SFPQ were subcloned into the
pBIND2 and pACT2 vectors using the BamHI and XbaI sites. A firefly luciferase
reporter vector for the mammalian two-hybrid assay (pGL4-luc2-GAL4UAS-
AP) was engineered by inserting a KpnI-NcoI fragment of pGL5 (Promega),
containing the yeast GAL4 upstream activating sequence (GAL4UAS) directly
upstream of the adenovirus major late promoter, into the backbone of pGL4.23
(Promega), replacing the minimal promoter in this vector (Supplementary Fig-
ure S2.3). A negative control reporter vector, which lacks the GAL4UAS (pGL4-
luc2-AP) was engineered by inserting a NheI-AgeI fragment of pGL4-luc2-GAL4UAS-
AP, containing the adenovirus promoter and partial luciferase coding sequence,
into pGL4.23 (Promega) (Supplementary Figure S2.4). All constructs were veri-
fied by Sanger sequencing.
Cell culture and transfection
HEK293 cells were obtained from ECACC (cat. no. 85120602) and cultured in
DMEM supplemented with 10% foetal bovine serum. Transfections were per-
formed using GeneJuice (Merck-Millipore) according to the manufacturer?s in-
structions.
BRET assay
BRET assays were performed as described (Deriziotis et al., 2014a). Briefly, HEK293
cells were transfected in 96-well plates with plasmids encoding YFP- and luci-
ferase-fusion proteins. After 36-48 h, Enduren live cell luciferase substrate (Promega)
was added at a final concentration of 60 µ M. Cells were cultured for a further
4 h, and emission readings (integrated over 10 s) were taken using a TECAN
F200PRO microplate reader using the Blue1 and Green1 filter sets. Expression
levels of the YFP-fusion proteins were measured by taking fluorescence inten-
sity readings using the filter set and dichroic mirror suitable for green fluores-
cent protein (excitation 480 nm, emission 535 nm). The corrected BRET ratio
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was calculated with the following formula: [Green1(experimental condition)/Blue1(expe-
rimental condition)]-[Green1(control condition)/Blue1(control condition)]. The control condi-
tions used luciferase or YFP fused to a C-terminal nuclear localization signal.
Fluorescence microscopy
HEK293 cells were seeded on coverslips coated with poly-L-lysine. Cells were
cultured for 30 h post-transfection, and then fixed with 4% paraformaldehyde.
Nuclei were stained with Hoechst 33342. Fluorescence images were acquired
using an Axiovert A-1 fluorescent microscope with ZEN Image software (Zeiss).
Pull-down assays
Cells were cultured in 6-well plates and transfected with HisV5-tagged FOXP2,
NONO, or SFPQ, or empty pHisV5 vector, together with myc-tagged FOXP2,
NONO, or SFPQ, or pMyc vector. After 48 h cells were lysed in 25 mM sodium
phosphate pH 8.0, 250 mM NaCl, 1% Triton X-100, 20 mM imidazole, 1% v/v
PMSF and 0.5% v/v EDTA-free protease inhibitor cocktail set III (Sigma-Aldrich).
An aliquot of the lysate (10% ) was retained as the input sample and the remain-
der was incubated with His-tag Dynabeads (Life Technologies) overnight at 4◦
C with rotation. Beads were washed with 25 mM sodium phosphate pH 8.0, 250
mM NaCl, 0.1% Triton X-100, 20 mM imidazole. His-V5-tagged proteins were
eluted in 25 mM sodium phosphate pH 8.0, 250 mM NaCl, 0,1% Triton X-100,
400 mM imidazole. Proteins were resolved on 10% SDS-polyacrylamide gels
and transferred to PVDF membranes using a TransBlot Turbo Blotting appara-
tus (Bio-Rad). Membranes were blocked in PBS containing 5% milk and 0.1%
Tween-20, and were then incubated overnight at 4◦ C with primary antibody in
PBS containing 5% milk. The following antibodies were used: anti-V5 tag (Gene-
tex cat. no. GTX42525, 1:3000); anti-Myc tag (Abcam cat. no. ab9106, 1:1000).
After washing, membranes were incubated with horseradish peroxidase-conju-
gated goat anti-mouse or anti-rabbit IgG for 45 min at room temperature. Pro-
teins were visualized using Novex ECL Chemiluminescent Substrate Reagent
Kit (Life Technologies) and a ChemiDoc XRS+ imaging system (Bio-Rad).
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Mammalian two-hybrid assay
Protein interactions were assayed using the CheckMate Mammalian Two-Hybrid
System (Promega). In brief, HEK293T cells were seeded in clear-bottomed white
96-well plates and cultured for 24 h. Cells were transfected in triplicate with an
equimolar mixture of pACT2 and pBIND2 constructs (5 mol each per well), to-
gether with the firefly luciferase reporter construct pGL4-luc2-GAL4UAS-AP or
the negative control reporter pGL4-luc2-AP (5 fmol), and the pGL4.74 Renilla
luciferase normalization control (2 fmol). The total mass of transfected DNA
was adjusted to 6 ng with filler plasmid. After 48 h, cells were lysed with pas-
sive lysis buffer and firefly and Renilla luciferase activities were measured using
the Dual Luciferase Reporter Assay System (Promega) with a TECAN F200PRO
microplate reader. In order to correct for variation in transfection efficiency,
each firefly luciferase activity value was normalized to the respective Renilla
luciferase activity value.
3.3 results
3.3.1 Evaluation of candidate FOXP2-interacting proteins
As part of previous work in our group to identify potential interacting pro-
teins, FOXP2 protein complexes immunoprecipitated using a FOXP2-specific
antibody were analysed by mass spectrometry (Elahi, 2008). FOXP2 protein
complexes were purified from four different sources: (1) SH-SY5Y (human neu-
roblastoma) cells stably expressing wild-type FOXP2; (2) SH-SY5Y cells stably
expressing FOXP2.pR553H, the variant found in the KE family; (3) HEK293
cells, which endogenously express FOXP2; and (4) embryonic mouse brain at
day E16.5, a time point of high Foxp2 expression. The proteins identified in the
immunoprecipitated complexes are summarized in Table 3.2.
To prioritize potential FOXP2-interacting proteins, I first excluded previously
reported FOXP2 interactors (i.e. FOXP1, FOXP2 and FOXP4) and probable non-
specific interactors (histones, ribosomal subunits). I then selected proteins that
(1) are localized to the cell nucleus, (2) are expressed in the brain, and (3) were
identified in two or more experiments. This filtering process resulted in a short-
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list of 6 putative FOXP2 interactors: FOXR1, NCOR1, NONO, PRKRIR, SBF1
and SFPQ.
Table 3.2: Candidate FOXP2-interacting proteins previously suggested by
immunoprecipitation and mass spectrometry.
Immunoprecipitation was performed on 4 different sources: SH-SY5Y cell line stably
expressing wild-type FOXP2 (a); SH-SY5Y cell line stably expressing FOXP2.pR533H
(b); HEK293 cells (c); and mouse brain at embryonic day E16.5 (d). Proteins identified
with p<0.05 are indicated with an "X". Italicized words highlight biological information
suggesting that the interaction is not physiologically relevant.
Gene
name
a b c d Description Expression
Tissue Cell compart-
ment
ACTB X Beta-actin Ubiquitous Cytoplasm
ACTL6B X Chromatin remodeller Brain Nucleus
ARMC3 X Beta-catenin-like protein Ubiquitous
BPTF X Nucleosome-remodelling factor Ubiquitous Cytoplasm/
nucleus
CRB1 X Calcium receptor Brain Membrane/ se-
creted
CTSD X Protease Brain Secreted
EEF1A2 X Protein elongation factor Brain Nucleus
EGF X Growth factor Brain Membrane
EIF4B X X Protein translation initiation factor Ubiquitous Cytoplasm
FN1 X Extracellular matrix Ubiquitous Secreted
FOXP1 X Transcription factor Brain Nucleus
FOXP2 X X Transcription factor Brain Nucleus
FOXP4 X Transcription factor Brain Nucleus
FOXR1 X X Transcription factor Brain Nucleus
GABRA3 X GABA receptor subunit Brain Membrane
GFAP X Intermediate filament Brain Cytoplasm
GRIN3A X Glutamate receptor ionotropic Brain Membrane
H2AZ X X Histone Ubiquitous Nucleus
HIST1H2AB X Histone Ubiquitous Nucleus
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HIST1H2AG X Histone Ubiquitous Nucleus
HIST1H2BK X Histone Ubiquitous Nucleus
HIST1H3A X Histone Ubiquitous Nucleus
HIST1H4A X Histone Ubiquitous Nucleus
HIST2H2BF X X Histone Ubiquitous Nucleus
HNRPK X Ribonucleoprotein Brain Cytoplasm/
nucleus
HNRPL X Ribonucleoprotein Brain Cytoplasm/
nucleus
HSP90AA1 X Chaperone Ubiquitous Cytoplasm
HSP90AB1 X Chaperone Ubiquitous Cytoplasm
IFIH1 X Helicase Ubiquitous Cytoplasm/
nucleus
KIF21A X Microtubule-binding motor pro-
tein
Ubiquitous Cytoplasm
LRSAM1 X X E3 ubiquitin-protein ligase Spinal cord Cytoplasm
NACA X Protein translation complex sub-
unit
Ubiquitous Cytoplasm
NCOR1 X X Trancriptional co-repressor Ubiquitous Nucleus
NEB X Structural protein Muscle Cytoplasm
NONO X X DNA- and RNA binding protein Brain Nucleus
NPM1 X Nucleolar phosphoprotein Ubiquitous Cytoplasm/
nucleus
PKM X Pyruvate kinase isozyme Proliferating
cells
Cytoplasm/
nucleus
RNF149 X E3 ubiquitin-protein ligase Brain Membrane
RPL10 X Large ribosomal subunit Ubiquitous Cytoplasm
RPL6 X X Large ribosomal subunit Ubiquitous Cytoplasm
RPL7 X Large ribosomal subunit Ubiquitous Cytoplasm
RPL9 X Large ribosomal subunit Ubiquitous Cytoplasm
RPS3 X Large ribosomal subunit Ubiquitous Cytoplasm
RPS4X X Large ribosomal subunit Ubiquitous Cytoplasm
RPS6 X Large ribosomal subunit Ubiquitous Cytoplasm
SBF1 X X Pseudophosphatase Ubiquitous Nucleus
SERPINB7 X Inhibitor of lys-specific proteases Ubiquitous Cytoplasm
SFPQ X X DNA- and RNA binding protein Ubiquitous Nucleus
SHROOM3 X Structural protein Brain Cytoplasm
SYNCRIP X Ribonucleoprotein Ubiquitous Cytoplasm/
nucleus
THAP12 X X Kinase modulator Ubiquitous Nucleus
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TMEFF1 X Egf-like domains containing pro-
tein
Brain Membrane
TRIM21 X X E3 ubiquitin-protein ligase Heart and
lung
Cytoplasm/
nucleus
VIM X X Class-iii intermediate filaments Fibroblasts Cytoplasm
WNT7A X Frizzled receptor ligand Brain Secreted
WWP2 X E3 ubiquitin-protein ligase Brain Nucleus
From this list, NONO and SFPQ were chosen as a primary focus because
they are transcription factors, and are also known to interact with each other
(Fox et al., 2005), which is consistent with both proteins being pulled-down in
the same protein complexes. NONO and SFPQ, together with a third protein,
PSPC1, form the Drosophila behaviour/human splicing (DBHS) protein family
(Knott et al. , 2016). DBHS proteins form homo- and heterodimers (Fox et al. ,
2005) and have roles in transcriptional activation and repression, splicing, pre-
mRNA processing and RNA transport (Amelio et al. , 2007; Dong et al. , 2007;
Izumi et al. , 2014; Kanai et al. , 2004; Kaneko et al. , 2007; Kim et al. , 2011;
Park et al. , 2013).Although NONO and SFPQ are expressed in the brain, little
is known regarding their roles in neural processes. NONO is implicated in the
regulation of the circadian clock function, acting as a transcriptional cofactor
of PER proteins (Kowalska et al. , 2012, 2013) and SFPQ is involved in the ac-
tivation of neural-specific alternative splicing (Kim et al. , 2011). NONO and
SFPQ therefore represented particularly interesting candidates for interaction
with FOXP2.
3.3.2 Bioluminescence Resonance Energy Transfer assay
To try to confirm the interaction between FOXP2 and NONO/SFPQ, I first used
the Bioluminescence Resonance Energy Transfer (BRET) assay, a method which
allows the monitoring of protein-protein interactions in living cells, and which
has been used successfully in prior studies of FOXP2 (Deriziotis et al. , 2014b).
To test for an interaction between two proteins using the BRET assay, the two
proteins of interest are expressed as fusion proteins in cultured cells: one pro-
tein (the donor) is fused to Renilla luciferase (RLuc), and the second (the ac-
ceptor) is fused to yellow fluorescent protein (YFP). An interaction between the
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Figure 3.1: BRET assay for testing interaction between FOXP2 and NONO/SFPQ.
(a) HEK293 cells were transfected with FOXP2 fused to Renilla luciferase, and FOXP2,
NONO or SFPQ fused to YFP. (b) HEK293 cells were transfected with NONO fused to
Renilla luciferase, and FOXP2, NONO and SFPQ fused to YFP. (c) HEK293 cells were
transfected with SFPQ fused to Renilla luciferase, and FOXP2, NONO and SFPQ fused
to YFP. Values are mean corrected BRET ratio± SEM (n = 3).
two proteins may bring the RLuc and YFP moieties in sufficient proximity to
allow resonance energy transfer to occur from RLuc to YFP when a luciferase
substrate is supplied, which leads to a shift in the wavelength of the emitted
light (the BRET signal).
When RLuc-FOXP2 (donor) was co-expressed with YFP-NONO or YFP-SFPQ
(acceptor), there was no increase in the BRET signal compared with the control
(Figure 3.1a). Similar results were obtained when the assay was performed with
FOXP2 as the acceptor and NONO or SFPQ as the donor (Figure 3.1b,c). In con-
trast, both the homodimerization of FOXP2 and the interaction between NONO
and SFPQ were efficiently detected (Figure 3.1), confirming the suitability of
the assay to detect protein-protein interactions involving these transcription
factors. The results of the BRET assay therefore do not support the existence of
an interaction between FOXP2 and NONO/SFPQ.
In parallel to the BRET experiments, the subcellular localization of the FOXP2,
NONO and SFPQ proteins was examined by transfecting cells with fusions of
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these proteins to the fluorescent proteins YFP and mCherry. FOXP2, NONO
and SFPQ all localize to the cell nucleus (Figure 3.2a), confirming that the lack
of interaction between these proteins in the BRET assay is not due to mislo-
calization of one or more proteins. FOXP2 presents a diffuse distribution in
the nucleus, whereas NONO and SFPQ exhibit a speckled pattern, as reported
in previous studies (Fox et al. , 2005; Shav-Tal & Zipori, 2002) (Figure 3.2a).
Co-transfections of YFP-tagged SFPQ/NONO and mCherry-tagged FOXP2 sug-
gest that FOXP2 is not incorporated into the SFPQ/NONO-containing nuclear
substructures (Figure 3.2b), consistent with a lack of interaction between these
proteins.
3.3.3 Pull-down assay
The BRET assay is a sensitive and versatile technique for detecting protein-
protein interactions because it can detect weak and transient interactions, and
it is applied to proteins in their native environment within living cells. However
for some pairs of interacting proteins, the BRET assay may give a false negative
result because the luciferase and YFP moieties are not sufficiently close, or not
appropriately oriented, to allow resonance energy transfer to occur. Because the
putative interaction between FOXP2 and NONO/SFPQ was initially detected
by immunoprecipitation, I next attempted to confirm the interaction using a
pull-down assay. Cells were transiently transfected with a bait protein carry-
ing an N-terminal hexahistidine and V5 epitope (HisV5) tag, and a prey pro-
tein carrying an N-terminal Myc epitope tag. Bait-containing complexes were
pulled down from cell lysates using magnetic beads coated with cobalt, which
has a high affinity for histidine. The bait and prey proteins were detected by im-
munoblotting. The His-tag/cobalt pull-down system offers an advantage over
co-immunoprecipitation strategies because the latter require an antibody with
high affinity and specificity for the protein of interest, as well as optimization
of binding and elution conditions for each antibody-antigen pair.
In cells co-transfected with HisV5-FOXP2 and Myc-FOXP2, Myc-tagged FOXP2
was detected in the affinity-purified (elution) fraction, demonstrating the ef-
ficacy of the pull-down (Fig. 3a). However, HisV5-FOXP2 did not pull down
Myc-tagged SFPQ, suggesting that SFPQ does not interact with FOXP2 in these
cells (Figure 3.3a). In cells transfected with HisV5-tagged FOXP2, NONO, or
empty vector together with Myc-FOXP2, an enrichment of Myc-FOXP2 in the
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Figure 3.2: Co-localization of FOXP2 with NONO and SFPQ in HEK293 cells. (a-c)
Fluorescence micrographs of cells transfected with FOXP2 fused to mCherry (a), NONO
fused to YFP (b) and SFPQ fused to YFP (c). (d) Fluorescence micrographs of cells trans-
fected with FOXP2 fused to mCherry (red) and NONO or SFPQ fused to YFP (green).
Nuclei were stained with Hoechst 33342 (blue). Scale bars represent 10 µm.
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Figure 3.3: Cobalt-affinity pull-down assay for interaction between FOXP2 and
NONO/SFPQ. (a) Pull- down assay to test for interaction of FOXP2 with SFPQ. HEK293
cells were transfected with HisV5- tagged FOXP2 (bait) or empty vector together with
myc-SFPQ or myc-FOXP2 (prey). His-tagged species were isolated using cobalt affinity
purification. Western blots of total lysate (input) and affinity-purified material (elution)
were probed with anti-V5 tag antibody to visualize FOXP2 (top panels). Myc-SFPQ and
myc-FOXP2 were visualized using anti-myc antibody (bottom panels). (b) Pull-down
assay to test for interaction of FOXP2 with NONO. HEK293 cells were transfected with
HisV5-tagged FOXP2, NONO or empty vector (baits) together with myc-FOXP2 (prey).
His-tagged species were isolated using cobalt affinity purification. Western blots of to-
tal lysate (input) and affinity-purified material (elution) were probed with anti-V5 tag
antibody to visualize NONO and FOXP2 (top panels). Myc-FOXP2 and myc-FOXP2 was
visualized using anti-myc antibody (bottom panels).
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eluted material was observed only when HisV5-FOXP2 was used as the bait
(Figure 3.3b). No enrichment of Myc-FOXP2 compared to the control condition
was observed when HisV5-NONO was used as the bait, suggesting that the pres-
ence of FOXP2 in the affinity-purified fraction was due to non-specific binding
(Figure 3.3b). Thus, the pull-down assay also fails to support the existence of
an interaction between FOXP2 and NONO/SFPQ.
3.3.4 Mammalian Two-Hybrid assay
Affinity purification can be a reliable technique for detecting protein-protein
interactions. However the appropriate experimental conditions must be identi-
fied for each specific pair of proteins, because it is critical that the interaction of
interest is preserved after the cells have been lysed. Excessively stringent wash-
ing steps can result in the loss of specific interactors. Conversely, non-specific
binding of the prey protein to the affinity matrix can result in contamination
of the eluted material if binding conditions or washing steps are not strin-
gent enough. In some cases it may not be possible to achieve ideal balance of
conditions that retain specific interactions while eliminating non-specific ones.
Therefore, I employed a third technique, the mammalian two-hybrid (M2H) as-
say, to assess the putative interaction of FOXP2 with NONO and SFPQ.
In the M2H assay, bait and prey proteins are fused to a GAL4 DNA-binding
domain (encoded by the pBIND2 vector) and a VP16 transcriptional activation
domain (encoded by the pACT2 vector), respectively. Cells are transfected with
the two vectors coding for the fusion proteins, together with a reporter vector
that contains tandem GAL4 DNA binding sites upstream of a basic promoter
and the firefly luciferase gene. An interaction between the bait and prey pro-
teins physically connects the GAL4 and VP16 domains, creating a functional
transcriptional activator that will drive transcription of the reporter firefly lu-
ciferase gene (Figure 3.4a, Supplementary Figure S2.5). The sensitivity with
which luciferase activity can be detected makes the M2H assay potentially able
to pick up weak and transient interactions. In addition, the interaction is not
detected in real time, as in the case of the BRET assay; rather it is captured
over a longer period in the expression of the luciferase protein, which may also
increase sensitivity. The M2H assay must however be used with caution when
investigating protein-protein interactions of transcription factors. For example,
when fused to the GAL4 DNA-binding domain, a transcription factor may acti-
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vate transcription in the absence of any interaction with the VP16 transactiva-
tion domain fusion protein, leading to a high background signal that can make
the results challenging to interpret.
I first verified that the M2H assay was effective, by using the known interaction
between the proteins Id and MyoD as a positive control, and empty bait/prey
vectors as a negative control (Finkel et al. , 1993). A reporter vector that lacks
the GAL4 binding sites served as an additional negative control. These exper-
iments confirmed that an increase in luciferase activity occurred only when
both the MyoD and Id fusion proteins, and the reporter construct containing
the GAL4 binding sites, were present (Figure 3.4b).
No interaction was observed between FOXP2 and NONO/SFPQ, when FOXP2
was expressed as the bait protein and NONO/SFPQ as the prey (Figure 3.4c).
The assay could not be performed in the reverse configuration, with FOXP2 as
the prey, because FOXP2 activated luciferase transcription when fused to the
VP16 activation domain, suggesting that the reporter plasmid contains binding
sites for FOXP2 (data not shown). In contrast, the interaction between SFPQ
and NONO was readily detected (Figure 3.4d) (Fox et al. , 2005; Knott et al. ,
2016). Thus, the mammalian two-hybrid assay also provides little support for
the existence of an interaction between FOXP2 and NONO/SFPQ.
3.4 discussion
In the work described in this chapter I sought to define novel FOXP2-interacting
proteins by evaluating an existing dataset of putative interactors generated by
a previous mass spectrometry screen. The most promising of these putative
FOXP2 interactors, NONO and SFPQ, were selected for in-depth follow-up.
However, the interaction between FOXP2 and SFPQ/NONO consistently failed
to validate, whether using BRET assays, pull-down methods or a mammalian
two-hybrid system. The use of these three complementary methodologies, each
of which optimally detects protein-protein interactions with different character-
istics, reduces the probability that the lack of interaction observed in our vali-
dations is a false negative result. Moreover, these assays were able to detect the
known interactions of the proteins under investigation, such as the homodimer-
ization of FOXP2 and the heterodimerization of NONO and SFPQ, indicating
that the methods used are suitable for detecting interactions of these transcrip-
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Figure 3.4: Mammalian two-hybrid assay for interaction of FOXP2 with NONO/SFPQ
(a) Schematic representation of the mammalian two-hybrid assay. Cells are transfected
with plasmids coding for Proteins “X” and “Y” fused to the GAL4 DNA binding DNA
binding domain (pBIND2 vector) and to the VP16 transcriptional domain (pACT2 vec-
tor), respectively; and a reporter vector that contains GAL4 DNA binding sites upstream
of the firefly luciferase gene. An interaction between proteins “X” and “Y” physically
connects the GAL4 DNA-binding domain and the VP16 transactivation domain, recon-
structing a functional transcriptional factor that will activate expression of the firefly lu-
ciferase reporter gene.(b) Validation of the mammalian two-hybrid assay. HEK293 cells
were transfected with pBIND2-MyoD or empty pBIND2; pACT2-ID or empty pACT2;
the GAL4UAS firefly reporter plasmid or a control reporter lacking the GAL4UAS bind-
ing sites; and a normalizer vector that expresses Renilla luciferase. c M2H assay for
FOXP2 interaction with NONO and SFPQ. HEK293 cells were transfected with pBIND2-
FOXP2; pACT2-NONO, pACT2-SFPQ or empty pACT2; the GAL4UAS firefly reporter
plasmid; and a normalizer vector that expresses Renilla luciferase. d M2H assay for the
interaction between NONO and SFPQ. HEK293 cells were transfected with pBIND2-
NONO or empty pBIND2; pACT2-SFPQ or empty pACT2; the GAL4UAS firefly reporter;
and a normalizer vector that expresses Renilla luciferase. In (b)-(d), values are mean rel-
ative luciferase activity ± S.E.M. (n = 3)
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tion factors. FOXP2 and SFPQ/NONO also showed different patterns of local-
ization within the nucleus, which is not suggestive of a functional interaction.
It is therefore likely that NONO and SFPQ were false positive results in the
mass spectrometry experiments carried out previously. The immunoprecipi-
tation that was performed to isolate FOXP2-containing protein complexes in
these experiments may not have been effective due to the sub-optimal affinity
and specificity of the antibody used, or due to the composition of the lysis and
wash buffers. Of note, the band representing FOXP2 in the Coomassie-stained
polyacrylamide gels of precipitated proteins was not stronger following pull-
down with anti-FOXP2 compared to the control condition, casting doubt on the
efficiency of the pull-down (Elahi, 2008). In those prior experiments, FOXP2 it-
self was not identified in the mass spectrometry analysis of FOXP2-affinity pu-
rifications from HEK293 cells or mouse brain tissue, indicating inefficient pre-
cipitation in these samples. In addition, the known FOXP2 interactors FOXP1
and FOXP4, which would be expected to strongly co-precipitate with FOXP2
in all the conditions, were only identified in one condition (SH-SY5Y cells over-
expressing wild-type FOXP2) (Table 3.2). There were also insufficient replicates
included for each protein source to test the reproducibility of the results (Elahi,
2008).
The selection of NONO and SFPQ as putative FOXP2 interactors to further
investigate was based on multiple factors, including their biological function,
since both proteins are neural transcription factors and they are already known
to interact with one another (Fox et al. , 2005; Knott et al. , 2016), and the relative
strength of the data, since both proteins had been detected in experiments using
two different cell lines (Table 3.2). Following completion of the work described
in this chapter, mutations in NONO were reported to lead to neurodevelopmen-
tal disorders including intellectual disability, confirming the importance of this
transcription factor in brain development (Mircsof et al. , 2015; Reinstein et al.
, 2016). However, the phenotype associated with NONO mutations is not es-
pecially similar to that caused by FOXP2 haploinsufficiency. Because NONO
and SFPQ were among the most biologically-plausible and highest-confidence
candidates from the previous mass spectrometry effort, it appears unlikely that
other candidates identified in this screen would prove to be true FOXP2 interac-
tors upon further investigation. Thus, this chapter highlights the need for fresh
mass spectrometry-based screens to identify further candidate FOXP2 interac-
tors. Optimization of the pull-down methodology and data analysis pipeline,
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together with use of adequate replicates, represent important factors for im-
proving the sensitivity and specificity of such a screen.
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3.5 supplementary material
Supplementary Figure S3.1. Cloning strategy to generate M2H plasmid pBIND2.
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Supplementary Figure S3.2. Cloning strategy to generate M2H plasmid pACT2.
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Supplementary Figure S3.3. Cloning strategy to generate M2H plasmid
pGL4-luc2-GAL4UAS-AP.
Upstream 
Polyadenylation Signal 
and Transcription 
Pause site 
SV40 Late 
Polyadenilation 
signal 
GAL4 binding sites 
luc+ 
pG5luc 
Ampicillin  
resistance 
KpnI 
NcoI 
MCR 
SV40 Late 
Polyadenilation 
signal 
minimal 
Promoter 
luc2 
pGL4.23 
Ampicillin  
resistance 
KpnI 
NcoI 
GAL4 binding sites 
SV40 Late 
Polyadenil
ation signal 
luc2 
Ampicillin  
resistance 
MCR 
SV40 Late 
Polyadenilation 
signal 
GAL4 binding 
sites 
luc2 
pGL4-luc2-GAL4UAS-AP 
Ampicillin  
resistance 
Digestion with KpnI and NcoI Digestion with KpnI and NcoI 
Ligation 
3supplementary material 107
Supplementary Figure S3.4. Cloning strategy to generate M2H plasmid
pGL4-luc2-AP.
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Supplementary Figure S3.5. Diagram of the plasmids used in the M2H assay.
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P R O T E O M I C A N A LY S I S O F F OX P P R O T E I N S R E V E A L S
I N T E R AC T I O N S B E T W E E N C O R T I C A L T R A N S C R I P T I O N
FAC T O R S A S S O C I AT E D W I T H N E U R O D E V E L O P M E N TA L
D I S O R D E R S 1
Abstract: FOXP transcription factors play important roles in neurodevelopment,
but little is known about how their transcriptional activity is regulated. FOXP pro-
teins cooperatively regulate gene expression by forming homo- and hetero-dimers
with each other. Physical associations with other transcription factors might also
modulate the functions of FOXP proteins. However, few FOXP-interacting transcrip-
tion factors have been identified so far. Therefore, we sought to discover additional
transcription factors that interact with the brain-expressed FOXP proteins, FOXP1,
FOXP2 and FOXP4, through affinity-purifications of protein complexes followed by
mass spectrometry. We identified seven novel FOXP-interacting transcription factors
(NR2F1, NR2F2, SATB1, SATB2, SOX5, YY1 and ZMYM2), five of which have
well-established roles in cortical development. Accordingly, we found that these tran-
scription factors are co-expressed with FoxP2 in the deep layers of the cerebral cortex
and also in the Purkinje cells of the cerebellum, suggesting that they may cooperate
with the FoxPs to regulate neural gene expression in vivo. Moreover, we demonstrated
that etiological mutations of FOXP1 and FOXP2, known to cause neurodevelopmen-
tal disorders, severely disrupted the interactions with FOXP-interacting transcrip-
tion factors. Additionally, we pinpointed specific regions within FOXP2 sequence
involved in mediating these interactions. Thus, by expanding the FOXP interactome
we have uncovered part of a broader neural transcription factor network involved
in cortical development, providing novel molecular insights into the transcriptional
architecture underlying brain development and neurodevelopmental disorders.
1 This chapter has been published as: Estruch S.B., Quevedo-Calero M., Graham S.A., Vino A., Sollis
E., Deriziotis P., Fisher S.E. (2018). Proteomic analysis of FOXP proteins reveals interactions be-
tween cortical transcription factors associated with neurodevelopmental disorders. Human Molec-
ular Genetics. doi:10.1093/hmg/ddy035.
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4.1 introduction
Transcription factors have emerged as a key class of genes disrupted in mono-
genic forms of neurodevelopmental disorders such as intellectual disability (ID)
and autism spectrum disorder (ASD), consistent with the precise temporal and
spatial control of gene expression that underpins neurodevelopmental processes
(Silbereis et al. , 2016). Large-scale next-generation DNA sequencing studies
have been particularly successful in identifying monogenic ID/ASD-related dis-
orders caused by high-penetrance de novo mutations in transcription factor
genes (De Rubeis et al. , 2014; Kwan, 2013; Peter et al. , 2014).
Among the many families of human transcription factors, the FOXP sub-
family of forkhead box proteins is notable for the neurodevelopmental pheno-
types which have been associated with their disruption (Bowers & Konopka,
2012b; Charng et al. , 2016). The FOXP family includes four proteins: FOXP1,
FOXP2, FOXP3 and FOXP4 (Shu et al. , 2001). FOXP1, FOXP2 and FOXP4 ex-
hibit 55–65% sequence identity and show overlapping expression in the devel-
oping brain, as well as in other organs (Shu et al. , 2001; Teufel et al. , 2003).
FOXP3 is structurally divergent and its expression is limited to T lymphocytes
(Fontenot et al. , 2003). FOXP3 disruption causes an immunological disorder,
IPEX (immunodysregulation polyendocrinopathy enteropathy X-linked, OMIM
# 304790) syndrome, while mutations of FOXP1, FOXP2 and FOXP4 have each
been linked to distinct neurodevelopmental disorders. Heterozygous disrup-
tions of FOXP1 cause a broad neurodevelopmental syndrome, which includes
global developmental delay and ID, frequently accompanied by features of autism
and impaired speech and language abilities (OMIM # 613670) (Hamdan et al.
, 2010; Lozano et al. , 2015; O’Roak et al. , 2011; Sollis et al. , 2016; Srivastava
et al. , 2014). All pathogenic variants observed to date have occurred de novo,
consistent with the severe phenotype of the disorder (Sollis et al. , 2016). Het-
erozygous disruptions of FOXP2 cause a rare monogenic form of speech and
language impairment including childhood apraxia of speech as a core feature
(OMIM # 602081) (Estruch et al. , 2016a; Laffin et al. , 2012; Lai et al. , 2001; Mac-
Dermot et al. , 2005; Reuter et al. , 2016; Roll et al. , 2010; Turner et al. , 2013).
Unlike FOXP1-associated disorder, general cognitive functions may be within
the normal range, and both inherited and de novo cases have been reported (Gra-
ham & Fisher, 2015). Although the FOXP2-related disorder is less severe than
that resulting from FOXP1 disruption, individuals with FOXP2 and FOXP1 mu-
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tations display overlapping features such as language impairment, suggesting
that the syndromes may involve disruption of similar molecular and cellular
networks (Bacon & Rappold, 2012).
Disorders relating to FOXP4 disruption had not been reported until recently,
when Charng et al. described a homozygous frameshift variant in a child from
a consanguineous family affected by developmental delay and malformations
in the larynx and the heart (Charng et al. , 2016). It is interesting that this,
the only currently suspected case of FOXP4-related disorder, involves a reces-
sive mutation, in contrast to the dominant disorders described for FOXP1 and
FOXP2 disruptions. The potential complete absence of FOXP4 protein in this
child may also explain why the disorder appears to have broader effects in or-
gans other than the brain. Indeed, all three neurally-expressed FOXP proteins
also have roles in the development of other organs, but their neurodevelopmen-
tal functions appear to show more dosage sensitivity than roles in non-neural
tissues (Li, 2004; Li et al. , 2015b; Shu et al. , 2005, 2007). Although FOXP4 is the
strongest candidate causal gene in the case identified by Charng and colleagues,
additional observations of FOXP4 disruption are necessary to confirm its etio-
logical role, particularly since variants in two other genes were also found in a
homozygous state in the child and heterozygous state in the parents (Charng
et al. , 2016).
The precise mechanisms by which FOXP family members regulate transcrip-
tion are just beginning to be explored. Several studies have investigated FOXP2
and FOXP1 target genes in the brain (Araujo et al. , 2015; Spiteri et al. , 2007;
Vernes et al. , 2007, 2011) but genes regulated by FOXP4 remain to be discov-
ered. An important mechanism in regulation of gene expression is that tran-
scription factors act in a combinatorial fashion, and thus can generate the com-
plex patterns of gene expression underlying development of the brain and other
systems using a limited set of transcription factors (Silbereis et al. , 2016; Smith
& Matthews, 2016). The genes regulated by the FOXP proteins in specific cell
types are therefore likely to depend on the co-expression of other transcrip-
tion factors. Indeed, the transcriptional activity of FOXP1, FOXP2 and FOXP4
is regulated by their ability to form homo- and hetero-dimers with each other
through their leucine zipper domain (Li et al. , 2004). The three proteins show
partially overlapping patterns of expression in the brain, such that different
combinations of FOXP homo and hetero-dimers may regulate distinct target
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genes (Ferland et al. , 2003; Lai et al. , 2003; Sin et al. , 2015; Takahashi et al. ,
2008).
In addition to dimerization between FOXP family members, a small num-
ber of interactions between FOXP proteins and other transcription factors have
been reported. FOXP1 and FOXP2 interact with the neural transcription factor
TBR1, rare mutations of which cause ASD accompanied by language deficits
(Deriziotis et al. , 2014a). Notably, this interaction can be disrupted by etiologi-
cal mutations in either FOXP2 or TBR1 (Deriziotis et al. , 2014a). Other reported
FOXP-interacting transcription factors include GATAD2B and NKX2.1 (Chokas
et al. , 2010; Zhou et al. , 2008). We hypothesized that there may be further inter-
actions between FOXPs and other transcription factors with relevance to physio-
logical developmental processes and neurodevelopmental disorders. We there-
fore sought to identify transcription factors which may cooperate with FOXP
proteins in regulating gene expression during neurodevelopment, by applying a
mass spectrometry approach. We identified seven novel FOXP-interacting tran-
scription factors: NR2F1, NR2F2, SATB1, SATB2, SOX5, YY1 and ZMYM2. Sev-
eral of these novel interactors have well-established roles in the development of
the nervous system and/or are associated with neurodevelopmental disorders.
The interactions with these binding partners involve different regions of the
FOXP2 polypeptide, and are variably affected by different pathogenic variants
in FOXP1 and FOXP2. Thus our findings provide new clues to the molecular
function of the FOXP proteins, and point to a network of transcription factors
involved in cortical development, disruption of which manifests as neurodevel-
opmental disorder.
4.2 materials and methods
DNA constructs
The cloning of human FOXP2 (NM_ 014491), FOXP1 (NM_ 032682), FOXP4
(NM_ 001012426), has been described previously (Estruch et al., 2016b). The
coding sequences of TFDP1 (NM_ 007111), NR2F1 (NM_ 005654), NR2F2 (NM_
021005), SATB1 (NM_ 002971), SATB2 (NM_ 001172509), ZBTB2 (NM_020861),
TP53 (NM_000546), ZNF687 (NM_001304763), ZMYM2 (NM_003453), NFAT5
(NM_ 138714), YY1 (NM_ 003403) and SOX5 (NM_ 001330785) were amplified
using the primers listed in Supplementary Table S4.1 and cloned into pCR2.1-
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TOPO. Human fetal brain cDNA was used as template for PCR, except in the
cases of NR2F2 and NFAT5, which were amplified from the plasmids pAAV-
hNR2F2-RFP (Addgene, # 22926) and pEGFP-NFAT5 (Addgene, # 13627), re-
spectively. The cloning of FOXP2 variants p.Q17L, p.M406T, p.P416T, p.R553H,
p.N597H, p.R328∗ , P.Q390Vfs∗7, of synthetic truncated forms of FOXP2, and
of FOXP1 variants p.A339Sfs∗4, p.V423Hfs∗37, p.Y439∗ , p.R465G, p.R514C,
p.R252∗ , and p.W534R has been described previously (Estruch et al. , 2016a;
Sollis et al. , 2016). For expression of FLAG-tagged protein for affinity purifi-
cation, the coding regions of FOXP1, FOXP2 and FOXP4 were subcloned into
the pEF1α FLAGbio expression vector, provided by Dr. J.W. Wang (Kim et al.
, 2009b). For expression of fusion proteins with Renilla luciferase, yellow fluo-
rescent protein (YFP) and mCherry tags, cDNAs were subcloned into the pLuc,
pYFP, and pmCherry expression vectors, respectively, which have been described
previously (Deriziotis et al. , 2014a; Estruch et al. , 2016a). All constructs were
verified by Sanger sequencing.
Cell culture and transfection
HEK293 cells were obtained from ECACC (cat. No. 85120602) and cultured
in DMEM supplemented with 10% fetal bovine serum. Transient transfections
were performed using GeneJuice (Merck-Millipore) according to the manufac-
turer’s instructions. To generate stable cell lines expressing FLAG-tagged FOXP
proteins, HEK293 cells were transfected with pEF1αFLAGbio containing the
coding sequence of FOXP1, FOXP2, or FOXP4 using GeneJuice (Merck-Milli-
pore) according to the manufacturer’s instructions. Single clones were isolated
following selection with culture medium containing 10 µM puromycin. Expres-
sion of the tagged proteins in selected clones was confirmed by western blotting
of cell lysates using anti-FLAG antibody (Sigma). Selected stable cell lines were
maintained in DMEM supplemented with 10% fetal bovine serum and 5 µM
puromycin.
Affinity Purification and Mass Spectrometry (AP/MS)
HEK293 cell lines stably expressing FLAG-tagged FOXP1, FOXP2 or FOXP4, or
control cell lines, were expanded to twenty 15 cm dishes, washed with PBS, and
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harvested by scraping. The affinity purification procedure has been described
previously (van den Berg et al. , 2010). Briefly, nuclear extracts were dialysed
into buffer C-100 (20 mM HEPES pH 7.6, 0.2 mM EDTA, 1.5 mM MgCl2, 100
mM KCl, 20% glycerol) and then incubated with anti-FLAG M2 agarose beads
(Sigma) and benzonase (Novagen) for 3 h at 4◦ C. Beads were washed 5 times for
5 min with buffer C-100 containing 0.02% NP-40 (C-100∗ ) and bound proteins
were eluted 4 times for 15 min at 4◦ C with buffer C-100∗ containing 0.2 mg/ml
FLAG-tripeptide (Sigma). The purification of FOXP1, FOXP2 or FOXP4 was
checked by western blot using anti-FLAG antibody. The elution fractions were
pooled and proteins were TCA-precipitated, resolved by SDS-polyacrylamide
gel electrophoresis, stained with Colloidal Blue Staining Kit (Invitrogen) and
analyzed by mass spectrometry as described previously (Engelen et al. , 2011;
Gagliardi et al. , 2013; Ninkovic et al. , 2013; van den Berg et al. , 2010).
Mass-spectrometry analyses were performed on three independent purifica-
tions from FOXP1- and FOXP2-expressing cell lines, and two independent pu-
rifications from FOXP4-expressing cell lines. Each purification was performed
in parallel with stable cell lines transfected with empty control vector. To re-
move non-specific interactors, peptide lists were filtered using peptides found
in the control conditions or in the CRAPome database, a collection of common
contaminants in AP/MS data (Mellacheruvu et al. , 2013). Proteins with a Mas-
cot score lower than 45 were also excluded.
Western blotting
Proteins from cell lysates were resolved on 10% SDS-polyacrylamide gels and
transferred to PVDF membranes using a TransBlot Turbo Blotting apparatus
(Bio-Rad). Membranes were blocked in PBS containing 5% milk and 0.1% Tween-
20 and incubated overnight at 4◦ C with primary antibody. After washing, mem-
branes were incubated with horseradish peroxidase-conjugated goat anti-mouse
or anti-rabbit IgG for 45 min at room temperature. Proteins were visualized
using Novex ECL Chemiluminescent Substrate Reagent Kit (Invitrogen) and a
ChemiDoc XRS+ imaging system (Bio-Rad).
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BRET assay
BRET assays were performed as described previously (Deriziotis et al., 2014a).
Briefly, HEK293 cells were transfected in 96-well plates with plasmids encoding
YFP- and luciferase-fusion proteins. After 36-48 h, Enduren live cell luciferase
substrate (Promega) was added at a final concentration of 60 µ M. Cells were
cultured for a further 4 h, and emission readings (integrated over 10 s) were
taken using a TECAN F200PRO microplate reader using the Blue1 and Green1
filter sets. Expression levels of the YFP-fusion proteins were measured by taking
fluorescent readings using the filter set and dichroic mirror suitable for green
fluorescent protein (excitation 480 nm, emission 535 nm). The corrected BRET
ratio was calculated with the following formula: [Green1 (experimental condition)
/Blue1(experimental condition)] - [Green1(control condition) /Blue1(control condition)]. The
control conditions used luciferase or YFP fused to a C-terminal nuclear local-
ization signal (Deriziotis et al., 2014a).
Fluorescence microscopy
HEK293 cells were seeded on coverslips coated with poly-L-lysine. Cells were
transfected with plasmids encoding proteins of interest fused to YFP or mCherry.
Cells were cultured for 30 h post-transfection, and then fixed with 4 % para-
formaldehyde. Nuclei were stained with Hoechst 33342. Fluorescence images
were acquired using an Axiovert A-1 fluorescent microscope with ZEN Image
software (Zeiss).
Immunofluorescence
Immunofluorescence experiments were performed on mouse brain sections at
postnatal day 3 (P3). Brains were harvested and embedded in optimal cutting
temperature (OCT) compound on dry ice. Sagittal sections were prepared at
a thickness of 4 µ m using a Leica CM1950 cryostat and then preserved at -
20◦ C. Tissue sections were fixed in ice-cold acetone for 10 minutes at -20◦ C,
blocked using 10% donkey serum in PBS for 1 h at room temperature, and in-
cubated overnight at 4◦ C with primary antibody diluted in 2% donkey serum.
The following antibodies were used: goat anti-FOXP2 N-16 antibody (sc-21069,
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Santa Cruz), rabbit anti-FOXP2 antibody (ab16046, Abcam), rabbit anti-SOX5
(ab94396, Abcam), goat anti-SATB1 E-15 antibody (sc-5990, Santa Cruz), rabbit
anti-SATB2 antibody (ab34735, Abcam), rabbit anti-NR2F1 (ab181137, Abcam)
and rabbit anti-NR2F2 (ab42672, Abcam). After washing, tissue sections were
incubated with fluorescently-labeled secondary antibodies diluted in 2% don-
key serum: donkey anti-rabbit IgG Alexa488 (a21206, Invitrogen) and donkey
anti-goat IgG Alexa594 (a11058, Invitrogen). Slides were mounted with Vec-
taShield Antifade Mounting Medium with DAPI (Vector Labs) and then imaged
using Axiovert A-1 fluorescent microscope with ZEN Image software (Zeiss).
4.3 results
4.3.1 Identification of FOXP-interacting transcription factors
To identify transcription factors that may cooperate with FOXP proteins to
regulate gene expression, we generated HEK293 cell lines stably expressing
FOXP1, FOXP2 or FOXP4 fused to an N-terminal FLAG tag. HEK293 cells en-
dogenously express all three FOXP proteins as well as many other neural genes
(Shaw et al. , 2002; Stepanenko & Dmitrenko, 2015). FLAG affinity-purified pro-
tein complexes from these cell lines were analyzed by mass spectrometry (Fig-
ure 4.1a,b). Three independent experiments were performed for FOXP1 and
FOXP2, and two experiments for FOXP4. After filtering out non-specific interac-
tors, a total of 381 putative FOXP-interacting proteins were identified, with sub-
stantial overlap between the three FOXP proteins (Figure 4.1c, Supplementary
Table S4.2). For each FOXP protein, the other two FOXPs were among the in-
teracting proteins identified in each experiment, reflecting heterodimerization
between FOXP family members (Li et al. , 2004) (Supplementary Table S4.2).
Moreover, the set of putative FOXP-interacting proteins included previously re-
ported interaction partners such as CTBP1, CTBP2 and GATAD2B, confirming
that the affinity purification procedure retrieved physiologically relevant FOXP-
interacting proteins (Chokas et al. , 2010; Estruch et al. , 2016a) (Supplementary
Table S4.2).
The transcription factors among the putative FOXP-interacting proteins were
identified, resulting in a set of 28 proteins (Figure 4.1c, Table 4.1, Supplemen-
tary Table S4.2). To prioritize potential interacting transcription factors of most
interest for further investigation, we excluded previously reported FOXP inter-
4results 117
75 
100 
150 
250 
50 
37 
25 
10 
MW  
(kDa) 
Control FOXP4 FOXP1 FOXP2 
a b 
FOXP1 
FOXP2 
FOXP4 
29 
8 
44 
2 
23 
0 
6 
2 
235 
10 
21 
2 
23 
4 
c 
75 
100 
MW  
(kDa) 
FOXP1 
75 
100 
75 
100 
10%  
input wash 
co
n
tro
l 
FO
XP
 
co
n
tro
l 
FO
XP
 
FOXP2 
FOXP4 
elutions 
1 2 3 4 
All proteins 
Transcription factors 
 
Figure 4.1: Identification of FOXP1-, FOXP2- and FOXP4-interacting proteins. (a)
Affinity purifications of FOXP protein complexes using HEK293 cell lines stably express-
ing FLAG- FOXP1 (top panel), -FOXP2 (middle panel) and -FOXP4 (bottom panel) pro-
tein complexes. FLAG-tagged species were isolated using a FLAG affinity purification
strategy. Western blots of total lysate (10% Input), washed proteins (wash), and affinity-
purified material (elutions) were probed with an anti-FLAG antibody. (b) Coomassie-
stained SDS- polyacrylamide gels of the affinity purifications of FOXP1, FOXP2, FOXP4
and control purification. Arrows indicate bands corresponding to FOXP1, FOXP2 or
FOXP4 for each IP. (c) Venn diagram showing the overlaps between the proteins (pur-
ple) or transcription factors (light blue) identified in each FOXP purification.
actors, and then selected proteins that were present in two or more replicates,
or that had a known involvement in neurodevelopmental disorder. Because the
FOXP proteins have high sequence similarity and are likely to have shared in-
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teractors, the appearance of a protein in two experiments with different FOXPs
was treated as a replicate. We also included transcription factors if two or more
members of the same family of transcription factors were observed (Supplemen-
tary Table S4.3). This selection resulted in a filtered list of 12 putative FOXP
interactors for follow up.
4.3.2 Validation of interactions between FOXPs and transcription factors
To validate the selected putative FOXP-interacting transcription factors, we used
a Bioluminescence Resonance Energy Transfer (BRET) assay. The BRET assay
allows protein-protein interactions to be observed in live cells, and its effec-
tiveness has previously been shown for successfully confirming interactions
between FOXPs and other proteins (Deriziotis et al. , 2014b,a; Estruch et al. ,
2016b,a; Sollis et al. , 2016). In the BRET assay, cells are transfected with a pro-
tein of interest fused to Renilla luciferase, and a candidate interaction partner
fused to yellow fluorescent protein (YFP). An interaction between the two pro-
teins under investigation can bring the luciferase and YFP moieties into suffi-
cient proximity for resonance energy transfer to occur, causing a shift in the
wavelength of the emitted light.
We generated YFP-fusion proteins for the 12 putative FOXP interactors, and
tested them for interaction with luciferase-fusions of FOXP1, FOXP2 and FOXP4
using the BRET assay. We detected interactions between FOXP proteins and
seven of the 12 putative interactors: SOX5, SATB1, SATB2, NR2F1, NR2F2, YY1
and ZMYM2 (Figure 4.2a,b). In some cases a specific FOXP-cofactor interaction
was detected in the BRET assay that was not identified in the mass spectrome-
try screen. For example, NR2F1, NR2F2 and SATB1 (identified through FOXP4
interactome screening) interacted with FOXP1 and FOXP2 in the BRET but had
not been detected by mass spectrometry for those two FOXP proteins (Figure
4.2b). This is likely due to the greater sensitivity of the targeted BRET inves-
tigations; these proteins may not have been detected among the complex mix-
ture of proteins isolated by affinity purification. Transfection of cells with YFP-
fusions of the interactors validated using the BRET assay and mCherry-FOXP2
showed that all seven interactors exhibited nuclear localization that completely
overlapped with FOXP2 (Figure 4.2c). ZMYM2 and SOX5 formed nuclear speck-
les when expressed as YFP-fusions, which caused partial re-distribution of co-
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Table 4.1: List of candidate FOXP-interacting transcription factors identified in the
mass spectrometry screens
∗ Tentative association
Gene
Symbol
Function Associated Phenotype
BNC2 Regulation of skin pigmentation
CDC5L Regulation of cell cycle
EMSY DNA repair
FOXC1 Embryonic and ocular development Iris hypoplasia and glau-
coma
FOXP1 Brain, heart and lung development ID with language impair-
ment
FOXP2 Brain, heart and lung development Severe language impairment
FOXP4 Brain, heart and lung development Developmental delay*
FUBP1 Regulation of cell cycle
GATAD2B Brain development ID
HIC2 Unknown function
NFAT5 Regulation of inflammatory response
NR2F1 Brain and heart development ID with optic atrophy
NR2F2 Brain and heart development Congenital heart defects
RFX1 Unknown function
SATB1 Regulation of immune system and
brain development
SATB2 Brain and bone development ID with language impair-
ment
SOX13 T-cell development
SOX5 Brain and bone development ID with language impair-
ment
TFDP1 Regulation of cell cycle ID with language impair-
ment*
TP53 Regulation of cell cycle Li-Fraumeni syndrome
YY1 Embryonic development ID
ZBTB2 Regulation of cell cycle
ZBTB39 Unknown function
ZFHX4 Brain and muscle development Ptosis
ZMYM2 Immune system regulation
ZNF148 Unknown function ID with language impair-
ment
ZNF687 Bone development Paget disease of bone
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expressed FOXP2, consistent with the presence of a physical interaction be-
tween ZMYM2/SOX5 and FOXP2 (Figure 4.2c).
Five candidate interactors (NFAT5, TFDP1, TP53, ZBTB2 and ZNF687) did
not show evidence of interaction in the BRET assay. The lack of interaction in
this assay was not due to the candidate interactors being localized outside the
nucleus in live cells, as all these proteins showed total or partial nuclear localiza-
tion, overlapping with that of FOXP2 (Figure 4.2c). NFAT5, ZBTB2 and TFDP1
were present in the cytoplasm, as has been reported previously, but still showed
overlapping expression with FOXP2 in the nucleus (Ishida et al. , 2005; Jeon et al.
, 2009) (Figure 4.2c). The failure to observe an interaction with these proteins
in the BRET assay does not exclude that these proteins might be true FOXP in-
teractors. For a signal to be detected in the BRET assay, the luciferase and YFP
peptides need to be in close proximity and also must be oriented correctly so
that resonance energy transfer may occur. Therefore certain pairs of interactors
may not allow for efficiency resonance transfer (Sun et al. , 2016). In addition,
the affinity purification procedure can purify large complexes of proteins, some
of which may interact only indirectly with the bait protein (Budayeva & Cristea,
2014; Hayes et al. , 2016). Pairs of proteins that interact indirectly are less likely
to produce a signal in the BRET assay because the interaction-mediating pro-
teins are not overexpressed, and the distance between the protein pair may
also be too great for efficient energy transfer. Therefore, NFAT5, TFDP1, TP53,
ZBTB2 and ZNF687 may have been isolated by affinity purification due to indi-
rect interaction with the FOXP bait protein.
4.3.3 Neural transcription factors interact with distinct sites within FOXP proteins
We next sought to determine which FOXP regions are involved in the inter-
actions with each of the transcription factors validated using the BRET assay.
Here, we focused on FOXP2, building on our prior experience with mapping
interaction sites within this particular protein. Specifically, we performed fur-
ther BRET assays using a series of synthetic variants of FOXP2 isoform I (NM_
014491.3, NP_055306.1) truncated at the N- or C-terminus, which have been
employed previously to map the binding sites of FOXP2 interaction partners
(Figure 4.3a) (Deriziotis et al. , 2014a; Estruch et al. , 2016a,b). For SOX5 and
ZMYM2, an N-terminal FOXP2 fragment containing residues 1-258 of isoform
I retained the ability to interact, while the counterpart C-terminal fragment
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Figure 4.2: Validation of identified FOXP-interacting proteins. (a) Bioluminescence
resonance energy transfer (BRET) assay for interaction of FOXP1, FOXP2 and FOXP4
variants with the putative FOXP-interacting transcription factors. HEK293 cells were
transfected with Renilla luciferase-FOXP1, -FOXP2 or –FOXP4 (donor) and YFP (accep-
tor) fusion proteins of the putative FOXP-interacting transcription factors. The control
acceptor protein is a nuclear-targeted YFP. Values are mean corrected BRET ratios ±
S.E.M (n = 3).
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Figure 4.2: (Cont.) (b) Heatmap summarizing the results of the affinity purification fol-
lowed by mass spectrometry (AP/MS) and the BRET assays. Grey shading indicates inter-
action. (c)Fluorescence micrographs of HEK293 cells transfected with YFP-fusions of the
putative FOXP-interacting transcription factors, together with FOXP2 fused to mCherry.
Nuclei were stained with Hoechst 33342 (Scale bar = 15 µm).
(residues 259-715) did not, indicating that the critical binding determinants for
SOX5 and ZMYM2 lie within the N-terminal 258 residues of FOXP2 (Figure
4.3b,c). In addition, SOX5 and ZMYM2 interacted with a naturally-occurring
alternative FOXP2 isoform (isoform III) that lacks the N-terminal 92 amino
acids of other isoforms (Supplementary Figure S4.1), narrowing down the criti-
cal region to residues 93 to 258.The N-terminal region of FOXP2 also mediates
interaction with the transcription factor TBR1, and with members of the PIAS
family of proteins which are involved in FOXP2 post-translational modification,
which suggests that this region may coordinate multiple protein-protein inter-
actions (Deriziotis et al. , 2014a; Estruch et al. , 2016b). The region includes two
polyglutamine tracts of unknown function that are expanded in FOXP2 rela-
tive to other FOXP family members. Shortening of these tracts to bring them
into line with the sequence of FOXP1 does not affect interaction with TBR1 or
PIAS proteins in cellular assays (Deriziotis et al. , 2014a; Estruch et al. , 2016b).
Tract shortening also did not affect interaction with SOX5 and ZMYM2 in the
current study, as expected given that these proteins also interact with FOXP1
(Supplementary Fig. S4.2). Thus, the binding sites for these proteins may lie in
the glutamine-rich regions flanking the polyglutamine tracts
For the paralogous transcription factors SATB1 and SATB2, only C-terminally
truncated FOXP2 forms containing an intact forkhead DNA-binding domain re-
tained a full ability to interact with SATB1/2, suggesting that the interaction
requires an intact forkhead domain together with additional elements from
the N-terminal region of FOXP2 (Figure 4.3d). Interestingly, a previous mass
spectrometry study reported SATB1/2 in affinity purifications of FOXP1 and
FOXP3 as well as of FOX proteins from several other subfamilies (Li et al. ,
2015a). Given that SATBs interact with diverse FOX proteins that have substan-
tial structural divergence, it is highly likely that the forkhead DNA-binding
domain itself plays an important role in mediating the interaction.
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Figure 4.3: Mapping of the regions in FOXP2 that mediate protein-protein interac-
tions (a) Schematic representation of synthetic truncated forms of FOXP2 isoform I
(NM_014491.3, NP_055306.1). Known domains are labeled: glutamine-rich (Q-rich) re-
gion (hatched shading) including long and short poly-glutamine tracts, zinc finger (ZF),
leucine zipper (LZ), and forkhead domain (FOX). Nuclear localization signals are indi-
cated with red bars. A synthetic nine-residue nuclear targeting sequence (orange bars)
was appended to the C-terminus of variants that lack one or both of the endogenous
nuclear localization signals. (b-e,g) BRET assay for interaction of synthetic truncated
FOXP2 variants with FOXP-interacting transcription factors. HEK293 cells were trans-
fected with truncated FOXP2 variants fused to Renilla luciferase (donor) and SOX5 (b),
ZMYM2 (c), SATB1 (d), SATB2 (d), NR2F1 (e), NR2F2 (e) or YY1 (g) fused to YFP
(acceptor). The control donor protein is a nuclear-targeted luciferase. Values are mean
corrected BRET ratios normalized to full-length FOXP2 ± S.E.M. (n = 3). (f) Schematic
representation of FOXP2 showing the putative NRF2 binding motif (light blue bar). The
sequence alignment of the region shows the putative NRF2 binding motif in FOXP2 par-
alogues FOXP1 and FOXP4.
The second pair of paralogous transcription factors in our screen, NR2F1
and NR2F2, displayed normal interaction with a FOXP2 form truncated be-
yond residue 422, but reduced interaction with more severely truncated forms,
suggesting a role for the region encompassing residues 330-422 (Figure 4.3e).
Accordingly, normal interaction was observed with a C-terminal fragment of
FOXP2 beginning at residue 330, whereas a fragment beginning at residue 423
showed little or no binding (Figure 4.3e). Residues 330-422 include a leucine
zipper domain which mediates dimerization, and a zinc finger domain with un-
known function.
FOXP2 dimerization does not appear to be essential for interaction with NR2F1/2,
because we found that a synthetic dimerization-deficient FOXP2 variant re-
tained the ability to interact with NR2F1 (Supplementary Figure S4.2d) (Li et al.
, 2004). Interestingly, the zinc finger domain in FOXP2 contains a short amino
acid sequence (residues 360-367) with high similarity to the NR2 binding motif
F/YSXXLXXL/Y, which has been shown to mediate the interaction of NR2F1/2
with other transcription factors and co-repressors (Chan et al. , 2013) (Figure
4.3f). This motif is conserved in FOXP1 but not FOXP4, which could explain
why NR2F1/2 interacted with FOXP1 and FOXP2, but not FOXP4, in our BRET
assays (Figure 4.2a,b) – the presence of NR2F1/2 in FOXP4 complexes analyzed
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by mass spectrometry may then be due to an indirect interaction mediated by
FOXP1/2.
Finally, in the case of YY1, all of the truncated FOXP2 variants tested retained
some degree of interaction, suggesting that the interaction between FOXP2 and
YY1 may involve multiple binding sites (Figure 4.3g).
4.3.4 Disorder-related FOXP variants disrupt interactions with transcription fac-
tors
We next investigated etiological variants of FOXP proteins related to neurode-
velopmental disorders, assessing their effects on the transcription factor inter-
actions that we identified. Heterozygous disruptions of the FOXP2 gene cause a
rare form of speech and language disorder (Graham & Fisher, 2015). The disor-
der was first reported in a three-generation family, in which all of the affected
members carry the FOXP2 variant p.R553H, which is unable to bind to its typ-
ical DNA target sequence (Lai et al. , 2001; Vernes et al. , 2006). Several other
variants in FOXP2 have since been reported in individuals with neurodevelop-
mental disorders; functional studies indicate that some of these are etiological
variants whereas others are benign rare variants (Figure 4.4a) (Estruch et al. ,
2016a; Laffin et al. , 2012; MacDermot et al. , 2005; Reuter et al. , 2016; Roll et al.
, 2006; Turner et al. , 2013). Etiological variants had been shown to severely dis-
rupt core molecular aspects of FOXP2 protein function, such as transcriptional
activity and subcellular localization (Estruch et al. , 2016a). Using the BRET as-
say, we examined the effects of seven rare variants on the interaction of FOXP2
with the transcription factors identified in our interactor screen (Figure 4.4b-h).
Four of these seven rare variants had been shown to be benign in prior cellular
assays (Estruch et al. , 2016a). All four of these benign rare variants displayed
normal interaction with the novel interaction partners, whereas almost all in-
teractions involving one of the three pathogenic FOXP2 variants were either
abolished or disrupted (Figure 4.4b-i).
Heterozygous mutations of the FOXP1 gene result in a neurodevelopmen-
tal syndrome characterized by mild to moderate ID with features of ASD and
speech and language impairments (Lozano et al. , 2015; Sollis et al. , 2016). We
examined the effects of seven etiological variants of FOXP1 on interactions with
the six FOXP1-interacting transcription factors identified in our screen. The eti-
ological FOXP1 variants comprised four truncated and three missense variants.
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Figure 4.4: Etiological mutations in FOXP2 disrupt protein interactions (a) Schematic
representation of the FOXP2 protein isoform I (NM_014491.3, NP_055306.1) show-
ing rare variants found in individuals with neurodevelopmental disorders. Pathogenic
variants are shown in red and benign variants in black. Known domains are la-
beled: glutamine-rich (Q-rich) region (hatched shading), long (QL) and short (QS) poly-
glutamine tracts, zinc finger (ZF), leucine zipper (LZ) and forkhead domain (FOX). Nu-
clear localization signals are indicated with red bars. (b-h) BRET assays for interaction
of FOXP2 variants with FOXP-interacting proteins. HEK293 cells were transfected with
Renilla luciferase-FOXP2 wild type (WT) or variants (donor) and YFP (acceptor) fusions
of SOX5 (b), SATB1 (c), SATB2 (d), NR2F1 (e), NR2F2 (f), YY1 (g) or ZMYM2 (h).
The control acceptor protein is a nuclear-targeted YFP. Values are mean corrected BRET
ratios normalized to wild-type FOXP2 ± S.E.M. (n = 3). (i) Heatmap summarizing the re-
sults of the BRET assays between FOXP2 variants and the FOXP-interacting transcription
factors. White squares indicate an unaffected interaction; a hatched pattern, a reduced
interaction; and grey shading, a severely reduced interaction.
The truncated variants did not interact with any of the transcription factors
tested in our assays, whereas two of the three missense variants retained some
degree of interaction with one or more interaction partner (Figure 4.5b-h). The
FOXP1 missense variants p.R465G and p.R514C retained the ability to inter-
act with SOX5 (Figure 4.5b). Accordingly, co-expression of these variants with
SOX5 led to mislocalization of SOX5 into the nuclear aggregates formed by the
abnormal FOXP1 proteins, an effect not observed when SOX5 was co-expressed
with other FOXP1 variants (Figure 4.5i). Thus, most etiological FOXP1 and
FOXP2 variants represent a loss of function with respect to interaction with
other neural transcription factors. However the FOXP1 p.R465G and p.R514C
variants may exert dominant negative effects in vivo by interfering with the
function of interacting transcription factors such as SOX5. Such differences in
the behaviour of different protein variants has the potential to contribute to
phenotypic variation observed between individuals with FOXP1-related disor-
der (Sollis et al. , 2016).
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Figure 4.5: Etiological mutations in FOXP1 disrupt protein interactions. (a) Schematic
representation of the FOXP1 protein (NM_032682, NP_116071) showing rare variants
found in individuals with neurodevelopmental disorders. Known domains are labeled:
glutamine-rich (Q-rich) region (hatched shading), zinc finger (ZF), leucine zipper (LZ)
and forkhead domain (FOX). Nuclear localization signals are indicated with red bars.
(b-g) BRET assays for interaction of FOXP1 variants with the FOXP-interacting proteins.
HEK293 cells were transfected with Renilla luciferase-FOXP1 wild type (WT) or vari-
ants (donor) and YFP (acceptor) fusions of SOX5 (b), SATB1 (c), NR2F1 (d), NR2F2
(e), YY1 (f) or ZMYM2 (g). The control acceptor protein is a nuclear-targeted YFP. Val-
ues are mean corrected BRET ratios normalized to wild-type FOXP1 ± S.E.M. (n = 3).
(h) Heatmap summarizing the results of the BRET assays between FOXP2 variants and
the FOXP-interacting transcription factors. White squares indicate an unaffected inter-
action; a hatched pattern, a reduced interaction; and grey shading, a severely reduced
interaction. (i) Fluorescence micrographs of HEK293 cells transfected with YFP-fusions
of FOXP1 wild-type or etiological variants, together with SOX5 fused to mCherry. Nuclei
were stained with Hoechst 33342. (Scale bar = 15 µm).
4.3.5 FOXP2 is co-expressed with interacting transcription factors in specific neu-
ronal subpopulations
We sought to identify the cell types in which the newly identified interactions
between FOXP2 and transcription factors may be physiologically relevant. Of
the seven FOXP-interacting transcription factors validated using the BRET as-
say, ZMYM2 and YY1 are ubiquitously expressed, while SOX5, SATB1, SATB2,
NR2F1 and NR2F2 are all neural transcription factors that are expressed in
subsets of neurons within the cerebral cortex (Huang et al. , 2011; Kim et al.
, 2009a; Lai et al. , 2008; Tripodi et al. , 2004). We therefore examined the co-
localization of Foxp2 with the interacting neural transcription factors in mouse
brain by immunostaining (Figure 4.6). Brains from mice at postnatal day 3 were
used because by this point in development the cortical layers have formed and
layer-specific Foxp2 expression can readily be detected (Ferland et al. , 2003).
Foxp2 was observed in the deep layers of the cortex, as well as in the striatum,
as previously reported (Figure 4.6) (Ferland et al. , 2003) Each of the five neu-
ral transcription factors showed a different pattern of expression in the cortex.
Sox5 exhibited extensive co-expression with Foxp2 in deep layer cortical neu-
rons (Figure 4.6). Satb2 expression was found throughout all the six layers of
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the cortex and its expression coincided with Foxp2 in a subpopulation of neu-
rons of layer V (Figure 4.6). Satb1 was detected in layers IV to VI, including a
subpopulation of Foxp2-expressing cells (Figure 4.6). Nr2f1 was expressed in
all the layers of the cortex, including the vast majority of Foxp2-positive cells
in layers V and VI (Figure 4.6). In contrast, and despite being expressed in a
few scattered cells in the cortex layers I, IV and V, Nr2f2 was not co-expressed
with Foxp2 in any cortical neurons (Figure 4.6). However, Nr2f2 was found to
be extensively co-expressed with Foxp2 in the Purkinje cells of the cerebellum,
another key neuronal subtype with high Foxp2 expression (Figure 4.7). These
data are consistent with the prevailing view that expression of different combi-
nations of transcription factors is essential to determining and maintaining cell
identity and function.
4.4 discussion
In this study, through mass spectrometry-based proteomics followed by tar-
geted analysis using BRET, we identified and characterized the interactions be-
tween FOXP family proteins and seven neurally-expressed transcription factors.
We demonstrated co-expression of the interactors with Foxp2 in functionally-
relevant neuronal subtypes in the early post-natal mouse brain, confirming that
the reported interactions are of potential physiological significance in vivo. We
found that different interaction partners have distinct binding sites within the
FOXP2 protein, and that disorder-associated variants in FOXP1 and FOXP2 gen-
erally cause broad disruption of protein-protein interactions, but in some cases
may lead to a dominant-negative effect in which abnormal FOXP protein may
interfere with the functions of a normal interactor.
The interaction partners we identified have important, yet diverse, roles in
neurodevelopment. Sox5 is expressed in deep cortical layers during embryonic
and early post-natal stages and controls timing of the generation of distinct
corticofugal neuron subtypes (Lai et al. , 2008). Loss of Sox5 results in aber-
rant differentiation and abnormal migration of cortical projection neurons (Lai
et al. , 2008). Satb2 is a key regulator of cortical development and is expressed
throughout all cortical layers (Huang et al. , 2011; Szemes et al. , 2006). The
neural functions of Satb1 have not been as extensively investigated as its roles
in the immune system (Alvarez et al. , 2000), but it is reported to regulate de-
velopment of cortical interneurons and facilitate cortical neuron plasticity by
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Figure 4.6: FOXP2 is co-expressed with SOX5, SATB1, SATB2 and NR2F2 in the cere-
bral cortex. (a) Immunofluorescence experiments to assess endogenous co-expression
of Sox5, Satb1, Satb2, Nr2f1 and Nr2f2 with FoxP2 in the cerebral cortex of P3 mice
brains. A white line indicates the cerebral cortex, layer numbers are indicated. A dashed
white line demarks the striatum (str) (scale bar = 200 µm). (b) Magnified views of the
region indicated with a white square in (a). White arrows indicate cells that co-express
both FoxP2 and the FoxP2-interacting transcription factor (Scale bar = 50 µm). For(a)
and (b), Foxp2 protein expression is shown in red; FOXP2-interacting proteins, in green;
and nuclei stained with DAPI, in blue
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Figure 4.7: FOXP2 is co-expressed with NR2F2 in the Purkinje cells in the cerebellum
Immunofluorescence experiments to assess endogenous co-expression of Nr2f2 with
FoxP2 in the cerebellum of P3 mice brains. Foxp2 protein expression is shown in red;
Nr2f2, in green; and nuclei stained with DAPI, in blue. (Scale bar = 200 µm).
modulating dendritic spine density (Balamotis et al. , 2012; Denaxa et al. , 2012).
Nr2f1 regulates the differentiation of motor neurons, axonal projection and cor-
tical arealization and, together with Nr2f2, plays a role in cell migration and
regulation of neurogenesis (Armentano et al. , 2006, 2007; Faedo et al. , 2008;
Tomassy et al. , 2010; Tripodi et al. , 2004). The interactions we demonstrated
between these proteins and FOXP family members may therefore impact on
a range of crucial processes in cortical development and maturation. Protein-
protein interactions and their downstream consequences are naturally limited
to the cell populations in which the proteins are co-expressed. Our analysis of
co-expression of Foxp2 and interacting transcription factors in early post-natal
mouse cortex shows that the subpopulations of co-expressing cells vary from a
minor fraction of cells to the majority of deep layer projection neurons. Foxp1
and Foxp4 show different patterns of expression in the developing cortex com-
pared to Foxp2, leading to further combinations of protein-protein interactions
with differing functional outcomes.
In addition to roles in cortical development, our findings highlight potential
interactions in the cerebellum. We found co-expression of Nr2f2 and Foxp2 in
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Purkinje cells of the cerebellum; expression of the individual proteins in Purk-
inje cells has been reported previously in separate studies (Ferland et al. , 2003;
Kim et al. , 2009a; Lai et al. , 2003). Nr2f2 regulates cerebellar growth and pat-
terning (Kim et al. , 2009a), while Foxp2 has been implicated in dendritic out-
growth and arborization of Purkinje cells (Usui et al. , 2016) and mice lacking
functional Foxp2 have small cerebellums (Groszer et al. , 2008). Foxp4, which is
similarly expressed in Purkinje cells, may also be involved in the maintenance
of dendritic arborization (Tam et al. , 2011).
FOXP1, FOXP2 and FOXP4 have all been implicated in human genetic dis-
orders with neurodevelopmental phenotypes. Several of the FOXP-interacting
transcription factors identified in this study are known to cause neurodevelop-
mental disorders through haploinsufficiency. SOX5 haploinsufficiency results
in ID and language impairment (OMIM # 616803) (Lamb et al. , 2012; Nes-
bitt et al. , 2015). De novo mutations in SATB2 cause syndromic ID, usually
with absent or near absent speech, and often cleft palate or dental anomalies
(OMIM # 612313) (Bengani et al. , 2017; Zarate & Fish, 2016; Zarate et al. , 2017).
Mutations in NR2F1 cause Bosch-Boonstra-Schaaf optic atrophy syndrome, a
dominant disorder characterized by optic atrophy and ID, frequently accompa-
nied by hypotonia, seizures, ASD and oromotor dysfunction (OMIM # 615722)
(Bosch et al. , 2014; Chen et al. , 2016a). YY1 haploinsufficiency leads to a
syndrome that includes ID often accompanied by motor problems and vari-
ous congenital malformations (OMIM # 617557) (Gabriele et al. , 2017; Vissers
et al. , 2010). ZMYM2 de novo mutations have been found in large-scale ex-
ome sequencing studies of cases of ASD (Neale et al. , 2012). However, since
ZMYM2 is ubiquitously expressed, further cases of disruptions are needed in
order to confidently establish its involvement in neurodevelopmental disorders.
Of note, following completion of experiments for this study, recurrent de novo
mutations in ZNF148, another transcription factor identified in our mass spec-
trometry screen, have been identified in individuals with developmental delay
and ID (OMIM # 617260) (Stevens et al. , 2016). The differing levels of ID and
speech/language impairment associated with disruption of FOXP proteins and
their interacting transcription factors suggests that reduced levels of these tran-
scription factors lead to differing, but potentially related, disturbances in down-
stream gene expression and cortical development.
Most of the identified FOXP-interacting transcription factors control cortical
development in an interconnected fashion, cooperating with each other but also
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forming positive and negative loops of regulation between them (Greig et al. ,
2013). For instance, to maintain the specific neuronal identities in deeper layers
of the cortex, SOX5 directly represses Fezf2, a key node of the cortical transcrip-
tional network, in layer VI and the subplate (Shim et al. , 2012), which at the
same time is repressed by TBR1 (Han et al. , 2011), an ASD-related transcription
factor also known to interact with FOXP2 and FOXP1 (Deriziotis et al. , 2014a).
In contrast, in layer V, SATB2 promotes the expression of SOX5 and Fezf2, while
Fezf2 represses SATB2 (McKenna et al. , 2015). Also, NR2F1, SATB2 and SOX5
control the development of cortical projection neurons at least in part by re-
pressing the same target gene: the transcription factor BCL11B (Alcamo et al. ,
2008; Britanova et al. , 2008; Lai et al. , 2008; Tomassy et al. , 2010). Strikingly,
NR2F1 and NR2F2 physically interact with transcription factors BCL11B and
BCL11A (Chan et al. , 2013), which also plays roles in cortical development by
repressing TBR1 (Cánovas et al. , 2015). BCL11A haploinsufficiency has recently
been identified as a cause of sporadic ID (Dias et al. , 2016). Therefore, a number
of genetically-distinct neurodevelopmental disorders may have shared roots in
this complex regulatory network of transcription factors that orchestrates cor-
tical development, and our results contribute to extend the characterization of
this network. It will be interesting in the future to further determine the spe-
cific roles the FOXPs play in this network and, in general, better understand the
transcriptional architecture underlying cortical development.
Clearly the proteins investigated here are only a subset of the biologically-im-
portant interactors of FOXP proteins. Our mass spectrometry screens provide
the largest list of candidate FOXP-interacting proteins reported to date, and
represent a resource for further investigation of protein networks surrounding
these transcription factors. We elected to focus on transcription factors with
potential roles in neurodevelopment, and a logical next step would be to con-
sider proteins mediating transcription factor activity, such as chromatin modi-
fying and remodelling complexes. For example, the candidate FOXP-interacting
proteins include the chromatin remodeler SETD2, haploinsufficiency of which
leads to Luscan-Lumish syndrome (OMIM # 616831), a neurodevelopmental
disorder characterized by ID and macrocephaly accompanied by speech delay
(Lumish et al. , 2015; Luscan et al. , 2014). In addition, FOXP proteins have
roles in multiple tissues and candidate interactors in our screen may be of rele-
vance to the function of FOXPs in non-neuronal contexts. For example, FOXP1,
FOXP2 and FOXP4 are all expressed in the embryonic heart, and mice lacking
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Foxp1 or Foxp4 die before birth due to heart defects (Ferland et al. , 2003; Li,
2004; Teufel et al. , 2003; Wang et al. , 2004). Heterozygous mutations in our
confirmed FOXP-interaction transcription factor NR2F2 cause a variety of con-
genital heart defects (Al Turki et al. , 2014), and a critical role in heart develop-
ment has also been described for our confirmed interactor YY1 (Beketaev et al.
, 2015). Therefore the FOXPs may co-operate with NR2F2 and YY1 to regulate
downstream target genes important for cardiac development.
Our strategy employed affinity purification coupled to mass spectrometry to
screen for potential FOXP-interacting transcription factors, followed by valida-
tion of selected candidate interactors using a BRET assay. These two methods
have different strengths in relation to identifying protein interaction partners.
The affinity purification method gives a proteome-wide picture of protein inter-
actions, but may miss weak or transient interactions because it is performed on
cell lysates, and may suffer from false-positives due to non-specific and indirect
interactions. In contrast, BRET is a targeted method which monitors protein in-
teractions in living cells, can detect transient interactions, is less vulnerable to
false positives, but may give false negatives due to the constraints on energy
transfer (Deriziotis et al. , 2014b). We show here that this two-stage approach
is effective in identifying high-confidence protein interaction partners with po-
tential biological importance.
In conclusion, our findings situate the FOXPs within a broader molecular net-
work that orchestrates cortical development, and thus provide novel clues as to
how these proteins work to build a functioning brain, and why their deficiency
leads to neurodevelopmental disorders.
4.5 supplementary material
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Supplementary Figure 4.1: FOXP2 isoforms interaction with FOXP-interacting pro-
teins. (a) Schematic representation of synthetic FOXP2 variants. Known domains are
labeled: glutamine-rich (Q-rich) region (hatched shading), long (QL) and short (QS) poly-
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Q tracts, zinc finger (ZF), leucine zipper (LZ) and forkhead domain (FOX) (b-h) BRET
assays for for interaction of FOXP2 isoforms with FOXP-interacing proteins. HEK293
cells were transfected with Renilla luciferase-FOXP2 wild type (WT) or variants (donor)
and YFP (acceptor) fusions of SOX5 (b), ZMYM2 (c), SATB1 (d), SATB2 (e), YY1 (f),
NR2F1 (g) or NR2F2 (h). The control acceptor protein is a nuclear-targeted YFP. Values
are mean corrected BRET ratios normalized to wild-type FOXP2 ± S.E.M (n=3).
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Supplementary Figure 4.2: Synthetic FOXP2 variants interaction with SOX5, ZMYM2
and YY1. (a) Schematic representation synthetic FOXP2 poly-Q deletion variants. Known
domains are labeled: glutamine-rich (Q-rich) region (hatched shading), long (QL) and
short (QS) poly-Q tracts, zinc finger (ZF), leucine zipper (LZ) and forkhead domain
(FOX) (b-c) BRET assays for interaction of FOXP2 poly-Q synthetic variants with FOXP-
interacting proteins. HEK293 cells were transfected with Renilla luciferase-FOXP2 wild
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type (WT) or variants (donor) and YFP (acceptor) fusions of SOX5 (b) or ZMYM2 (c).
The control acceptor protein is a nuclear-targeted YFP. Values are mean corrected BRET
ratios normalized to wild-type FOXP2 ± S.E.M. (n = 3). (d) BRET assay for the interaction
of a FOXP2 synthetic variant lacking residue E400 (key residue for homo-dimerization
through the leucine zipper) with NR2F1. HEK293 cells were transfected with Renilla
luciferase-FOXP2 wild type (WT) or variant (donor) and YFP (donor) fusion of NR2F1.
The control acceptor protein is a nuclear-targeted YFP. Values are mean corrected BRET
ratios normalized to wild-type FOXP2 ± S.E.M. (n = 3).
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Abstract: De novo missense variants in BCL11A were identified in three unrelated
infants with developmental delay through trio-based exome sequencing performed
as part of the Deciphering Developmental Disorders study. The variants in these
patients are notably clustered within the N-terminal region of the protein, further
suggesting that disruption of BCL11A function is the cause of the disorder in these
patients. BCL11A encodes a zinc finger transcription factor, expressed in both the
hematopoietic system and the developing brain. Whole gene deletions affecting BCL11A
have previously been described in individuals with neurodevelopmental disorders. A
microdeletion only affecting BCL11A was found in a child with childhood apraxia of
speech together with mild autistic traits, developmental delay and hypotonia. BCL11A
haploinsufficiency has also been suggested to underlie some of the clinical features of
the rare chromosome 2p16.1-p15 deletion syndrome, which is characterized by intel-
lectual disability, dysmorphic features, microcephaly, and skeletal and organ abnor-
malities, although not all individuals with this syndrome have deletions encompass-
ing BCL11A. The role of BCL11A in brain development is poorly understood, but the
gene is expressed in the developing cortex, hippocampus, basal ganglia and cerebel-
lum, and has recently been reported to play a role in the specification of subcortical
projection neurons by repressing expression of TBR1, a gene recurrently mutated in
cases of autism. The missense variants found in the new patients lie outside the zinc
finger DNA-binding domains, in a region of unclear function. We therefore sought to
characterize the effects of these variants on protein function in order to confirm their
etiological role, and to illuminate the molecular mechanism of disorder. We found
that all three variants disrupt the localization of BCL11A within the nucleus and
abolish protein dimerization and transcriptional regulatory activity.
1 Results in this chapter have been published as part of: Dias C.∗, Estruch S.B.∗, Graham S.A., McRae
J., Sawiak S.J., Hurst J.A. , Joss S.K., Holder S.E., Morton J.E.V., Turner C., Thevenon J., Mellul K.,
Sanxhez-Andrade G., Ibarra-Soria X., Deriziotis P., Santos R.F., Lee S., Faivre L., Kleefstra T., Liu
P., Hurles M.E., DDD Study, Fisher S.E., Logan D.W. (2016). BCL11A haploinsufficiency causes an
intellectual disability syndrome and dysregulates transcription. The American Journal of Human
Genetics, 99(2), 253-274. doi:10.1016 /j.ajhg.2016.05.030. ∗joint first authors
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Our results therefore strongly support a causal role for BCL11A missense variants
in the developmental delay of these patients, and contribute to the delineation of a
novel monogenic intellectual disability syndrome. Furthermore the characterization
of these variants reveals a key role for the N-terminal region of BCL11A in mediating
protein dimerization and regulation of transcription, and suggest that this region
may be a mutational hotspot.
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5.1 introduction
The Deciphering Developmental Disorders (DDD) study has contributed sig-
nificantly to the understanding of neurodevelopmental disorders through the
identification of novel causative genes on a large scale (Deciphering Develop-
mental Disorders Study, 2015). Large studies of this kind could prove to be a
powerful tool for discovery of language-related genes, as a large proportion of
the patient cohort exhibit speech and language deficits. The strategy of identi-
fying de novo variants in patients with severe sporadic disorders by exome se-
quencing can enable disorder genes to be identified based on the recurrence of
mutations in the same gene in patients with similar phenotypes. For some genes
there are insufficient patients, or the phenotype is not distinctive enough, to al-
low pathogenicity to be conclusively assigned to the variants based on statistical
analysis of the sequencing data alone. In such cases, functional characterization
of the variants can provide compelling evidence of pathogenicity.
The DDD identified de novo missense mutations in the BCL11A gene (also
known as CTIP1 or EVI9) in three patients with intellectual disability (ID). This
gene is a promising candidate for involvement in neurodevelopmental disorder.
Haploinsufficiency of BCL11A has been suggested to be a key contributor to the
clinical features of the 2p15p16.1 microdeletion syndrome (OMIM # 612513), a
very rare genetic disorder caused by a heterozygous deletions in the short arm
of chromosome 2 that encompasses several different genes. The first 2p15p16.1
deletion was described in 2007 in two individuals who presented with pheno-
types that included developmental delay, structural brain abnormalities, dys-
morphic features, gross motor impairments, ID and autistic behaviors (Rajcan-
Separovic et al. , 2007). Since then, several cases presenting similar phenotypic
profiles have been reported with partially overlapping deletions of this chromo-
somal region that range from 0.3 to 5.7 Mb (Peter et al. , 2014). The 2p15p16.1
microdeletion syndrome presents a variable neurodevelopmental phenotype
but some features are common in all the patients, such as ID, abnormal muscle
tone, gross motor delays, growth retardation, non verbal or low verbal status
and craniofacial and skeletal dysmorphic features (Peter et al. , 2014). In 2014,
the smallest deletion, which involved only the BCL11A gene, was reported in
an individual who presented with mild ID, motor delay, hypotonia and CAS
(Peter et al. , 2014). The proband differed from other microdeletion cases in
that he did not have any craniofacial or skeletal anomalies and he presented a
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milder form of ID. Moreover, while other microdeletion cases exhibited mild
to severe language delays, this individual presented a distinctive speech pheno-
type, specifically characterized by childhood apraxia of speech (CAS), as well
as dysarthria, which was likely caused by the general hypotonia. Interestingly,
the BCL11A gene is located within a dyslexia susceptibility candidate region
(DYX3), previously identified in several dyslexia studies using linkage analysis,
although evidence of association of common variants in the gene has not been
reported (Carrion-Castillo et al. , 2013).
BCL11A is a zinc finger transcription factor that is expressed at high levels
in the hematopoietic system and also in the fetal brain (Satterwhite et al. , 2001).
BCL11A (CTIP-1, COUP-TF interacting partner 1) was first identified, together
with its close homologue BCL11B (CTIP-2, COUP-TF interacting partner 2), as
a binding partner of NR2F2 (COUP-TFII) in a yeast two-hybrid screen (Avram
et al. , 2000). BCL11A acts as a co-repressor of NR2F1 and NR2F2 but it can also
function as a transcription factor and bind DNA to regulate gene expression in-
dependently (Avram et al. , 2002). Alternative splicing of BCL11A produces
multiple isoforms: the most abundant ones are known as the extra long (XL, ac-
cession AJ404611), long (L, accession AJ404612), short (S, accession AJ404613),
and extra short (XS, accession AY692278) isoforms (Figure 5.1). BCL11A-XL is
the most abundant isoform in blood cells while BCL11A-L is most abundant in
the brain (Kuo & Hsueh, 2007; Liu et al. , 2006; Satterwhite et al. , 2001). Iso-
forms S and XS can act as natural antagonists of the L and XL isoforms by form-
ing hetero-dimers with them and preventing their binding to DNA (Kuo et al.
, 2009). All four isoforms share exons 1 and 2, which encode a non-canonical
C2CH zinc finger domain (shaded green box in Figure 5.1). This type of zinc
finger usually mediates protein-protein interactions and is a putative hetero-
and homo-dimerization domain (Avram et al. , 2000; Liu et al. , 2006). All iso-
forms except for BCL11A-XS also contain a non DNA-binding C2H2 zinc finger
domain (shaded grey). Only BCL11A-XL and –L have the DNA-binding C2H2
zinc fingers (shaded blue boxes in Figure 5.1), which allow these isoforms to
regulate gene expression by direct binding to DNA. The proline-rich domain
(shaded yellow in Figure 5.1), which usually mediates multiple transcriptional-
related protein (Hsieh et al. , 1994); and a glutamate-rich domain (shaded pink),
which is involved in regulating gene expression (Chou & Wang, 2015) are also
specific to the L and XL isoforms. Although BCL11A is expressed in both the
hematopoietic system and the developing brain (Kuo and Hsueh, 2007; Leid et
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al., 2004; Saiki et al., 2000), its functions have primarily been studied in the
hematopoietic system, where BCL11A is essential for B-cell development; in
the absence of this gene no B-cells are produced (Liu et al. , 2003). BCL11A
is also functionally important in the development of erythrocytes where it me-
diates the switching between fetal and adult forms of hemoglobin (Sankaran
et al. , 2010). Fetal hemoglobin, which has an α 2γ 2 subunit composition, is
able to bind oxygen with greater affinity than the adult form, which has an α
2β 2 composition, giving the developing fetus better access to oxygen from the
mother bloodstream (Sankaran et al. , 2010). The switch from expression of γ
subunits to expression of β subunits occurs over the first few months of postna-
tal life and crucially involves transcriptional repression of the γ-globin gene by
BCL11A (Xu et al. , 2010). A single-nucleotide polymorphism (SNP) identified
at the BCL11A locus decreases the expression of BCL11A in erythroblasts 3.5-
fold, resulting in the continued expression of fetal γ-globin in adults (Sankaran
et al. , 2010). Remarkably, reducing the levels of BCL11A in a mouse model of
sickle cell disease (which is caused by mutation of the hemoglobin β subunit) re-
activates transcription of fetal hemoglobin, which is sufficient to ameliorate the
symptoms of the disease (Xu et al. , 2011). Currently, post-natal hematopoietic-
specific suppression of BCL11A is being developed as a potential therapy for
patients with sickle cell disease (Bjurström et al. , 2016; Hossain & Bungert,
2017).
The functions of BCL11A in the brain have been far less well studied than
in the hematopoietic system. In the developing brain, BCL11A is expressed in
several regions including the cortex, hippocampus, striatum, cerebellum, and
spinal cord (Kuo & Hsueh, 2007; Leid et al. , 2004) and it has been shown to
negatively regulate axon branching and dendrite outgrowth (Kuo et al. , 2009).
Knocking down isoform L of Bcl11a in cultured neurons resulted in increased
dendrite number and total dendrite length, as well as a higher number of axonal
branches, as compared to control neurons. Down-regulation of Bcl11a-L also
increased the arbor complexity of both axons and dendrites (Kuo et al. , 2009).
Strikingly, overexpression of a construct that encoded a truncated version of
Bcl11a-L (resembling Bcl11a-S) promoted neurite arborization, mimicking the
effect of Bcl11a-L knockdown. This suggests that Bcl11a-S may function as an
endogenous negative regulator for Bcl11a-L by interacting with it and prevent-
ing it from binding to DNA (Kuo et al. , 2009). The negative effects of Bcl11a-L
on axon morphogenesis may be controlled in part by its physical interaction
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Figure 5.1: Schematic representation of BCL11A isoforms. BCL11A most abundant
isoforms are the extra long (XL), long (L), short (S), and extra short (XS) isoforms. Known
domains are shown: the glutamate-rich domain (Glu) is shaded in red; the proline-rich
domain (Pro), in green; the C2CH zinc finger (ZF), in yellow; the non-DNA binding
C2H2 zinc finger, in grey; and the DNA-binding C2H2 zinc finger domain, in dark blue.
The different exons (E) and the numbers of amino acids that compose each exon are
indicated at the top.
with the ID-related transcription factor CASK, since disruption of the interac-
tion between CASK and Bcl11a increased axon outgrowth and branching (Kuo
et al. , 2010).
More recently, Bcl11a has been reported to control the migration of cortical
projection neurons by repressing the expression of Sema3c (Wiegreffe et al. ,
2015) and to be involved in determining the identity of the different types of
cortical projection neurons (Woodworth et al. , 2016). In the absence of Bcl11a,
corticothalamic and deep-layer callosal projection neurons show impaired dif-
ferentiation, and deep-layer neurons adopt characteristics of subcerebral pro-
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jection neurons. In contrast, overexpression of Bcl11a in the brain results in
suppressed expression of subcerebral projection neuron specific genes, result-
ing in an abnormal projection of this subtype of projection neuron; instead of
projecting to subcerebral brain regions, they abnormally project to the thala-
mus and across the corpus callosum, resembling corticothalamic and callosal
projection neurons (Woodworth et al. , 2016). This suggests that Bcl11a is cru-
cial for determining and maintaining the identity of these specific subtypes of
projection neurons.
Many known BCL11A interaction partners play important roles during neu-
rodevelopment, such as NR2F1 and NR2F2 (Avram et al. , 2000, 2002; Chan
et al. , 2013), which are critical determinants of cortical development; NR2E1
(Chan et al. , 2013; Estruch et al. , 2012), which is a neurogenesis regulator; or
CASK (Kuo et al. , 2010), which carries out multiple functions in neurons. No-
tably, most of these are transcription factors, which suggests that they could
interact with Bcl11a to cooperatively regulate downstream target genes impor-
tant for brain development. Bcl11a target genes include Dcc and Map1b, which
mediate the effects of Bcl11A on neurite branching and outgrowth (Kuo et al. ,
2009), and the autism-related transcription factor Tbr1, the repression of which
by Bcl11A is necessary for specification of cortical subcerebral projection neu-
rons (Cánovas et al. , 2015). Interestingly, haploinsufficiency of TBR1 results in
autism spectrum disorder (ASD) together with language impairment and etio-
logical TBR1 variants disrupt the interaction with FOXP2, mutations of which
lead to CAS (Deriziotis et al. , 2014a). Also, Sema3c, which is required to control
migration of cortical projection neurons, is a major downstream target gene of
Bcl11a (Wiegreffe et al. , 2015).
There is therefore growing evidence that BCL11A is an important regulator
of neurodevelopment and that it is potentially implicated in neurodevelopmen-
tal disorders. In the work described in this chapter, I sought to confirm the role
of BCL11A in neurodevelopmental disorder by performing functional character-
ization of BCL11A variants arising from point mutations in patients with such
disorders. Assays in cell-based models support the hypothesis that the missense
mutations result in loss of function of the mutated proteins in vivo, highlighting
BCL11A haploinsufficiency as a cause of the disorder in the patients. These as-
says, combined with detailed clinical characterization of patients with BCL11A
variants by our collaborators, including identification of additional cases with
loss-of-function variants, provide the evidence to define a novel ID syndrome.
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5.2 material and methods
DNA constructs
The coding sequences of BCL11A-S (NM_138559), BCL11A-L (NM_018014),
NONO (NM_001145408) and NR2F1 (NM_005654) were amplified from hu-
man fetal brain cDNA using the primers in Table S1 and cloned into pCR2.1-
TOPO (Invitrogen). The patient missense mutations were introduced using the
Quik-Change Lightning SDM kit (Agilent). For expression of fusion proteins
with Renilla luciferase, YFP and mCherry, cDNAs were subcloned into the pLuc,
pYFP and pmCherry expression vectors, respectively, which have been described
previously, using the BamHI and XbaI sites (Deriziotis, Graham, Estruch, &
Fisher, 2014; Deriziotis, O’Roak, et al., 2014). For the mammalian one-hybrid
assay, a vector for expression of BCL11A fused in frame with the yeast GAL4
DNA-binding domain was created by cutting and re-ligating pBIND (Promega)
at the ClaI sites to remove the Renilla luciferase expression cassette. Wild-type
and mutant forms of BCL11A-L were subcloned into the BamHI and XbaI sites
of this vector. A reporter plasmid was generated by inserting a KpnI-NcoI frag-
ment of pG5luc (Promega) containing five GAL4 binding sites and a minimal
adenovirus major late promoter into the vector pGL4.23 (Promega), which con-
tains a codon-optimized firefly luciferase gene. A plasmid containing Renilla
luciferase downstream of the herpes simplex virus thymidine kinase promoter
(pGL4.74, Promega) was used for normalization.
Cell culture
HEK293 cells (ECACC, cat. no. 85120602) were cultured in DMEM supple-
mented with 10% FBS. Transfections were performed using GeneJuice (Merck-
Millipore) according to the manufacturer’s instructions.
Western blotting
Cells were transfected in 6-well plates and cultured for 48 h. Cells were lysed
for 10 min at 4◦ C with 100 mM Tris pH 7.5, 150 mM NaCl, 10 mM EDTA,
0.2% Triton X-100, 1% PMSF, and protease inhibitor cocktail. Cell lysates were
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cleared by centrifugation at 10,000 x g for 3 min at 4◦ C. Proteins were re-
solved on 10% SDS-polyacrylamide gels and transferred to PVDF membranes
using a TransBlot Turbo blotting apparatus (Bio-Rad). Membranes were blocked
in phosphate buffered saline containing 5% non-fat milk powder and 0.1%
Tween-20, and incubated overnight at 4◦ C with primary antibody. The fol-
lowing antibodies were used: anti-GFP (Clontech cat. no. 632380, 1:8000, for
YFP constructs); anti-β -actin (Sigma cat. no. A5441, 1:10,000). After washing,
membranes were incubated with horseradish peroxidase-conjugated goat anti-
mouse or anti-rabbit IgG for 45 min at room temperature. Proteins were visu-
alized using Novex ECL Chemiluminescent Substrate Reagent Kit (Invitrogen)
and a ChemiDoc XRS+ imaging system (Bio-Rad).
Cellular assay fluorescence microscopy
Cells were seeded on coverslips coated with poly-L-lysine. Cells were cultured
for 30 h post-transfection, and then fixed with methanol. Fluorescence images
were acquired using Zeiss Axiovert A-1 or Axio Imager 2 fluorescence micro-
scopes with ZEN Image software.
BRET assay
The BRET assay has been described in detail elsewhere (Deriziotis et al., 2014a).
Briefly, cells were transfected in white, clear-bottomed 96-well plates, in tripli-
cate, with 6 fmol Renilla luciferase fusion expression plasmid and 6 fmol YFP
fusion expression plasmid (total mass of DNA was adjusted to 60 ng with filler
plasmid). Renilla luciferase or YFP with a nuclear localization signal were used
as controls. Cells were cultured for 48 h post-transfection. Enduren luciferase
substrate (Promega) was added at a final concentration of 60 µM, and cells were
cultured for a further 4 h. Luminescence was measured in a TECAN Infinite
F200PRO microplate reader using the Blue1 and Green1 filters.
Mammalian one-hybrid assay
Cells were transfected in white, clear-bottomed 96-well plates, in triplicate,
with 8.5 fmol pBIND-BCL11A, 5 fmol firefly luciferase reporter plasmid, and 2
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fmol Renilla luciferase normalization plasmid (total mass of DNA was adjusted
to 60 ng with filler plasmid). Cells were cultured for 48 h post-transfection. Fire-
fly and Renilla luciferase activities were measured using the Dual Luciferase
Reporter Assay (Promega).
5.3 results
5.3.1 Identification of mutations in BCL11A
In the DDD cohort six individuals were identified with de novo heterozygous
variants in the BCL11A gene, from a total of 4,295 affected individuals studied
using whole exome sequencing (Figure 5.2; Table 5.1). The first three variants
to be discovered in the DDD cohort were all missense variants, which clustered
together in exon 2 of BCL11A (Patients 1, 2 and 3) (Deciphering Developmen-
tal Disorders Study, 2015). Three additional variants discovered later in an ex-
panded DDD cohort were all loss-of-function (LoF) variants (one nonsense, Pa-
tient 4, and two frameshift, Patients 5 and 6) (Figure 5.2b). Searching for addi-
tional BCL11A variants in other unpublished developmental disorder cohorts
uncovered three additional patients with de novo LoF variants (Patients 7 to
9). Finally, two patients with LoF variants were identified among cohorts of in-
dividuals with ASD in published exome sequencing studies; the relevance of
these variants to the patients’ phenotypes had been unclear at the time of orig-
inal publication (Patients 10 and 11). Thus, this study included a total of 11
patients, with 3 missense variants and 8 LoF variants.
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Figure 5.2: Variants in BCL11A found in patients with neurodevelopmental disorders.
(a) Schematic representation of BCL11A isoforms S, L and XL, and BCL11A missense
mutations. Known domains are shown: the C2CH zinc finger (ZF) is shaded in green;
the non-DNA binding C2H2 zinc finger, in grey; and the DNA-binding C2H2 zinc finger
domain, in dark blue. (b) Schematic representation of frameshift and nonsense BCL11A
variants.
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Interestingly, given the exonic structure of BCL11A, LoF variants might af-
fect each isoform differently (Table 5.2). Isoforms S and XS are unaffected by 5/8
patient LoF variants, suggesting that a functional S/XS isoform is insufficient
for normal neurodevelopment, consistent with the lack of DNA-binding capac-
ity for these isoforms (Table 5.2). All LoF variants are predicted to affect iso-
form L through nonsense-mediated RNA decay, whereas isoform XL might be
affected by either premature truncation or nonsense-mediated decay, depend-
ing on the type of mutation. Given that isoform L is known to be the major
isoform in the brain, all LoF variants might be expected to have comparable ef-
fects on neurodevelopment. However, it is possible that the differing effects on
isoform XL may contribute to the observed variability in phenotypic profiles of
the patients (Table 5.1).
Table 5.2: BCL11A patient variants effects on each isoform.
NMD, nonsense-mediated mRNA decay.
Patient # BCL11A Variant Predicted effect on each isoform
XL L S
1 p.T47P Substitution Substitution Substitution
2 p.C48F Substitution Substitution Substitution
3 p.H66Q Substitution Substitution Substitution
4 p.Q177* NMD NMD NMD
5 p.S679Qfs*47 Premature truncation NMD Unaffected
6 p.S515Lfs*5 Premature truncation NMD Unaffected
7 p.E593Gfs*9 Premature truncation NMD Unaffected
8 p.Q52* NMD NMD NMD
9 p.E65* NMD NMD NMD
10 p.L442Pfs*37 Premature truncation NMD Unaffected
11 p.L265Pfs*3 Premature truncation NMD Unaffected
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5.3.2 Clinical features of patients with BCL11A mutations
Clinical characterization of the patients was carried out by C. Dias. All indi-
viduals identified with BCL11A mutations presented with global delay in de-
velopmental milestones, including speech and language delay. Most patients
exhibit moderate ID, though the degree of cognitive dysfunction varies (Table
5.1). One of the two patients previously ascertained through an ASD study
(De Rubeis et al. , 2014; Iossifov et al. , 2014) is also known to have severe
ID (Patient 10); intellectual capacity was not reported in the other. Patient 2
has received a diagnosis of ASD, and four other patients present a spectrum of
behaviour abnormalities including repetitive behaviour and sensory problems.
Shared physical features among patients include joint laxity (87% ), strabismus
(100% ), microcephaly (55% ), thin upper lip and flat midface. 62% of patients
have external ear abnormalities (Table 5.1), which are more severe in patients
with nonsense and frameshift mutations. Patients 4, 5 and 6, all of whom have
nonsense or frameshift mutations, had blue sclerae in infancy. As well as the
BCL11A variant, Patient 6 also carries a probably pathogenic 4.3 Mb duplication
of 15q15.3q21.1, and a contribution of this duplication to the phenotype, specif-
ically to delayed skeletal maturation and short stature, cannot be excluded.
Fetal hemoglobin was significantly elevated in all patients in whom it was as-
sessed, including all those with missense mutations in BCL11A (Table 5.1). The
phenotypes of patients with missense and LoF variants are therefore similar,
suggesting that the effect of the missense variants is to impair normal protein
function. To determine if and how the missense variants affect protein function,
I performed in silico analyses of the variants, followed by functional character-
ization using cell-based assays.
5.3.3 Patient missense mutations cluster in a non-canonical zinc finger domain in
BCL11A
All three missense mutations are located in the N-terminal region of BCL11A,
which is reported to be required for homo- and hetero-dimerization of BCL11A
isoforms (Liu et al. , 2006), as well as for interaction with repressive nucleo-
some remodeling complexes (Cismasiu et al. , 2005). Specifically, these muta-
tions cluster in the non-canonical C2HC zinc finger domain of BCL11A (Figure
5.3). A zinc finger is a small protein structure domain that mediates protein-
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protein and protein-nucleic acid interactions. The C2H2 is the canonical zinc
finger domain and forms a stable secondary structure by the coordination of a
zinc atom by two cysteine residues and two histidine residues (Krishna et al. ,
2003).
DHDLLTCGQCQMNFPLGDILIFIEHKRKQCNGSL 
T47P C48F H66Q 
a 
b 
WT 
Zinc  
atom 
Cys48 Cys51 
His66 
Cys71 
C48F 
C48F 
H66Q H66Q 
C2HC zinc finger 
Non-DNA binding 
C2H2 zinc finger 
DNA binding 
C2H2 zinc finger 
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c d 
Figure 5.3: BCL11A missense substitutions cluster in the C2HC zinc finger domain
of BCL11A. (a) Schematic representation of BCL11A isoform XL showing the three mis-
sense variants clustering in the C2HC zinc finger domain. The C2CH zinc finger (ZF) is
shaded in yellow; the non-DNA binding C2H2 zinc finger, in grey; and the DNA-binding
C2H2 zinc finger domain, in dark blue. Core cysteine and histidine residues of the do-
main are shown in dark and light blue, respectively. (b-d) 3D models of C2HC zinc
finger (Protein Bata Bank [PDB] ID 2JYD) visualized with YASARA. The wildtype (WT)
C2HC zinc finger (b) consists of three cysteine residues, in dark blue, and one histidine
residue, in light blue, that hold in place the zinc atom, in red, to stabilize the secondary
structure. BCL11A variants p.C48F (c) and p.H66Q (d), in purple, directly disrupt core
cysteine and histidine residues of the domain.
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All of the zinc finger domains in BCL11A are of the C2H2 type, with the
exception of the N-terminal C2HC domain (Avram et al. , 2000).The C2HC is a
non-canonical type of zinc finger domain that utilizes 3 cysteine residues and
one histidine residue to hold the zinc atom in place and stabilize the secondary
structure (Krishna et al. , 2003). Molecular modelling suggests that the missense
mutation p.T47P is adjacent to a central cysteine residue of this domain while
p.C48F and p.H66Q affect core cysteine and histidine residues of the domain
(Figure 5.3b-d). This suggests that all three missense mutations are likely to
abolish zinc binding and disturb the folding of the C2HC zinc finger domain of
BCL11A, resulting in the loss of molecular interactions involving this domain.
5.3.4 Patient missense mutations disrupt cellular localization of BCL11A-L.
To study the impact of the missense mutations on BCL11A protein function, I
performed a battery of cellular assays focusing on BCL11A-L and BCL11A-S,
the two isoforms of BCL11A reported to be more abundant in the brain (Kuo &
Hsueh, 2007; Liu et al. , 2006; Satterwhite et al. , 2001). We generated mCherry
and YFP-tagged versions of these isoforms containing each of the three patient
missense mutations and expressed them in HEK293 cells (Figure 5.4).
The expression levels of wild-type and mutant BCL11A proteins were as-
sessed by western blotting of lysates from transfected cells (Figure 5.4a). Wild-
type BCL11A-L was detected at ∼ 120 KDa and BCL11A-S at ∼ 50 KDa. Proteins
with the three missense mutations were of identical molecular weight and ex-
pressed in similar amounts to each corresponding wild-type BCL11A isoform.
Subcellular localization of BCL11A protein variants was examined in HEK293
cells transfected with mCherry-tagged BCL11A-L and BCL11A-S. Consistent
with what was previously reported (Liu et al. , 2006), BCL11A-L was local-
ized to the nucleus and BCL11A-S was observed only in the cytoplasm. The
subcellular localization of the mutant forms of BCL11A-S was unaffected and
indistinguishable from the wildtype form (Figure 5.4b). Wildtype BCL11A-L
was found in nuclear paraspeckles in agreement with previous studies (Fox &
Lamond, 2010). Nuclear paraspeckles are subnuclear structures that may be in-
volved in the regulation of transcription and RNA processing, as inferred by the
presence of paraspeckle specific proteins (i.e. NONO, PSPC1 and SFPQ) that
are known to contribute to such processes (Fox & Lamond, 2010; Morimoto &
Boerkoel, 2013). Strikingly, all three patient missense mutations disrupted the
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paraspeckle distribution of BCL11A-L (Figure 5.4c) and showed a diffuse pat-
tern of localization in the nucleus.
The nuclear paraspeckle localization of wild-type BCL11A-L was demon-
strated by its co-localization with the paraspeckle-specific protein NONO (Fig-
ure 5.5a). Co-localization of the mutant forms of BCL11A-L with NONO was
severely reduced but did not completely disappear. To further investigate this
phenomenon, I used a bioluminescence resonance energy transfer (BRET) as-
say, which allows the monitoring of protein-protein interactions in living cells.
In the BRET assay, a protein of interest is expressed as a fusion with Renilla
luciferase (Luc) and a candidate interaction partner is expressed as a fusion
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Figure 5.4: Expression of wildtype and mutant BCL11A-L and –S isoforms in HEK293
cells. (a) Western blot of mutant and wildtype BCL11A-L and BCL11A-S isoforms.
HEK293 cells were transfected with mutant or wildtype (WT) BCL11A fused to YFP.
Blots of whole cell lysates were probed with anti-YFP to detect BCL11A and with
anti-β-actin to confirm equal loading. (b) Fluorescence micrographs of HEK293 cells
transfected with wildtype (WT) or mutant short isoform of BCL11A fused to mCherry
(red). Nuclei were stained with Hoechst 33342 (blue). (c) Fluorescence micrographs of
HEK293 cells transfected with wildtype or mutant long isoform of BCL11A fused to
mCherry (red). Nuclei were stained with Hoechst 33342 (blue). Scale bars represent 10
µm.
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Figure 5.5: BCL11A missense substitutions alter paraspeckle localization of isoform
L. (a) Fluorescence micrographs of cells transfected with wild-type or mutant BCL11A-
L fused to mCherry (red) and NONO fused to YFP (green). Nuclei were stained with
Hoechst 33342 (blue). Scale bars represent 10 µm. (b) Bioluminescence resonance energy
transfer (BRET) assay for interaction of wild-type or mutant BCL11A-L with NONO.
HEK293 cells were transfected with BCL11A-L fused to Renilla luciferase, and NONO
fused to YFP. Values are mean corrected BRET ratios ± SEM (n = 3).
with yellow fluorescent protein (YFP). An interaction between the two proteins
brings the Luc and YFP molecules into sufficient proximity to allow resonance
energy transfer to occur upon addition of a luciferase substrate, shifting the
wavelength of the emitted light from 480 nm to 530 nm. Using Luc-BCL11A-
L and YFP-NONO fusion proteins, I confirmed that BCL11A-L interacted with
NONO (Figure 5.5b), consistent with the co-localization observed in the nu-
clear paraspeckles. The patient mutations reduced, but did not completely abol-
ish, the interaction of BCL11A-L with NONO, which together with the reduced
co-localization suggested that a fraction of the expressed BCL11A mutant pro-
tein was still found in nuclear paraspeckles. Interestingly, NONO has recently
been implicated in ID, therefore the interaction between BCL11A and NONO
may represent a functional link between different ID syndromes (Mircsof et al.
, 2015).
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5.3.5 Patient missense mutations disrupt homo- and hetero-dimerization
The three patient missense mutations all lie within a non-canonical C2CH zinc
finger domain and two of the mutations disrupt a core cysteine and a core his-
tidine of this domain (Figure 5.3). This zinc finger domain is present in all
BCL11A isoforms (Figure 5.1), and is within the region of the protein reported
to mediate BCL11A dimerization, suggesting that it could potentially have a
central role in mediating homo- and hetero-dimerization of BCL11A isoforms.
I used the BRET assay coupled with fluorescence imaging of protein localiza-
tion to study the effects of these variants on homo- and hetero-dimerization of
BCL11A isoforms. The hetero-dimerization of BCL11A-L and BCL11A-XL with
BCL11A-S mediates the translocation of BCL11A-S from the cytoplasm into the
nucleus (Liu et al. , 2006). The results confirmed that wild-type BCL11A-L and
BCL11A-S form homo- and heterodimers (Figure 5.6a,b; Figure 5.7a,b) (Kuo
& Hsueh, 2007; Liu et al. , 2006) and that co-expression of BCL11A-L causes
BCL11A-S to translocate from the cytoplasm into nuclear paraspeckles (Fig-
ures 5.6c, 5.7c) (Liu et al. , 2006). In contrast, BCL11A-L isoforms carrying mu-
tations have a substantially reduced interaction with both L and S wild-type
BCL11A isoforms (Figure 5.6a,b) and an abolished capacity to translocate wild-
type BCL11A-S into the nucleus (Figure 5.6c). Analogous effects were observed
when the patient mutations were introduced into BCL11A-S (Figure 5.7). Taken
together, these results suggest that the variants could be blocking the correct
folding of the C2CH zinc finger domain, thereby disrupting the dimerization
ability of BCL11A.
5.3.6 Patient missense mutations do not disrupt interaction with NR2F1
BCL11A-L interacts with members of the nuclear receptor family 2F, NR2F1
and NR2F2, as well as with members of the nuclear receptor family 2E, NR2E1
and NR2E3, which are transcription factors expressed in neural tissues and
with important roles in brain development (Avram et al. , 2000; Chan et al. ,
2013; Estruch et al. , 2012). Moreover, mutations in NR2F1 have been reported
in patients with ID (Bosch et al. , 2014). I used the BRET assay to confirm
BCL11A interaction with NR2F1 and observed that none of the missense mu-
tations in BCL11A-L disrupted the interaction. This finding is in line with the
fact that the domains in BCL11A-L that mediate this interaction, which encom-
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Figure 5.6: Missense substitutions in BCL11A-L disrupt homo and hetero-
dimerization. (a) BRET assay for interaction of mutant BCL11A-L with wildtype (WT)
BCL11A-L. HEK293 cells were transfected with wildtype or mutant BCL11A-L fused to
Renilla luciferase (donor) and wildtype BCL11A-L fused to YFP (acceptor). The control
donor protein is a nuclear-targeted luciferase. Values are mean corrected BRET ratios ±
SEM (n = 3).
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Figure 5.6: (Cont.) (b) BRET assay for interaction of mutant BCL11A-L with wild-type
BCL11A-S. HEK293 cells were transfected with wildtype or mutant BCL11A-L fused
to Renilla luciferase (donor) and wildtype BCL11A-S fused to YFP (acceptor). Values
are mean corrected BRET ratios ± SEM (n = 3). c Fluorescence micrographs of HEK293
cells transfected with wildtype or mutant BCL11A-L fused to YFP (green), together with
wildtype BCL11A-S fused to mCherry (red). Nuclei were stained with Hoechst 33342
(blue). Scale bar represents 10 µm.
pass residues 310-325 and 651-670, are located some distance away from the
locations of the mutations (Chan et al. , 2013; Estruch et al. , 2012) (Figure
5.8a). When transfected alone, NR2F1 normally exhibits a diffuse nuclear distri-
bution (Figure 5.8b) but when co-expressed with wild-type BCL11A-L, NR2F1
showed a nuclear speckled pattern that coincided with BCL11A-L (Figure 5.8c).
In agreement with the BRET results, NR2F1 protein was diffuse in the nucleus
when co-expressed with the patient BCL11A patient missense variants, which
also localized in the nucleus in a diffuse manner (Figures 5.4c,5.8c).
5.3.7 Patient missense mutations disrupt transcriptional activity
BCL11A-L acts as a transcription factor by binding to DNA in a sequence-
specific manner via two C2H2 zinc finger domains, while BCL11A-S lacks the
DNA-binding zinc finger domains and is unable to bind to DNA (Figure 5.1)
(Avram et al. , 2002; Liu et al. , 2006). We used a mammalian one-hybrid (M1H)
assay to examine the effects of the patient missense mutations on the capacity
of BCL11A to regulate transcription. BCL11A-L was fused to the DNA-binding
domain of yeast GAL4 and co-transfected with a reporter plasmid containing
five sequential GAL4 binding sites upstream of a luciferase gene (Figure 5.9a).
Wild-type BCL11A-L produced a ∼ 2.5-fold activation of reporter transcription,
showing that BCL11A can stimulate transcription in this system. The activation
of reporter transcription was significantly reduced for all three mutant variants
(p<0.05, one-way ANOVA followed by Bonferroni post-hoc test; Figure 5.9b),
suggesting that these variants would have a reduced ability to regulate tran-
scription of BCL11A target genes in vivo.
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Figure 5.7: Missense substitutions in BCL11A-S disrupt homo and hetero-
dimerization. (a) BRET assay for interaction of mutant BCL11A-S with wildtype (WT)
BCL11A-S. HEK293 cells were transfected with wildtype or mutant BCL11A-S fused to
Renilla luciferase (donor) and wildtype BCL11A-S fused to YFP (acceptor). The control
donor protein is a nuclear-targeted luciferase. Values are mean corrected BRET ratios ±
SEM (n = 3).
5166 bcl11a mutations in neurodevelopmental disorders
Figure 5.7: (Cont.) (b) BRET assay for interaction of mutant BCL11A-S with wild-type
BCL11A-L. HEK293 cells were transfected with wildtype or mutant BCL11A-S fused to
Renilla luciferase (donor) and wildtype BCL11A-L fused to YFP (acceptor). Values are
mean corrected BRET ratios ± SEM (n = 3). (c) Fluorescence micrographs of HEK293
cells transfected with wildtype or mutant BCL11A-S fused to YFP (green), together with
wildtype BCL11A-L fused to mCherry (red). Nuclei were stained with Hoechst 33342
(blue). Scale bars represent 10 µm.
5.4 discussion
The results of this study demonstrate that missense variants in BCL11A found
in children with neurodevelopmental disorders have consistent deleterious ef-
fects on BCL11A localization, dimerization and transcriptional regulatory activ-
ity. Together with the clinical observation that patients with such variants have
elevated fetal hemoglobin and a profile of other clinical features similar to loss-
of-function mutations, the data support the hypothesis that these N-terminal
missense mutations result in a loss of BCL11A function that results in neurode-
velopmental impairments. The cellular assays suggest that BCL11A missense
mutations are hypomorphic alleles, where the loss of function may not be com-
plete. The missense mutations severely impair BCL11A transcriptional activity
and dimerization but they do not completely abolish the localization of BCL11A
in nuclear paraspeckles and do not alter its interaction with NR2F1. This could
explain the similar but milder phenotypes seen in the patients with missense
mutations, as compared to what is observed in patients with truncations, where
loss of function of the affected allele is expected to be complete.
The work described in this chapter identifies a novel syndrome in individu-
als with missense and truncating BCL11A mutations that is most notably char-
acterized by ID and persistence of fetal hemoglobin. While the patients do not
present consistent recognizable dysmorphic features, the presence of mild dys-
morphism with ID and persistence of fetal hemoglobin define a clinical syn-
drome, with the latter providing a valuable diagnostic tool. Persistence of fetal
hemoglobin has also been noted in individuals with chromosomal microdele-
tions encompassing BCL11A (Basak et al. , 2015; Funnell et al. , 2015). In individ-
uals with 2p15p16.1 deletions that do not disrupt the BCL11A coding sequence,
testing for persistence of fetal hemoglobin could be a useful method for ascer-
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Figure 5.8: Missense substitutions in BCL11A-L do not affect interaction with NR2F1.
(a) BRET assay for interaction of mutant BCL11A-L with wildtype (WT) NR2F1.
HEK293 cells were transfected with wildtype or mutant BCL11A-L fused to Renilla lu-
ciferase (donor) and wildtype NR2F1 fused to YFP (acceptor). The control donor protein
is a nuclear-targeted luciferase. Values are mean corrected BRET ratios ± SEM (n = 3).
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Figure 5.8: (Cont.) (b) Fluorescence micrographs of HEK293 cells transfected with
NR2F1 fused to YFP. (c) Fluorescence micrographs of HEK293 cells transfected with
wildtype or mutant BCL11A-L fused to mCherry (red), together with NR2F1 fused to
YFP (green). For (b) and (c), Nuclei were stained with Hoechst 33342 (blue). Scale bar
represents 10 µm.
taining whether critical regulatory sequences have been deleted, leading to loss
of BCL11A expression. Fetal hemoglobin persistence is asymptomatic and does
not affect the normal performance of the hematopoietic system in individuals
with BCL11A disruptions.
BCL11A has previously been proposed as a susceptibility gene for ASD (De Rubeis
et al. , 2014). However, despite a high frequency of behaviour abnormalities
among patients with BCL11A disruptions, only 30% fulfill the diagnostic crite-
ria for ASD, whereas all have ID. Thus in contrast to ID, ASD is a variable fea-
ture of the BCL11A syndrome. The microdeletion spanning only the BCL11A
gene in a child with CAS suggested a strong involvement of this gene in speech
and language development (Peter et al. , 2014). The findings here support a
role of BCL11A in communication skills, but in this set of cases the language
phenotype is predominantly characterized by a considerable delay of language
development. Moreover, the clinical profiles also underscore the importance of
this gene in other features, such as developmental delay, ID and hypotonia. A
recent review of 36 cases of 2p15p16.1 microdeletion syndrome further con-
firmed that the phenotype caused by BCL11A haploinsufficiency includes dis-
ruptions of speech or language functions, but the manifestation of these signs
is variable and the affected patients also present other mild cognitive deficits
and weak muscular tone (Lévy et al. , 2017). Recently, a new frameshift mu-
tation was identified in a child with CAS, dyspraxia, mild ID and hypotonia
across motor systems including the oral and speech motor systems (Soblet et al.
, 2017). Taken together, these findings point towards a broad role of BCL11A in
the development of social cognitive abilities.
Results in this chapter have been published as part of a larger study that
included a mouse model of BCL11A haploinsufficiency (Dias et al. , 2016). No-
tably, mice carrying only one copy of the BCL11A gene exhibit microcephaly
together with impaired social behaviour, a phenotypic profile that is consistent
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Figure 5.9: BCL11A missense substitutions disrupt transcriptional regulation. (a)
Schematic representation of the mammalian one-hybrid (M1H) assay to asses transcrip-
tional regulatory activity. (b) M1H assay for BCL11A-L transcriptional regulatory ac-
tivity. HEK293 cells were transfected with wildtype or mutant BCL11A-L fused to the
DNA-binding domain of GAL4, together with a firefly luciferase reporter plasmid con-
taining GAL4 binding sites, and a Renilla luciferase normalization plasmid. Values are
mean firefly luciferase activity normalized to Renilla luciferase activity ± SEM (n = 3),
expressed relative to the control (∗∗∗p < 0.001, one-way ANOVA followed by Bonferroni
post hoc correction).
with that observed in patients with loss-of-function mutations of the human
orthologue. This supports the hypothesis that haploinsufficiency of BCL11A is
sufficient to cause neurodevelopmental disorder. Additionally, large-scale tran-
scriptomic analyses of this mouse model revealed differences in gene expres-
sion in the cortex and the hippocampus between heterozygous and wildtype
neonatal mice. Together with the impaired transcriptional activity that I demon-
strated for the BCL11A missense mutations, these findings suggest that tran-
scriptional dysregulation is an underlying etiological mechanism in the associ-
ated syndrome.
The functional experiments described in this chapter also add to the knowl-
edge of BCL11A function, supporting the hypothesis that the zinc finger do-
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main in the N-terminus of the protein is involved in dimerization and is neces-
sary for transcriptional regulatory activity. Notably, the DNA-binding domains
of BCL11A remain intact in patients with missense BCL11A variants, but regu-
lation of transcription is impaired. Thus, cell-based assays and patient features
(clinical and hematological) indicate the importance of protein-protein interac-
tions for the role of BCL11A in regulating gene expression. This implies that the
N-terminus region of BCL11A has an underappreciated significance for tran-
scriptional repression of fetal hemoglobin and other target genes. This region
may prove to be a hotspot for disorder-related missense mutations in BCL11A
as more cases come to light. The suite of assays employed here to investigate the
functional consequences of missense mutations in BCL11A proved to be highly
effective in detecting the deleterious effects of these variants and therefore pro-
vides a framework for functional assessment of novel BCL11A variants in the
future.
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6.1 summary
The aim of this dissertation was to shed light on the biological foundations of
human speech and language by investigating the molecular function of tran-
scription factors related to monogenic language-related disorders. As described
in Chapter 1, the complex foundations of speech and language entail a challeng-
ing search for the underlying genes. Large-scale genetic association studies have
revealed a few common genetic variants with small contributions to speech
and language, but the most fruitful entry points into the biological bases have
come from investigating monogenic language-related disorders, such as cases
of childhood apraxia of speech (CAS) caused by rare FOXP2 mutations. FOXP2
was the first gene to be clearly linked with speech and language, and the vast
majority of current knowledge on relevant molecular mechanisms comes from
investigating its functions in cellular and animal models. FOXP2 encodes a tran-
scription factor that belongs to the FOXP subgroup of forkhead-box proteins. In
this subgroup, the related proteins FOXP2, FOXP1 and FOXP4 are expressed in
the central nervous system and play overlapping yet distinct roles in brain de-
velopment. FOXP1 is the closest homologue to FOXP2 and has been implicated
in an intellectual disability (ID) syndrome that includes language impairment.
The common aim of Chapters 2 to 4 was to identify and investigate novel
FOXP interaction partners. Deciphering the physical interaction networks of
the FOXP proteins can reveal valuable insights into the ways these transcrip-
tion factors contribute to brain development and how are they regulated, as
well as pinpointing novel language-related candidate genes. Prior to the work
described here, this particular aspect of the molecular biology of the FOXPs
had been scarcely studied. The two most commonly used protein-protein inter-
action screening methods are yeast two-hybrid (Y2H) assays and affinity purifi-
cation followed by mass spectrometry (AP/MS). Previous studies by our group
had used both these techniques to search for FOXP2 interacting proteins pro-
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viding a list of potential candidate partners that awaited confirmation with dif-
ferent methods.
In Chapter 2, I validated a putative interaction between FOXP2 and PIAS1
found in prior Y2H screens and demonstrated that it mediates the post-trans-
lational modification (PTM) of FOXP2 with SUMO molecules. I identified a ma-
jor single sumoylation site at K674 conserved in FOXP2 orthologues and par-
alogues, which suggests that sumoylation of this protein has an evolutionarily
ancient role. Abolishing the major sumoylation site disrupted FOXP2 sumoyla-
tion but did not produce any changes in subcellular localization, stability, tran-
scriptional regulation, dimerization with wild-type FOXP2, or interaction with
the co-repressor CtBP1. Sumoylation is a fast and dynamic process, which im-
plies that only a minor fraction of protein is sumoylated at a given time. There-
fore, the functional consequences of FOXP2 sumoylation may be subtle and
only detectable in the context of a developing organism. Additionally, I anal-
ysed sumoylation of the FOXP2 variant R553H, which disrupts the forkhead-
box domain and is known to be the cause of CAS in the large multigenerational
KE family. I found that the mutated protein is sumoylated to a lesser extent than
wild-type FOXP2 and shows a reduced interaction with PIAS proteins. These
results suggest that the forkhead-box domain may also be required for proper
sumoylation of FOXP2.
In Chapter 3, I sought to confirm the putative interactions of FOXP2 with
NONO and SFPQ, which were found in AP/MS screens previously performed
in our group. As neurodevelopmental transcription factors that interact with
each other, NONO and SFPQ were promising candidates for interaction with
FOXP2. I used a range of different complementary assays to test for FOXP2 in-
teractions with SFPQ and NONO, but such interactions could not be detected in
any of the experiments. In contrast, FOXP2 homo-dimerization and NONO in-
teraction with SFPQ were successfully observed with the techniques employed.
Based on the findings of this chapter, together with particular experimental
caveats of the previously performed AP/MS screens, it seems likely that NONO
and SFPQ were false positives in the original FOXP2 protein-protein interaction
screens. Thus, this work suggested that new mass spectrometry screens should
be performed in order to robustly identify novel FOXP2 interaction partners.
Consequently, in Chapter 4, I performed new AP/MS screens to search for
FOXP2 and also for FOXP1 and FOXP4 protein-protein interactions, providing
the most extensive list of putative FOXP interacting-proteins reported to date.
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I characterized the interaction between the FOXPs and 7 neurally-expressed
transcription factors– SOX5, NR2F1, NR2F2, SATB1, SATB2, ZMYM2 and YY1.
I demonstrated overlapping expression of these transcription factors with the
FOXPs in regions of the developing brain, which suggests that they can cooper-
ate in vivo to regulate downstream genes in neural sites of co-expression. Sev-
eral of the interacting transcription factors are known to be crucial for brain de-
velopment and are disrupted in individuals with neurodevelopmental and/or
psychiatric disorders. I showed that these interactions are disrupted by FOXP1
and FOXP2 mutations that cause language-related neurodevelopmental disor-
ders, revealing novel functional links between transcription factors underlying
such conditions. Finally, I identified specific regions in FOXP2 mediating the in-
teractions. The findings in this chapter highlight the power of proteomic-based
tools in expanding our understanding of the role of FOXP proteins and other
neural transcription factors in brain development, and in the biology of speech
and language.
In Chapter 5, I set the FOXPs aside to focus on a novel language-related can-
didate gene, BCL11A. Recent advances in DNA sequencing have revolutionized
the field of genetics making it easier, faster and cheaper to find molecular causes
of neurodevelopmental disorders. This is fueling the discovery of novel genes
with putative roles in neurodevelopment, and in speech and language, one of
which is BCL11A. This gene encodes a transcription factor that has mostly been
studied in relation to its functions in the hematopoietic system; few investiga-
tions have been carried out in a neuronal context. A microdeletion affecting
only the BCL11A gene found in a patient with CAS and mild ID highlighted a
possible role of this gene in speech and language. Deletions involving BCL11A
had been previously found in individuals with a neurodevelopmental pheno-
type that included some common features such as ID and variable degrees of
language impairment. In this chapter, I characterized the functional impacts
of three newly identified BCL11A missense variants found in several individu-
als with ID and delayed developmental milestones, including speech and lan-
guage delay. The substitutions in BCL11A cluster in the zinc-finger domain in
the N-terminal region. My functional assays revealed that BCL11A missense
mutations negatively affect several aspects of protein function including sub-
cellular localization, dimerization and transcriptional activity. Overall, these
experiments confirmed the pathogenic role of the missense mutations, and un-
covered roles of the N-terminal zinc-finger domain of BCL11A in protein dimer-
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ization, subcellular localization and transcriptional activity. By combining the
functional data with detailed clinical descriptions of the patient phenotypes
obtained by our collaborators, we were able to define a novel monogenic neu-
rodevelopmental disorder characterized by ID, persistence of fetal hemoglobin,
and other variable features (OMIM 617101).
6.2 fine-tuning foxp2 with post-translational modifications
Transcription factors are often regulated by post-translational modifications
(PTMs) (Filtz et al. , 2014; Skelly et al. , 2016). PTMs are reversible protein chem-
ical modifications that can transiently modulate protein function in a myriad of
ways (Seo & Lee, 2004). Typically, transcription factors are subject to a consider-
able number of PTMs, which are often interconnected with each other forming
complex regulatory systems (Filtz et al. , 2014; Skelly et al. , 2016). For instance,
it is known that FOXP3 can be acetylated, ubiquitinylated and phosphorylated
and that these PTMs affect many core aspects of FOXP3 function, such as tran-
scriptional activity and protein stability (van Loosdregt & Coffer, 2014). In con-
trast, the regulation of the other FOXP proteins (FOXP1/2/4) by PTMs has been
clearly underexplored.
In chapter 2, I demonstrated that FOXP2 is subject to sumoylation, the first
PTM reported for the major isoform of this protein. This finding was also re-
ported by two independent studies within the same period of time when we
published the results of chapter 2 (Meredith et al. , 2015; Usui et al. , 2016).
The three investigations agree on the basic molecular mechanisms of FOXP2
sumoylation: it occurs at lysine K674 and is promoted by members of the PIAS
family. However, there are some discrepancies regarding the effects that this
PTM has on FOXP2 function (Table 6.1). The consequences of sumoylation are
varied but the underlying principle is that it alters inter- and/or intramolecular
interactions to change protein localization, stability, and/or activity. My work
in HEK293 cells showed that the K674R substitution in FOXP2, which abolishes
the sumoylation site, behaves in a similar way to the wild-type protein in all the
assays that I performed (Table 6.1).
Conflicting with the work in this dissertation and with the investigations by
Meredith et al., Usui and colleagues reported that inhibition of sumoylation re-
sulted in an increased cytoplasmic localization of FOXP2, and that the K674R
mutant was found both in the nucleus and in the cytoplasm in human HEK293
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Table 6.1: Comparison of the effects of FOXP2 sumoylation on protein function ob-
served in three independent studies. The effects of sumoylation on the functions of
FOXP2 have been investigated in three independent studies (Chapter 2, (Meredith et al.
, 2015; Usui et al. , 2016)) The different investigations found that some FOXP2 protein
functions were altered by sumoylation (Affected) and others were not (Unaffected).
Protein sta-
bility
Protein-
Protein
interac-
tions
Subcellular
localiza-
tion
Transcriptional activity
HEK293 hNP
Meredith
et al.
Unaffected Not tested Unaffected Affected Not tested
Chapter 2 Unaffected Unaffected Unaffected Unaffected Not tested
Usui et al. Unaffected Unaffected Affected Unaffected Affected
cells, and in the mouse brain (cortical layer 6 neurons and Purkinje cells in the
cerebellum) (Usui et al. , 2016). Thus, Usui et al. suggested that sumoylation is
required for nuclear localization of FOXP2 and that this PTM affects its tran-
scriptional activity, as cytoplasmic protein is not able to bind to DNA. However,
they did not find any substantial differences between wild-type and K674R
FOXP2 in the transcriptional repression of a canonical FOXP2 motif, in line
with the findings in Chapter 2. Conversely, Meredith et al. found that K674R
FOXP2 exhibited a reduced repression of DISC1, SRPX2 and MIR200c promot-
ers compared to wild-type protein (Meredith et al. , 2015). However, though
they were statistically significant, the differences between K674R and wild-type
FOXP2 were relatively small. The modulation of FOXP2 transcriptional activity
by sumoylation might be affecting an aspect of protein function that has not
been assessed in any of the studies, such as a specific DNA or protein inter-
action. Alternatively, it could be the case that the functional consequences of
sumoylation are subtle, and/or cell-type and promoter dependent. Usui et al.
found that CNTNAP2 mRNA levels were higher in human neural progenitor
cells expressing FOXP2 K674R than in those expressing the wild-type protein,
possibly suggesting that in human neuronal progenitor cells, FOXP2 sumoyla-
tion is necessary to repress CNTNAP2 expression (Usui et al. , 2016). However,
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none of the putative functional consequences of FOXP2 sumoylation has been
replicated in (at least) two independent studies and additional confirmatory
studies are needed.
In any case, the effects of sumoylation may precisely fine-tune FOXP2 activ-
ity in such a way that they may only be evident in the context of a developing
brain. It has been shown that in the brain, sumoylation has an impact on diverse
aspects of neuronal morphology and function, and that dysregulation of the
SUMO pathway often leads to neurological and neurodegenerative disorders
(Henley et al. , 2014). Strikingly, the work by Usui and colleagues suggests that
FOXP2 sumoylation in mice may be important for motor control and ultrasonic
vocalizations through the regulation of Purkinje cell growth in the developing
cerebellum (Usui et al. , 2016). In the study, they detected a sumoylated form
of FOXP2 protein in the neonatal cerebellum. According to their data, almost
all FOXP2 is sumoylated at specific neonatal stages (P7, P10, P14), which are
critical time points of cerebellar development (Usui et al. , 2016). This is an
unusual finding since other studies suggest that the fast dynamics of sumoyla-
tion means that only a minor fraction of a protein is sumoylated at a certain
time point (Wilson, 2017). FOXP2 knockdown in the neonatal cerebellum re-
sulted in a reduction of neuron outgrowth, a phenotype that could be rescued
by overexpressing the wild-type protein but not with a K674R mutant (Usui
et al. , 2016). Moreover, FOXP2 knockdown also altered motor function, as well
as the number and length of ultrasonic vocalizations, phenotypes that again
could only be rescued with wild-type FOXP2 but not with the K674R variant
(Usui et al. , 2016). In the future it will be crucial to confirm these findings with,
for instance, the generation of transgenic mice that express FOXP2 K674R only
in the cerebellum.
The sumoylation site in FOXP2 is conserved among its paralogues and or-
thologues, suggesting an ancestral role for this modification in the FOXP family.
In Chapter 2, I showed that FOXP1, like FOXP2, interacts with members of the
PIAS family and with SUMO molecules, which indicates that FOXP1 is proba-
bly sumoylated. Indeed, a subsequent study confirmed that FOXP1 is sumoy-
lated at the same conserved site as FOXP2 (K670 in FOXP1, K674 in FOXP2)
(Rocca et al. , 2017). That study demonstrated that FOXP1 sumoylation reg-
ulates transcription cooperating with the CtBP1 co-repressor complex to pro-
mote dendritic morphogenesis in rat neurons (Rocca et al. , 2017). In HEK293
cells, FOXP1 mutant K670R did not repress transcription in a luciferase assay
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using the SV40 promoter, a common binding promoter of FOXP1 and FOXP2.
Conversely, in chapter 2 I show, in the same cell line, that FOXP2 K674R re-
pressed the SV40 promoter with the same strength as wild-type FOXP2. In neu-
ronal cell lines, Rocca and colleagues reported that FOXP1 sumoylation is re-
quired for the regulation of CNTNAP2 expression, similarly to the findings that
Usui and colleagues reported for FOXP2 (Usui et al. , 2016; Rocca et al. , 2017).
This suggests that sumoylation affects the specific transcriptional activities of
FOXP1 and FOXP2 in different but overlapping ways to regulate neuronal de-
velopment.
The rapid and dynamic nature of sumoylation makes it a well-suited mecha-
nism to modify the activity of proteins such as FOXP2 and FOXP1 in response to
activity within neural circuits. Remarkably, activity-dependent calcium signal-
ing regulates the ability of FOXP1 sumoylation to recruit the CtBP1 co-repressor
complex, as neuronal activity results in the loss of HDAC2 from this complex
(Rocca et al. , 2017). In the future, it will be interesting to determine how FOXP2
sumoylation may be regulated in the brain in response to environmental cues,
and/or whether there are other mechanisms that regulate neural FOXP1 sumoy-
lation.
FOXP1/2 sumoylation is probably not the only PTM regulating transcrip-
tion factor function; hence, additional FOXP1/2 PTMs remain to be identified.
Various PTMs are known to fine-tune FOXP3 function, some of which lie on
residues that are conserved in the other FOXPs (van Loosdregt & Coffer, 2014).
For instance, FOXP3 lysine residues 268 and 393 are modified by ubiquitin to
regulate FOXP3 degradation (van Loosdregt et al. , 2013). These sites are con-
served in the other FOXPs and lie in the leucine zipper and forkhead domain,
respectively. Additionally, lysine 268 can be acetylated, which has been shown
to regulate both FOXP3 protein stability and transcriptional activity (Kwon et al.
, 2012). These findings pinpoint sites in FOXP1 and FOXP2 that may be post-
translationally modified, uncovering additional PTMs that potentially regulate
FOXP1 and FOXP2 other than sumoylation.
PTMs such as acetylation, ubiquitinylation or phosphorylation in FOXP1
and FOXP2 could be identified utilizing proteomic mass-spectrometry approaches.
Additionally, it would be interesting to analyze missense variants in patients
with neurodevelopmental disorders to see if these affect PTM sites.
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Figure 6.1: Protein interaction regions of FOXP2. Schematic representation of FOXP2
protein. Known domains are shown in grey: the glutamine-rich region (Q-rich), the
polyglutamine tracts shaded in a dashed pattern, the zinc finger (ZF), the leucine zip-
per (LZ), the forkhead domain (FOX) and the nuclear localization signals (NLS). The
regions in FOXP2 that mediate specific protein-protein interactions are indicated with
horizontal lines, which are colour-coded for each interaction partner. The sumoylation
site is indicated with an arrow.
6.3 novel functional regions in foxp proteins
When I started this thesis, the roles of the FOXP forkhead-box domain in DNA
binding and of the leucine zipper in homo- and hetero-dimerization were well
known, but the functional significance of other protein regions remained to be
discovered. The protein-protein interaction work of this dissertation has un-
covered new functions for uncharacterized regions of FOXP2, such as the N-
and C-terminal parts, and for known domains, such as the zinc finger and the
forkhead-box domains (Figure 6.1).
The N-terminal region of FOXP2 seems to coordinate several different protein-
protein interactions. This part of FOXP2 is essential for the interaction with the
transcription factors TBR1, SOX5, ZMYM2 and also the PIAS enzymes (Chap-
ters 2 and 4) (Deriziotis et al. , 2014a),and may additionally be important for the
interaction with SATB1 and SATB2 (Chapter 4). The N-terminal part of FOXP2
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is an intrinsically disordered region (IDR) (Viscardi et al. , 2017). This kind of
region is often found in transcription factors, in which it can also mediate differ-
ent protein interactions (Shammas, 2017; Wang et al. , 2015). IDRs lack stable
three-dimensional structures, which allows for a wide range of conformations
(Dyson & Wright, 2005). Their versatility in adopting different conformations
enables interactions with multiple proteins (Hsu et al. , 2012).
The conformational plasticity of IDRs also confers accessibility to PTM en-
zymes, such as PIAS proteins, and many PTMs occur preferentially in IDRs
(Mittag et al. , 2010). In line with this, FOXP2 sumoylation takes place at residue
K674 in the C-terminal region, which is also intrinsically disordered. Many
other PTMs may be occurring in the N-terminal and C-terminal regions of
FOXP2. As discussed in the previous section, it would be very interesting to
identify more PTMs regulating FOXP2 and investigate how they crosstalk with
each other to precisely control FOXP2 function.
Results in chapter 4 suggest that both the N-terminal and the forkhead-box
domain in FOXP2 are required for the interaction with SATB1 and SATB2 (Fig-
ure 6.1). This means that either the SATB proteins physically interact with both
domains or that FOXP2 has to be bound to DNA in order for the interaction to
occur.
Notably, the FOXP2 substitution p.R533H, which is located in the forkhead-
box domain and prevents the mutant protein from binding to DNA, disrupts
most of the FOXP2 protein-protein interactions and also its ability to be sumoy-
lated (Chapters 2 and 4), despite the fact that most of the mapped FOXP2
binding-regions for these interactions do not include this domain. A hypoth-
esis to explain this paradox would be that some FOXP2 protein-protein inter-
actions are DNA-dependent and can only occur if FOXP2 is bound to DNA.
Alternatively, it could be the case that the substitution p.R553H destabilizes
the forkhead-box domain, causing other protein regions to adopt an aberrant
conformation that renders them inaccessible to other proteins.
Finally, the BRET results in chapter 4 suggest the zinc-finger domain of
FOXP2 probably mediates the interaction with the transcription factors NR2F1
and NR2F2. Accordingly, this domain contains a site that partially overlaps with
a known NR2F binding motif (Chan et al. , 2013). This would be the first indica-
tion of the functional role of the zinc-finger domain in FOXP2. However, further
experiments involving the mutation of the core residues of the NR2F binding-
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Figure 6.2: Cortical expression patterns in the developing brain of transcription fac-
tors studied or mentioned in this thesis. Schematic vertical representation of the differ-
ent layers of the cortex. Dashed lines separate the different cortical layers and shaded are
the layers in which each transcription factor is expressed. Dashed shading indicates low
levels of expression (Alcamo et al. , 2008; Cánovas et al. , 2015; Denaxa et al. , 2012; Fer-
land et al. , 2003; Lai et al. , 2008; McKenna et al. , 2015; Szemes et al. , 2006; Takahashi
et al. , 2008; Tripodi et al. , 2004; Woodworth et al. , 2016)
motif in FOXP2 would need to be done in order to confirm that this region does
indeed mediate these interactions.
6.4 a transcription factor network underlying cortical develop-
ment
The cerebral cortex processes higher order cognitive functions, such as learn-
ing, planning and social behaviours, and also motor skills, which are critical
neuronal mechanisms underpinning speech and language (Donovan & Basson,
2016; Krishnan et al. , 2016). Cortical development is tightly controlled by
transcription factors that cooperate with each other to regulate gene expres-
sion forming complex molecular networks. Intriguingly, several of the FOXP-
interacting transcription factors characterized in chapter 4, namely SOX5, SATB1,
SATB2, NR2F1 and NR2F2, as well as the FOXPs, are expressed in the devel-
oping cortex. TBR1, which is able to interact with FOXP1 and FOXP2, is also
expressed in this part of the brain (Deriziotis et al. , 2014a). These transcription
factors display distinct yet overlapping patterns of expression throughout the
different layers of the cortex (Figure 6.2), indicating that interactions could be
occurring in vivo in specific layers of the cortex.
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Most of these transcription factors are known to play important roles in the
developing cortex. Among other functions, FOXP2 regulates neurite outgrowth
and synaptic plasticity in cortical neurons, as well as in other brain areas (Enard
et al. , 2009; Groszer et al. , 2008; Reimers-Kipping et al. , 2011; Vernes et al. ,
2011). A role for FOXP2 and also FOXP1 in controlling migration of cortical
and striatal neurons has also been reported in a few studies (Li et al. , 2015b).It
is well known that SOX5, TBR1 and SATB2 are essential transcription factors
for the development of a normal cortex. SOX5 controls the timing of the gener-
ation of the distinct corticofugal neuron subtypes and TBR1 is crucial for the
differentiation and identity determination of deep-layer projection neurons(Lai
et al. , 2008; Cánovas et al. , 2015). SATB2 is an important regulator of the dif-
ferentiation and axonal path finding of cortical projection neurons (Britanova
et al. , 2008).In contrast, its close homologue SATB1 is mostly known for its role
in the immune system, although there is a study indicating that in the brain
SATB1 helps regulate cortical interneuron development (Denaxa et al. , 2012).
The nuclear receptors NR2F1 and NR2F2 are also involved in cortical devel-
opment. NR2F1 regulates the differentiation of cortical motor neurons, axonal
projection and cortical arealization and, together with NR2F2, plays roles in cell
migration and regulation of neurogenesis (Tomassy et al. , 2010; Tripodi et al. ,
2004).
The functions of the protein-protein interactions identified here remains un-
known but there are different possible mechanisms (Figure 6.3). One plausible
scenario is that two transcription factors bind overlapping or adjacent binding
sites and cooperate with each other to regulate common target genes (Figure
6.3a). For example, a transcription factor may require an interacting partner to
first contact DNA so it can be brought in close proximity to bind a specific low-
affinity binding site (Deplancke et al. , 2016). Two interacting transcription fac-
tors can also be mutually dependent if the binding affinity of the pair together
is greater than the sum of the individual affinities(Deplancke et al. , 2016). An-
other possibility is that two interacting transcription factors contact distal DNA
sites creating a DNA loop that can alter the chromatin state and conformation
(Deplancke et al. , 2016) (Figure 6.3b). Alternatively, one transcription factor
could prevent the other from binding DNA by interacting with its binding do-
main or blocking its accessibility (Figure 6.3c), as has been suggested for the
interaction of Foxp2 and Nxk2.1 in the lung (Zhou et al. , 2008).
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Figure 6.3: Hypothetical different types of interplay between the FOXPs and their
interacting-transcription factors. (a) Cooperative binding to overlapping or adjacent
binding sites. (b) Binding to distant cis-elements forming a DNA loop. (c) Interaction
that blocks the binding of one ore both transcription factors to their DNA-binding sites.
TF, Transcription factor.
Interestingly, many of the cortical FOXP-interacting transcription factors
regulate the expression of each other and are connected through a network
of both transcriptional regulation and protein-protein interactions, which also
involves other language- and neurodevelopment-related transcription factors
(Figure 6.4). In layer VI and in the developing subplate, SOX5 and TBR1 di-
rectly repress the transcription of FEZF2, which is essential for maintaining the
specific neuronal identities of deep cortical neurons (Shim et al. , 2012; Han
et al. , 2011).
Besides interacting with FOXP2, SOX5 and TBR1 have also been hypoth-
esized to regulate FOXP2 expression in the developing cortex (Becker, 2016).
In layer V, FEZF2 represses SATB2, while SATB2 promotes the expression of
FEZF2 and also SOX5 (McKenna et al. , 2015). The repression of the transcrip-
tion factor BCL11B by NR2F1, SATB2 and SOX5 is important to control the de-
velopment of cortical projection neurons (Alcamo et al. , 2008; Britanova et al. ,
2008; Lai et al. , 2008; Tomassy et al. , 2010). BCL11B physically interacts with
BCL11A, and also NR2F1 and NR2F2 interact with both BCL11B and BCL11A
(Chan et al. , 2013; Estruch et al. , 2012). Moreover, in the developing cortex,
BCL11A represses TBR1 and also regulates SEMA3C, a signaling molecule that
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Figure 6.4: Potential molecular network of cortical transcription factors. Schematic
representation of the molecular interactions between FOXP- or language-related corti-
cal transcription factors. Red lines indicate transcriptional repression; green, transcrip-
tional activation and black, protein-protein interactions. Dashed lines indicate unpub-
lished findings from our group. FOXP-interacting transcription factors are dark-shaded.
provides guidance cues to migrating neurons (Cánovas et al. , 2015). It is im-
portant, though, to bear in mind that all of these regulatory and physical in-
teractions do not occur in the same neuronal subtypes and at the same time
during development, which adds an extra level of complexity to this intricate
transcription factor network.
Given their important roles in cortical development, it is perhaps not sur-
prising that the disruption of the genes encoding some of these transcription
factors result in neurodevelopmental disorders. Haploinsufficiency of SOX5,
SATB2, NR2F1 or YY1 results in ID syndromes, which partially overlap with
the phenotypes caused by mutations of FOXP1 and FOXP2 (Bacon & Rappold,
2012; Bosch et al. , 2014; Gabriele et al. , 2017; Nesbitt et al. , 2015; Zarate &
Fish, 2016). SOX5- and SATB2-related syndromes are particularly interesting
because subjects with heterozygous mutations in these genes present severely
altered language functions (Lamb et al. , 2012; Nesbitt et al. , 2015; Zarate
& Fish, 2016). BCL11A haploinsufficiency leads to a neurodevelopmental syn-
drome that includes motor and language delays (Chapter 5) and, intriguingly,
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work in our group recently identified two rare intronic SEMA3C variants in
multiple affected members of a family with developmental dyslexia Carrion-
Castillo (2016).
De novo mutations in TBR1 found in ASD patients have been shown to dis-
rupt its interaction with FOXP2 or the ID-linked protein CASK mutations dis-
rupting FOXP2 also negatively altered the FOXP2-TBR1 interaction (Deriziotis
et al. , 2014a). In chapter 4, I have shown that FOXP1 and FOXP2 pathogenic
variants disrupt many of the interactions with these transcription factors, which
points towards a convergent molecular etiology for distinct yet overlapping neu-
rodevelopmental disorders. In the future, it would be interesting to investigate
the other side of the coin, looking at how pathogenic mutations in each of the
FOXP-interacting transcription factors affect their association with the FOXPs,
and how this network of cortical transcription factors may be disrupted.
Overall, this shows that neurodevelopmental disorders linked to these tran-
scription factors are connected at the molecular level. The data presented here
support the hypothesis that shared molecular networks underlying cortical de-
velopment are involved in distinct neurodevelopmental disorders such as ASD,
ID and speech and language disorders (Kwan, 2013; Voineagu et al. , 2011).
Because these are transcription factors, the connections between them are not
only physical interactions between proteins but also negative or positive regula-
tory links. This implies that disrupting one gene can affect both the expression
and function of many other genes. Depending on which gene is affected, the
network can be destabilized in diverse ways leading to distinct neurodevelop-
mental phenotypes with variable degrees of severity. The disruption of one gene
of this network can also potentially lead to normal cortical development since
the network might be readjusted to compensate for the dysfunction of the gene
during development.
FOXP-interacting transcription factors are also co-expressed with the FOXPs
in further brain regions other than the cortex, and hence, some of these interac-
tions may also have other functions in the brain beyond cortical development.
In chapter 4, I reported that FOXP2 and NR2F2 physically interact and showed
that they are specifically co-expressed in the Purkinje cells of the cerebellum.
Other FOXP2 interacting partners, namely FOXP4, CTBP1, and CTBP2, are also
expressed in Purkinje cells. The cerebellum is classically known for its role in
motor functions but it is also involved in non-motor cognitive skills such as
speech and language (Mariën et al. , 2014). Among other structural alterations
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of the brain, individuals with CAS carrying FOXP2 mutations exhibit reduced
gray matter density in parts of the cerebellum, which could be relevant for their
speech and language impairment (Vargha-Khadem et al. , 2005). Disruptions of
Foxp2 in mice result in a reduction of cerebellar size (Groszer et al. , 2008).
Similarly, NR2F2 conditional knockout in the cerebellum results in decreased
cerebellar growth and, reduced differentiation of cerebellar neurons (Kim et al.
, 2009a)
Because disruptions of NR2F2 and FOXP2 lead to similar cerebellar phe-
notypes it is reasonable to hypothesize that the physical interaction between
FOXP2 and NR2F2 may be involved in cerebellar growth. To date, the molecu-
lar behaviour of FOXP2 and NR2F2 in cerebellar development has been scarcely
investigated. One study suggests that the decreased cerebellar growth upon
knocking out NR2F2 may be in part mediated by a reduced expression of IGF-1
(Kim et al. , 2009a). Also, another study reported that CNTNAP2 mRNA levels
are increased in the cerebellum of mice carrying a Foxp2 p.R552H mutation
(corresponding to p.R553H in its human orthologue), but did not demonstrate
that these increased CNTNAP2 mRNA levels were causing a reduced cerebellar
size (Fujita-Jimbo & Momoi, 2014). In any case, additional work encompassing
all possible downstream target genes will be needed to unravel how FOXP2 and
NR2F2 take part in the development of the cerebellum and what behavioural
consequences that may have.
This work highlights the importance of investigating the molecular links
between genes identified in complex neurodevelopmental disorders. The com-
plex heterogeneity of language-related disorders and the substantial comorbid-
ity between neurodevelopmental disorders suggests that complex shared molec-
ular networks underlie their etiologies. Therefore, in order to comprehend the
molecular neurobiological foundations of language-related disorders, we not
only have to keep on searching for associated genes in patient cohorts but also
we need to decipher whether these genes are functionally linked to each other.
In this dissertation I have only considered rare language-related gene variants,
but common variation should also be taken into account when investigating
language-related networks, as it is likely that common and rare gene variants
converge on the same molecular pathways.
The transcription factors studied in this dissertation might represent just
the tip of the iceberg of a broader molecular network. A logical next step would
be to further characterize and expand this network, first, by assessing whether
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there are other protein-protein interactions involving these transcription fac-
tors, and, second, by identifying more interaction partners. This could be done
in a relatively efficient way with methods like the BRET assay and AP/MS. What
would be more challenging but particularly valuable is to investigate in which
specific neuron subtypes and developmental time points these interactions oc-
cur.
Additionally, identifying the downstream target genes of these transcription
factors would also be extremely informative. Research on FOXP2 neural target
genes revealed that these participate in key pathways involved in brain devel-
opment (Spiteri et al. , 2007; Vernes et al. , 2007, 2011). Likewise, ChIP-seq
experiments for TBR1 and FOXP1 highlighted that their downstream pathways
are enriched for genes involved in ASD (Araujo et al. , 2015; Notwell et al. ,
2016). Finally, it would also be interesting to search for shared target genes of
different transcription factors and see whether they are also involved in brain
development and/or mutated in neurodevelopmental disorders.
Systems biology methodologies combined with the systematic characteriza-
tion of neural gene function make it possible to fully and deeply characterize
language-related molecular networks. This type of approach combines experi-
mental data with statistical methods to model large sets of gene networks.
6.5 the expanding foxp interactome
A major part of this thesis has involved the identification and characterization
of FOXP-interacting proteins. In Chapter 2 I characterized the interaction be-
tween FOXP2 and PIAS proteins and discovered that this mediated the sumoy-
lation of FOXP2, and in Chapter 4 I identified and characterized seven FOXP-
interacting transcription factors, thereby expanding the FOXP interactome (Fig-
ure 6.5).
In chapter 4, I searched for FOXP-interacting proteins using affinity purifi-
cation coupled by mass spectrometry (AP/MS). The fact that my screens iden-
tified several known FOXP interactors (i.e. FOXP1, FOXP2, FOXP4, GATAD2B,
CTBP1, CTBP2) indicated that the technical approach was effective (Chapter 4,
Supplementary Table S4.2). The AP/MS screens identified more than 100 puta-
tive FOXP-interacting proteins (Chapter 4, Supplementary Table S4.2), of which
I chose to focus on 12 transcription factors for validation. Therefore, within the
identified proteins there could be more interesting candidate FOXP-interactors
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Figure 6.5: The FOXP interactome. Network diagram of FOXP protein-protein interac-
tions and post-translational modifications at least confirmed with two different experi-
mental approaches. Lines indicate protein-protein interactions. Protein-protein interac-
tions identified in this dissertation are shaded in dark blue purple font. A pink border
indicates that the genes encoding these proteins have been associated with neurodevel-
opmental disorders. Shaded in light blue are the members of the FOXP family. A dashed
line indicates an unclear interaction. Different shapes represent different types of pro-
teins: ovals are transcription factors; triangles, enzymes; and pentagons, structural pro-
teins. A small circle represents sumoylation.
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to confirm and further characterize in the future. Examples include the tran-
scription factor ZNF148, recurrent de novo mutations of which have been iden-
tified in individuals with developmental delay and ID (Stevens et al. , 2016),
and the chromatin remodeler SETD2, haploinsufficiency of which leads to a
neurodevelopmental syndrome characterized by ID and macrocephaly accom-
panied by speech delay (Lumish et al. , 2015; Luscan et al. , 2014).
One of the major limitations of AP/MS lies in the difficulty to detect weak
or transient protein-protein interactions (such as interactions with enzymes),
which, presumably, might have not been captured in our screens. Protein-protein
interaction screening methods that allow the detection of weak and transient
interactions, such as Y2H, represent a reasonable complementary approach to
AP/MS screens. In chapter 2, I characterized the interaction of FOXP2 with
PIAS1, which was first identified in Y2H screens previously performed in our
group. These screens also identified additional putative FOXP-interacting pro-
teins (Chapter 2, Supplementary Table S2.3), but these need to be further con-
firmed. Additionally, it could be worthwhile to perform new Y2H screens using
different batches of brain cDNA prey libraries. Because the composition and
relative abundances of cDNAs in each batch is variable (Sainz, 1993), the cD-
NAs encoding some FOXP-interacting proteins may have not been present or
could have been too little expressed in the cDNA batch used to perform the
Y2H screens.
Similarly, in the AP/MS screens, FOXP-interacting proteins (such as TBR1)
might have not been identified because they are not expressed in the cell line
employed (i.e. HEK293 cells). Also, this cell line may lack specific biological
cues necessary for the FOXPs to bind some protein partners. Therefore, a log-
ical next step would be to carry out the experiments using different cell lines,
such as neural cell lines or tissue that endogenously expresses FOXP proteins.
However, this approach hits upon a challenge because FOXP2-expressing cell
types are post-mitotic neurons that no longer divide and are therefore chal-
lenging to grow and manipulate. Therefore, obtaining a sufficient amount of
FOXP2-expressing neurons to perform AP/MS screens is not clearly feasible.
Alternatively, recently emerged genome-editing techniques such as CRISPR/-
Cas9 could be used to genetically engineer a mouse line that expresses endoge-
nous FOXPs fused to an epitope tag, therefore enabling a more efficient and spe-
cific affinity purification of FOXP complexes. Future advances in the proteomics
field, such as continued improvements in the sensitivity of mass spectrometry
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methods and increasingly sophisticated data analysis to discriminate between
spurious results and biologically relevant interactions will lead to more effec-
tive ways of detecting protein-protein interactions, which will help expand the
neural FOXP interactome.
6.6 the value of functional characterization studies in language-
related disorders
Advanced DNA sequencing techniques are accelerating the discovery of genes
involved in complex neurodevelopmental conditions such as speech and lan-
guage impairment. Therefore, it is becoming more and more important to dis-
cern which genetic variants are causal and which ones are incidental to the phe-
notype of interest. Predictive algorithms are commonly used to rank sequence
variants according to their predicted degree of pathogenicity. In silico modeling
of protein-coding mutations in the three-dimensional structure of the protein is
also a valuable tool that can help predict the impact of a mutation on the struc-
ture of the protein. However, data from computational methods need to be inter-
preted with caution, as they are predictions and can seldom provide sufficient
proof of causality. Functional characterization in living model systems is there-
fore crucial to clarify a pathogenic role for a suspected causal variant. Moreover,
this kind of functional work also sheds light on the molecular functions of the
protein being disrupted and therefore on the biology underlying the disorder.
The relevance of functional characterization of variants in speech and lan-
guage impairment has been principally proven by studies of FOXP2 variants in
cases of CAS. p.R553H, which was found to co-segregate with CAS in a large
multigenerational pedigree, was the first FOXP2 variant to be functionally char-
acterized (Vernes et al. , 2006). This substitution is located in the forkhead-box
domain of the encoded protein and functional assays in cellular models re-
vealed that it severely disrupts FOXP2’s binding to DNA and transcriptional
activity as well as its subcellular localization, confirming a causal role in the
disorder. Variants p.R328∗ and p.Q390Vfs∗ , which result in truncated FOXP2
proteins that lack the forkhead-box domain, also impair the ability of FOXP2 to
bind to DNA (Estruch et al. , 2016a).
In Chapter 4, I found that disorder-related FOXP1 and FOXP2 variants showed
altered interactions with the newly discovered FOXP-interacting transcription
factors. The protein interaction assays revealed that FOXP2 variants p.Q17L,
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p.M406T, p.P416T and p.N597H exhibited similar behaviour to the wild-type
protein, further supporting the view that they are incidental to the phenotype,
as observed in a previous study (Estruch et al. , 2016a). In contrast, the etio-
logical FOXP2 variants p.R553H, p.R328∗ and p.Q390Vfs∗ 7, as well as all of
the FOXP1 variants that I assessed, had an abolished or reduced ability to in-
teract with most of the FOXP-interacting transcription factors. These findings
further support the pathogenic roles of these variants, and add novel insights
into the molecular mechanisms by which they can lead to neurodevelopmental
disorders (Estruch et al. , 2016a; Sollis et al. , 2016).
Intriguingly, the interaction between FOXP2 p.R553H variant and SATB2
was slightly less reduced than for the other transcription factors, and co-expression
of both proteins led to the mislocalization of SATB2 in the cytoplasm. In a sim-
ilar way, FOXP1 variants p.R465G and p.R514C retained the ability to interact
with SOX5, which was abnormally redistributed into nuclear aggregates upon
co-expression with these variants. The same effects were observed for the inter-
action between FOXP2 p.R465G variant and ZMYM2. These findings suggest
that the relevant variants might additionally interfere with the normal function
of a subset of interacting transcription factors, which may also contribute to
pathology. This is in line with previous studies that propose a partial dominant-
negative effect for these variants by interfering with the function of wild-type
FOXPs (Estruch et al. , 2016a; Sollis et al. , 2016).
In Chapter 5, I functionally characterized three de novo missense BCL11A
variants identified in patients with neurodevelopmental disorders that included
language impairment. The three substitutions lie within a non-canonical zinc
finger domain with previously unknown function and affected many aspects of
protein function such as subcellular localization, homo-dimerization and tran-
scriptional activity, suggesting that the loss of function of BCL11A caused the
disorder. Moreover, this implies that the non-canonical zinc finger domain and,
more concretely, the specific residues mutated are involved in the aforemen-
tioned BCL11A protein functions. This work highlights the power of functional
characterization not only in ascertaining the contribution of particular variants
to disorder, but also in the discovery of novel molecular aspects of the function
of the protein. Identifying new functional protein domains can help interpret
further variants in that region identified in patients in the future.
Results in chapter 5 were published as a part of a study that included the
characterization of a mouse model of BCL11A haploinsufficiency (Dias et al.
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, 2016). Mice carrying only one copy of the gene showed abnormal social be-
haviour and microcephaly, in line with the phenotype observed in human pa-
tients. Furthermore, comparative transcriptomic analyses between heterozygous
and wild-type neonatal brains revealed transcriptional dysregulation in the cor-
tex and the hippocampus of the haploinsufficient mice, consistent with the re-
sults from my luciferase assays. Interestingly, in the differentially expressed
genes there is a considerable enrichment for genes belonging to pathways in-
volved in neurodevelopment, such as semaphorin-plexin and slit-robo signaling
pathways. Notably, members of the Semaphorin and the Robo families of genes
belonging to these pathways have been associated with dyslexia and SLI, respec-
tively (Carrion-Castillo, 2016; Chen et al. , 2017; Hannula-Jouppi et al. , 2005;
St Pourcain et al. , 2014a). This work demonstrates how coupling functional ex-
periments in cellular and animal models allows for a thorough delineation of
the molecular etiology underlying neurodevelopmental disorders that include
speech and language impairment.
The rapid pace of discovery of language-related genes, pathways and net-
works will require the development of efficient, systematic methods to interro-
gate gene function. Functional interpretation of genetic variants is nowadays
one of the major bottlenecks in the field, as experiments using cellular and
animal models are laborious, expensive and time-consuming and it is not yet
feasible to perform them in a systematic way to filter or rank variants from se-
quencing studies. Existing methods that perturb the expression or inhibit the
function of a gene product involve systematic mutagenesis using RNA interfer-
ence or overexpression approaches using cDNA, ORF and miRNA expression
libraries. Although these are useful methods, they do not allow the modeling of
single nucleotide changes.
The recently emerged genome editing technique CRISPR/Cas9 is beginning
to be used for the systematic functional analysis of whole genomes (Rauscher
et al. , 2017). Similarly, massively parallel single-amino acid mutagenesis tech-
niques, which enable missense mutational scans, can also be extremely useful to
interpret single nucleotide variants identified by clinical sequencing (Kitzman
et al. , 2015; Shendure & Fields, 2016). Approaches like this allow for the char-
acterization of both coding and non-coding DNA variation, but they have been
more extensively used to assess regulatory DNA regions, such as enhancers
(Patwardhan et al. , 2012). This is perhaps not surprising, since the impact of
mutations in regulatory regions can be clearly assessed by measuring gene ex-
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pression. For instance, Cas9-mediated in situ saturating mutagenesis has been
used to characterize an erythroid enhancer of human BCL11A, which is sub-
ject to common genetic variation associated with the fetal hemoglobin levels
(Canver et al. , 2015). Conversely, the effects of protein-coding substitutions can
be multiple and unpredictable, therefore it is more challenging to find simple
scalable tests that can be coupled to high-throughput methodologies. However,
this has been successfully done to functionally analyze the impact of nearly
2000 missense substitutions of uncertain significance in the tumor suppressor
gene BRCA1 on its core functions (Starita et al. , 2015).
High-throughput methods like the above-mentioned represent highly promis-
ing approaches to systematically characterize the impact of missense variants
in language-related disorders.
6.7 the big picture of functional genomics in language-related
disorders.
Developmental disorders of speech and language affect approximately 10% of
children at school entry and have major impacts on educational success, so-
cial relationships and job opportunities (Norbury et al. , 2016). Speech therapy
can significantly ameliorate certain speech and language deficits in children
with these disorders (Ullrich et al. , 2009). According to the American speech-
language-hearing association, it is important to start these therapies as early as
possible to guarantee an optimal outcome, since the earlier the intervention, the
more effective it is in restoring speech and language abilities for a given subject.
However, probands with language-related disorders may present with com-
plex phenotypes in which often some cognitive deficits are overlooked. Func-
tional genomics studies in language-related disorders can offer the possibility
of a genotype first-approach in the diagnosis of neurodevelopmental disorders
(Stessman et al. , 2014). A comprehensive characterization of the genetic causes
of monogenic neurodevelopmental syndromes will allow for earlier and clearer
diagnoses by genotyping the proband prior to fully characterizing the pheno-
type in sporadic cases.
The molecular characterization of monogenic language-related disorders can
also provide valuable biomarkers to facilitate reliable low-cost diagnosis of a
specific syndrome. This is the case for the BCL11A-related syndrome described
in chapter 5. Because of the non-neural role of BCL11A in repressing fetal
6the big picture of functional genomics 193
hemoglobin, haploinsufficiency leads to abnormally elevated fetal hemoglobin
levels. This hematopoietic phenotype does not represent a health risk for the
patient and can be successfully used as a physiological biomarker, enabling
detection of this syndrome with a simple blood test coupled to genetic analy-
sis. It is therefore important to also understand the non-neuronal functions of
language-related genes and use this knowledge to comprehend the complete
phenotype.
In this dissertation, I take monogenic language-related disorders as entry
points to the molecular basis of speech and language abilities. Ideally, the best
cases to do so would be the ones that solely present language impairment. How-
ever, patients with language impairment in isolation are not normally referred
for genetic analysis because the phenotype is not usually considered in a clinical
context. Genetic data on this type of subjects usually come from research stud-
ies and are not as abundant as those for other neurodevelopmental conditions
(i.e. ASD, schizophrenia). Hence, it has been challenging to recruit sufficiently
large cohorts to guarantee the necessary power to carry out genome-wide asso-
ciation studies.
So far, the most convincing monogenic cases of clearly disproportionate ef-
fects on the speech and language domain are those arising from FOXP2 muta-
tions. Undoubtedly, the discovery of FOXP2 disruption in the KE family was
a groundbreaking finding and this has provided an extremely valuable molec-
ular window into the neurobiological basis of speech and language. However,
speech and language skills are certainly influenced by numerous other genetic
factors, most of which remain to be discovered.
Exploiting FOXP2 molecular networks has successfully led to the discovery
of novel language-related genes that are implicated in speech and language-
related disorders, such as FOXP2-interacting transcription factors FOXP1, TBR1,
SOX5 and SATB2 or target genes like CNTNAP2. The phenotypes caused by mu-
tations in these genes are broader than the one typically caused by FOXP2 hap-
loinsufficiency, including additional cognitive impairments such as ID or ASD.
However, these genes also offer molecular gateways into speech and language
disorders. Language is deeply intermingled with other cognitive abilities at ge-
netic, molecular, anatomical, and phenotypic levels. Therefore it is necessary to
contemplate other behavioural traits when investigating aspects of speech and
language impairment.
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Intriguingly, BCL11A is indirectly connected with FOXP1 and FOXP2, since
they share NR2F1 and NR2F2 as interaction partners (Figure 6.4). But, most
likely, not all the genetic factors influencing speech and language will neces-
sary revolve around FOXP2 and it will be necessary to study different genetic
pathways in order to fully comprehend the genetic foundations of speech and
language. For instance, probands with GRIN2A mutations present a wide range
of epilepsy syndromes together with severe speech impairment that can include
dysarthria, speech dyspraxia, and both receptive and expressive language delay
(Turner et al. , 2015). GRIN2A encodes a subunit of NMDA receptors, ionotropic
glutamate receptors that regulate mediate calcium transport through the mem-
branes of excitatory synapses. Another NMDA receptor subunit is encoded by
GRIN2B, mutations of which lead to a wide range of neurodevelopmental dis-
orders including motor and language disorders, ASD, attention deficit hyperac-
tivity disorder (ADHD), developmental delay, epilepsy and schizophrenia (Hu
et al. , 2016). The study of the molecular dynamics of GRIN2A and GRIN2B
gene function in the excitatory synapses, or other language-related molecular
pathways yet to be discovered, can also tell us something about speech and lan-
guage.
However, as discussed earlier, the monogenic cases that may be of most di-
rect relevance for understanding the neurobiology of speech and language are
those in which language impairments occur against a background of normal
non-verbal cognitive abilities. Chen and colleagues recently reported whole-
exome sequencing in a cohort of 43 probands with specific language impair-
ment (SLI) and found several potentially pathogenic genetic variants. Some of
these were in genes that were already related to language, such as GRIN2A,
ROBO1 or ERC1, but a few others may point to new candidate language-related
genes, such as OXR1, SCN9A and KMT2D (Chen et al. , 2017).
In the future, intensive analyses of genotype-phenotype correlations of a
range of neurodevelopmental disorders will be crucial to decipher how specific
genetic factors contribute to speech and language. Advances in computational
methodologies will eventually allow generation of comprehensive networks to
model the complicated molecular links underlying speech and language. Incor-
porating data from experimental studies into large in silico molecular networks
will be of vital importance to enhance the veracity of such models and support
their biological relevance.
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Computational systems biology methods allow the effective integration of
multiple large data sets that come from different sources. These will be essential
to keep up with the rapid pace at which genetic data is being generated using
next-generation sequencing techniques and the potentially large amount of data
that will arise from systematic functional characterizations. Moreover, to fully
understand the biology of speech and language, findings from other disciplines
such as neuroscience, evolutionary anthropology and linguistics will also need
to be taken into account and integrated with molecular genetic data.
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Abstract
Background: Heterozygous disruption of FOXP2 causes a rare form of speech and language impairment. Screens of
the FOXP2 sequence in individuals with speech/language-related disorders have identified several rare protein-altering
variants, but their phenotypic relevance is often unclear. FOXP2 encodes a transcription factor with a forkhead box
DNA-binding domain, but little is known about the functions of protein regions outside this domain.
Methods: We performed detailed functional analyses of seven rare FOXP2 variants found in affected cases, including
three which have not been previously characterized, testing intracellular localization, transcriptional regulation,
dimerization, and interaction with other proteins. To shed further light on molecular functions of FOXP2, we
characterized the interaction between this transcription factor and co-repressor proteins of the C-terminal binding
protein (CTBP) family. Finally, we analysed the functional significance of the polyglutamine tracts in FOXP2, since tract
length variations have been reported in cases of neurodevelopmental disorder.
Results: We confirmed etiological roles of multiple FOXP2 variants. Of three variants that have been suggested to cause
speech/language disorder, but never before been characterized, only one showed functional effects. For the other two,
we found no effects on protein function in any assays, suggesting that they are incidental to the phenotype. We
identified a CTBP-binding region within the N-terminal portion of FOXP2. This region includes two amino acid
substitutions that occurred on the human lineage following the split from chimpanzees. However, we did not
observe any effects of these amino acid changes on CTBP binding or other core aspects of FOXP2 function.
Finally, we found that FOXP2 variants with reduced polyglutamine tracts did not exhibit altered behaviour in
cellular assays, indicating that such tracts are non-essential for core aspects of FOXP2 function, and that tract
variation is unlikely to be a highly penetrant cause of speech/language disorder.
Conclusions: Our findings highlight the importance of functional characterization of novel rare variants in FOXP2
in assessing the contribution of such variants to speech/language disorder and provide further insights into the
molecular function of the FOXP2 protein.
Keywords: Transcription factor, Speech, Language, Functional genetics, Neuroscience
Background
FOXP2 is a member of the forkhead box (FOX) family
of transcription factors and has crucial roles in the
development of the brain and other organs [1, 2]. Het-
erozygous disruptions of the FOXP2 gene cause a rare
and severe speech and language disorder (OMIM 602081)
[3]. This disorder was first reported in a three-generation
pedigree (the KE family), in which approximately half of
the individuals have difficulties with learning to make the
co-ordinated orofacial movements required for speech
(childhood apraxia of speech, CAS), together with wide-
ranging impairments in comprehension and production of
spoken and written language, but without major deficits in
other aspects of cognitive functioning [4]. All affected
members of the family were found to carry a missense
variant in FOXP2 that alters a critical residue within the
DNA-recognition helix of the FOX domain and thus pre-
vents DNA binding and regulation of transcription [4–6].
A number of individuals have since been reported to
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present with severe speech/language difficulties together
with heterozygous whole gene deletions or chromosomal
translocations disrupting FOXP2, confirming the necessity
of two functional copies of this gene for typical speech
and language development [3].
Screening of the FOXP2 coding region for protein-
altering variants has been performed in a few small
cohorts of children with speech articulation disorders
similar to those reported in the KE family [7–9]. In
addition, to address the possibility that FOXP2 disruption
might also be a factor in other disorders characterized by
speech/language problems, similar screens have been
performed in individuals with specific language impair-
ment, speech sound disorder, autism, schizophrenia, and
epilepsy of the speech cortex [10–18]. There are no com-
mon non-synonymous variants in FOXP2 in the general
population, and relatively little coding sequence variation
has been observed in individuals with speech/language-re-
lated disorders, indicating that FOXP2 disruptions are a
rare cause of such disorders, which likely have a highly
heterogeneous genetic basis. Nonetheless, screening for
FOXP2 variants in individuals with neurodevelopmental
phenotypes has identified a small number of rare protein-
altering variants, including five missense variants, one
stop-gain variant, one 2-bp deletion resulting in a frame-
shift, and several in-frame insertions or deletions of glu-
tamine residues within polyglutamine tracts. However, the
contribution of individual rare variants to disorder often
remains unclear because the genetic evidence in isolation
is insufficient to confirm a causal or contributory role, and
the effect of the variant on protein function is unknown.
To clarify the etiological contribution of the rare FOXP2
variants reported to date in individuals with neurodevelop-
mental disorders, we performed functional characterization
of these variants by assaying their effects on a range of
molecular properties. In addition, we characterize the
interaction between FOXP2 and the co-repressors of
the C-terminal binding protein (CTBP) family, which
may have a central role in FOXP2-mediated transcrip-
tional repression. Finally, we provide the first detailed
examination of the role of the polyglutamine tract in
FOXP2 function, in order to shed light on the contribu-
tion of tract length variation to disorder.
Methods
DNA constructs
The cloning of human FOXP2 (NM_014491), FOXP1
(NM_032682), and CTBP1 (NM_001328) and mouse
Foxp2 (NM_053242) has been described previously [6, 19].
The coding sequence of CTBP2 (NM_001329) was ampli-
fied from human foetal brain cDNA using the primers listed
in Additional file 1. The FOXP2 p.Q17L, p.M406T,
p.P416T, p.R553H, p.N597H, p.N303T, p.S325N, and
p.N303T/p.S325N variants were generated by site-
directed mutagenesis using the Quick-Change Site-
Directed Mutagenesis kit (Stratagene) following the
manufacturer’s protocol. (Note that the numbering of
FOXP2 variants throughout this manuscript is given
with respect to the coding sequence of the predomin-
ant isoform, NM_014491, which normally encodes a
715 amino-acid protein.) Primers used in site-directed
mutagenesis are listed in Additional file 2. The FOXP2
p.R328* variant and synthetic truncated forms of FOXP2
were generated using the primers listed in Additional file
1. Synthetic FOXP2 variants with reduced polyglutamine
tracts were generated using a PCR-based strategy [20]. All
FOXP2 variants were initially generated in an intermedi-
ary plasmid, pCR2.1-TOPO (Life Technologies), and the
entire coding sequence of FOXP2 was verified by Sanger
sequencing before being subcloned into the final expres-
sion vector. For expression of fusion proteins with Renilla
luciferase, yellow fluorescent protein (YFP), mCherry, and
three tandem N-terminal Myc tags, cDNAs were sub-
cloned into the pLuc, pYFP, pmCherry, and pMyc expres-
sion vectors, respectively, which have been described
previously [19–21]. The SRPX2 luciferase reporter plas-
mid was generated by subcloning a 1146-bp region of the
SRPX2 promoter into the promoterless firefly luciferase
vector pGL4.23 (Promega), as described previously [21].
All constructs were verified by Sanger sequencing.
Plasmid sequences are available upon request.
Cell culture and transfection
HEK293 were obtained from ECACC (cat. no. 85120602)
and cultured in DMEM supplemented with 10% foetal
bovine serum. Transfections were performed using
GeneJuice (Merck-Millipore) according to the manufac-
turer’s instructions.
Western blotting
HEK293 cells were transfected in 6-well plates and cul-
tured for 48 h. Cells were lysed for 10 min at 4 °C with
100 mM Tris pH 7.5, 150 mM NaCl, 10 mM EDTA,
0.2% Triton X-100, 1% PMSF, and protease inhibitor
cocktail. Cell lysates were cleared by centrifugation at
10,000×g for 3 min at 4 °C. Proteins were resolved on
10% SDS-polyacrylamide gels and transferred to PVDF
membranes using a TransBlot Turbo Blotting appar-
atus (Bio-Rad). Membranes were blocked in PBS con-
taining 5% milk and 0.1% Tween-20 and incubated
overnight at 4 °C with primary antibody. The following
antibodies were used: anti-GFP (Clontech cat. no.
632380, 1:8000, for YFP constructs); anti-Myc tag
(Abcam cat. no. ab9106, 1:1000); and anti-β-actin
(Sigma cat. no. A5441, 1:10,000). After washing, mem-
branes were incubated with horseradish peroxidase-
conjugated goat anti-mouse or anti-rabbit IgG for
45 min at room temperature. Proteins were visualized
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using Novex ECL Chemiluminescent Substrate Re-
agent Kit (Invitrogen) and a ChemiDoc XRS+ imaging
system (Bio-Rad).
BRET assay
Bioluminescence resonance energy transfer (BRET) assays
were performed as described [19]. Briefly, HEK293 cells
were transfected in 96-well plates with DNA plasmids
encoding YFP- and luciferase-fusion proteins. After 36–
48 h, Enduren Live Cell Luciferase Substrate (Promega)
was added at a final concentration of 60 μM. Cells were
cultured for a further 4 h, and emission readings (inte-
grated over 10 s) were taken using a TECAN F200PRO
microplate reader using the Blue1 and Green1 filter
sets. Expression levels of the YFP-fusion proteins were
measured by taking fluorescent readings using the filter
set and dichroic mirror suitable for green fluorescent
protein (excitation 480 nm, emission 535 nm). The cor-
rected BRET ratio was calculated with the following
formula: [Green1(experimental condition)/Blue1(experimental
condition)] − [Green1(control condition)/Blue1(control condition)].
The control conditions used luciferase or YFP fused to
a C-terminal nuclear localization signal.
Fluorescence microscopy
HEK293 cells were seeded on coverslips coated with poly-
L-lysine. Cells were cultured for 30 h post-transfection
and then fixed with methanol. Nuclei were stained with
Hoechst 33342. Fluorescence images were acquired using
an Axiovert A-1 fluorescent microscope with ZEN Image
software (Zeiss).
Fluorescence-based quantitation of protein expression
levels
HEK293 cells were transfected in triplicate with YFP-tagged
FOXP2 variants and mCherry, in clear-bottomed black 96-
well plates. Cells were cultured at 37 °C with 5% CO2 in a
TECAN M200PRO microplate reader equipped with a Gas
Control Module for live-cell kinetic assays. Fluorescence in-
tensity was measured 48 h post-transfection. For each well
and time point, the background-subtracted YFP intensity
was divided by the background-subtracted mCherry inten-
sity. Triplicate conditions were averaged.
Luciferase reporter assays
HEK293 cells were seeded in clear-bottomed white 96-
well plates and transfected in triplicate. For the SV40
assay, cells were transfected with 12 ng of pGL3-promoter
firefly luciferase reporter construct containing the SV40
promoter (Promega), 5 ng of pRL-TK Renilla luciferase
normalization control (Promega), and 16 ng of YFP-
FOXP2 (wild-type or variant) or YFP control construct.
For the SRPX2 assay, cells were transfected with 4.3 ng of
SRPX2 luciferase reporter construct, 5 ng of pGL4.74
Renilla luciferase normalization control (Promega), and
45 ng of YFP-FOXP2 (wild-type or variant) or YFP control
construct. After 48 h, luciferase activity was measured in a
TECAN F200PRO microplate reader using the Dual-
Luciferase Reporter Assay system (Promega).
Statistical analysis
The statistical significance of the luciferase reporter
assays and BRET assays was analysed using a one-way
analysis of variance (ANOVA) followed by Bonferroni’s
post hoc correction.
Results
Rare FOXP2 variants implicated in neurodevelopmental
disorder
We examined seven rare FOXP2 variants that have been
observed in individuals with neurodevelopmental disorders,
including five missense variants, one stop-gain variant, and
one frameshift variant (Table 1, Fig. 1a). For three of the
variants examined (p.N597H, p.P416T, p.Q390Vfs*7), this is
the first report of any functional characterization. The
remaining four variants have been studied previously to
varying extents and are included here for comparison with
the uncharacterized variants. All of the variants were add-
itionally characterized using novel assays that have not been
used to study FOXP2 in prior literature. Two of the vari-
ants are of particular interest because of their uncertain sig-
nificance with regard to the phenotype of the affected
cases. The p.N597H variant was found by targeted sequen-
cing in a proband with CAS and was described as a likely
pathogenic variant, but it was not ascertained if this variant
occurred de novo, and no functional characterization was
performed [7]. The p.M406T variant was identified in a
proband with an epilepsy-aphasia spectrum disorder (focal
epilepsy with continuous spike-and-waves during sleep),
cognitive and language deficits, and polymicrogyria of the
left rolandic operculum [15]. The variant was also carried
by two siblings who were not known to have any neuro-
logical abnormality and was inherited from the father, who
did not display any neurological or MRI abnormalities. It
was suggested that this variant plays an etiological role in
the epilepsy-aphasia spectrum disorder observed in the
proband, acting as a risk factor with incomplete penetrance
[15]. However, the contribution of this variant to the
phenotype is tentative because of the lack of segregation
with the disorder, the atypical phenotypic presentation in
comparison to other cases of FOXP2 disruption, and the
limited functional characterization performed to date.
The seven FOXP2 variants were expressed as fusion
polypeptides with YFP in HEK293 cells. The expression
of these YFP-tagged variants (and of all other YFP-tagged
forms of FOXP2 used in this study) was verified by western
blotting, as shown in Additional file 3. Direct measurement
of fluorescence intensity in live cells indicated that the
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Table 1 Rare FOXP2 variants in individuals with neurodevelopmental disorders
Variant descriptiona Frequency in ExACb Phenotype and inheritance pattern Role in disorderc Reference
p.Q17L (missense) c.50A > T chr7:114426561A >
T rs201649896
56/120570 (1 homozygote) Found in a proband with CAS but not in an affected sibling.
Parental genotypes not determined
Probably incidental MacDermot et al. [8]
p.M406T (missense) c.1217 T > C chr7:114653960
T > C no rs ID
Not observed Found in a proband with rolandic epilepsy and polymicrogyria,
in two unaffected siblings and in unaffected father
Uncertain significance Roll et al. [15]
p.P416T (missense) c.1246C > A chr7:114653989C >
A rs369313543
1/121328 Present in two siblings with severe stuttering. Absent in
affected father. Inherited from mother, who does not stutter
but has oral motor impairments
Probably incidental Turner et al. [9]
p.R553H (missense) c.1658G > A chr7:114662075G >
A rs121908377
Not observed Segregates with CAS in three generations of the KE family Causal Lai et al. [4]
p.N597H (missense) c.1789A > C chr7:114663469A >
C no rs ID
1/120986 Found in a proband with CAS. Parental genotypes not
determined
Uncertain significance Laffin et al. [7]
p.R328* (stop-gain) c.982C > T chr7:114642616C >
T rs121908378
Not observed Present in a proband with CAS and in affected sibling.
Inherited from affected mother
Causal MacDermot et al. [8]
p.Q390Vfs*7 (frameshift) c.1168_1169del chr7:
114652276_ 114652277del no rs ID
Not observed De novo variant in a proband with sporadic CAS, dysarthria,
and fine motor apraxia
Causal Turner et al. [9]
aVariants are described in accordance with Human Genome Variation Society recommendations (www.hgvs.org/mutnomen, accessed June 2016) with reference to the major transcript NM_014491.3
(ENST00000350908). Genomic coordinates refer to the hg38 assembly. The rs ID number is provided for variants that are present in dbSNP
bVariant allele frequency in the Exome Aggregation Consortium (ExAC) dataset (http://exac.broadinstitute.org, accessed June 2016)
cVariants are described as causal if they segregate perfectly with childhood apraxia of speech (CAS) affection status, or if they occurred de novo in sporadic cases, and if they additionally have been demonstrated to
cause loss of protein function, or are very likely to do so because of protein truncation. Variants are described as probably incidental if they do not segregate with CAS and are observed in the Exome Aggregation
Consortium (ExAC) dataset. Other variants are described as of uncertain significance
Note: This table does not include newly described variants that were reported by Reuter et al. [58] after the completion of the present study
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missense variants and the truncated p.Q390Vfs*7 variant
are expressed at broadly similar levels to the wild-type pro-
tein, whereas the p.R553H and p.R328* variants may have
slightly increased expression (Fig. 1b). In cells of people car-
rying the p.R328* and p.Q390Vfs*7 variants, the expression
levels of these protein variants are likely to be very low due
to nonsense-mediated decay of the aberrant transcripts, al-
though this has not been formally tested due to the lack of
FOXP2 expression in accessible tissue [8, 9]. The inclusion
of these truncated variants in functional assays provides a
useful comparison with missense variants because the
truncated variants lack the DNA-binding domain and
hence cannot function normally in transcriptional
regulation.
Effects of variants on nuclear localization and
transcriptional regulation
The effect of the variants on FOXP2 localization was ex-
amined by direct imaging of the YFP-fusion proteins in
transfected cells (Fig. 1c). Wild-type FOXP2 exhibited
nuclear localization, with exclusion from nucleoli, as re-
ported previously (Fig. 1c) [6, 22]. The two previously
a
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Fig. 1 Functional characterization of rare FOXP2 variants. a Schematic representation of the FOXP2 protein showing rare variants found in
individuals with neurodevelopmental disorders. Stop-gain and frameshift variants are shown in black and missense variants in red. Known
domains are labelled: glutamine-rich (Q-rich) region (hatched shading) including polyglutamine tracts (solid shading), zinc finger (ZF), leucine
zipper (LZ) and forkhead domain (FOX). Nuclear localization signals are indicated with red bars. b Fluorescence-based measurement of FOXP2
expression level. HEK293 cells were transfected with YFP-FOXP2, together with mCherry for normalization. Fluorescence intensity was measured
48 h post-transfection. Values are mean YFP/mCherry fluorescence ratios ± S.D. (n = 3), expressed relative to the value for wild-type (WT) FOXP2.
c Fluorescence micrographs of HEK293 cells transfected with YFP-FOXP2. Nuclei were stained with Hoechst 33342. d, e Luciferase reporter assays
for transcriptional regulatory activity of FOXP2. HEK293 cells were transfected with a firefly luciferase reporter vector containing the SV40 promoter
(d) or the human SRPX2 promoter (e), together with a Renilla luciferase normalization plasmid and YFP-FOXP2, or YFP alone (control). Values are
mean relative luciferase activity ± S.D. (n = 3), expressed relative to the control. Asterisks indicate significant differences compared to wild-type
(WT) FOXP2 (p < 0.05, one-way ANOVA followed by Bonferroni post hoc correction). NS not significant. Exact p values for both the SV40 and the
SRPX2 assays are <0.0001 for the control and the R553H, R328*, and Q390Vfs*7 variants, and >0.9999 for all other variants
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characterized etiological variants, p.R553H and p.R328*,
showed disrupted nuclear localization and formation of
aggregates, also consistent with earlier reports (Fig. 1c)
[6, 22]. The uncharacterized Q390Vfs*7 variant formed
cytoplasmic aggregates similar to those observed for the
p.R328* variant, consistent with the loss of endogenous
nuclear localization signals in these truncated variants
(Fig. 1a,c) [22]. The p.Q390Vfs*7 variant therefore has a
similarly deleterious effect on protein localization as the
two known etiological variants. None of the other mis-
sense variants showed any sign of abnormal localization,
including the putatively pathogenic p.N597H and p.M406T
variants (Fig. 1c). Altered localization has been reported
previously for the p.M406T variant, but in multiple in-
dependent experiments, we did not observe any loss of
nuclear localization for this variant [15]. Thus, with the
exception of the p.R553H variant, all the missense variants
retain the nuclear localization necessary for transcriptional
regulatory activity.
To assess the ability of the FOXP2 variants to regulate
transcription, we performed luciferase reporter assays
using the SV40 promoter, a viral promoter which is re-
pressed by FOXP2 [6, 23]. The etiological p.R553H and
p.R328* variants exhibited the expected loss of repression
activity in this assay [6] (Fig. 1d). The uncharacterized
p.Q390Vfs*7 variant showed a comparable loss of repres-
sion to the other etiological variants (Fig. 1f). In contrast,
the remaining four missense variants showed similar
activity to the wild-type protein (Fig. 1d). To verify these
results using an endogenous human FOXP2 target gene,
we performed luciferase reporter assays using a region of
the SRPX2 promoter [15]. As observed for the SV40 pro-
moter, the truncated variants and the p.R553H variant
showed loss of repressive activity, whereas the other mis-
sense variants did not differ significantly in activity from
the wild-type protein (Fig. 1e). The p.M406T variant has
previously been reported to show reduced transcriptional
repression activity in relation to the SRPX2 promoter [15].
Small differences between the promoter regions and vec-
tor backbones used in this and the previous study might
account for these conflicting results. Nonetheless, our data
indicate that the p.M406T variant does not exhibit a gen-
eralized reduction in transcriptional regulatory activity.
Effects of variants on protein dimerization
FOXP2 and other proteins of the FOXP subfamily form
dimers via their leucine zipper domains, a property
which appears to be essential for transcriptional regulatory
activity [24] (Fig. 1a). In FOXP3, loss of dimerization cap-
acity as a result of an in-frame single amino acid deletion
in the leucine zipper domain results in an immunological
disorder known as IPEX syndrome (MIM 304790), with
disease severity comparable to that resulting from loss of
DNA-binding activity in FOXP3 [25, 26]. Variants
affecting the dimerization of FOXP2 might therefore be a
cause of speech/language disorder. Additionally, FOXP2
variants that have lost DNA-binding capacity but retain
dimerization ability might interfere with the function of
wild-type protein in cells of affected individuals, and thus
exert a dominant-negative effect. Notably, FOXP2 not only
forms homodimers but can also heterodimerize with
FOXP1 and FOXP4, proteins which have partially over-
lapping expression patterns in the developing brain [24,
27–29]. (Note that FOXP3 is expressed only in haemato-
poietic cells.) Heterodimerization among certain FOXP
proteins may therefore be an important mechanism for
differential regulation of target genes in different neuronal
subtypes. Of note, heterozygous disruption of FOXP1
results in a severe neurodevelopmental phenotype that in-
cludes language deficits, potentially reflecting dysregula-
tion of some of the same target genes impacted by FOXP2
disruption [30, 31].
Two of the five FOXP2 missense variants reported in
individuals with neurodevelopmental disorders lie within
or near the leucine zipper domain, which spans residues
p.V388-L409 (Fig. 1a). These variants (p.M406T and
p.P416T) could therefore affect FOXP2 dimerization.
The interaction between FOXP2 variants and wild-type
FOXP2 was assayed using a BRET assay, which enables
protein-protein interactions to be monitored in live cells
[19]. The interaction of the FOXP2 variants with wild-
type FOXP1 and FOXP4 was also examined. As expected,
wild-type FOXP2 was able to homodimerize and also to
heterodimerize with FOXP1 and FOXP4 (Fig. 2a–c) [24].
The truncated p.R328* and p.Q390fs*7 variants were not
able to dimerize with the wild-type proteins, consistent
with the loss of the leucine zipper domain in these vari-
ants (Fig. 2a–c). Thus, even if these abnormal proteins are
present in cells of affected individuals despite the acti-
vation of nonsense-mediated decay mechanisms, they
could not interfere with the function of wild-type pro-
teins via dimerization. In contrast, the p.R553H variant
found in the KE family has a normal leucine zipper domain
and showed only a modest reduction in interaction with
wild-type FOXP2, FOXP1, and FOXP4 (Fig. 2a–c). Fur-
thermore, co-transfection of wild-type FOXP2 with the
p.R553H variant led to some wild-type protein being
mislocalized to the cytoplasm (Fig. 2d). Mislocalization
of wild-type protein was not observed upon co-transfection
with the non-interacting variants p.R328* and p.Q390Vfs*7
(Fig. 2d). The p.R553H variant might therefore interfere
with the function of wild-type FOXP2 in cells of people
carrying this variant, and this effect could contribute
to the phenotype observed in the affected members of
the KE family. All four of the other missense variants
generally demonstrated normal dimerization capacity
(Fig. 2a–c). The p.P416T variant showed a statistically
significant difference in interaction with FOXP1 (Fig. 2b),
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but this difference was not consistently observed across
independent experiments. Therefore, despite being located
in or near the leucine zipper domain, the p.M406T
and p.P416T variants do not appear to affect FOXP2
dimerization and are unlikely to exert a pathogenic ef-
fect via this mechanism.
Effects of variants on interaction with the co-repressors
CTBP1 and CTBP2
A further mechanism by which variants in FOXP2 might
lead to speech/language disorder is through disruption
of protein-protein interactions between FOXP2 and crucial
mediators of transcriptional regulation. Relatively, little is
known about the interaction partners of FOXP2; however,
proteins of the CTBP family have been identified as candi-
date FOXP2 interactors in multiple independent yeast two-
hybrid screens [24, 32–34]. The CTBP family consists of
two proteins, CTBP1 and CTBP2, which function as
co-repressors for multiple transcription factors [35, 36].
The interaction between FOXP2 and CTBP1 has previ-
ously been validated by us using the BRET assay, and
by others via co-immunoprecipitation, but the inter-
action with CTBP2 has not yet been confirmed [19, 24].
Using the BRET assay, we validated the interaction
between CTBP2 and FOXP2 and found that this inter-
action produces a notably higher BRET signal than the
Fig. 2 Interaction of rare FOXP2 variants with wild-type FOXP proteins. a–c Bioluminescence resonance energy transfer (BRET) assays for interaction of
FOXP2 variants with wild-type (WT) FOXP proteins. HEK293 cells were transfected with YFP-FOXP2 variants (acceptor) and Renilla luciferase (donor) fusions
of FOXP2 (a), FOXP1 (b) or FOXP4 (c). The control acceptor protein is a nuclear-targeted YFP. Values are mean corrected BRET ratios ± S.D. (n= 3). Asterisks
indicate significant differences compared to wild-type (WT) FOXP2 (p < 0.05, one-way ANOVA followed by Bonferroni post hoc correction). NS
not significant. Exact p values for a are <0.0001 for the control and the R553H, R328* and Q390Vfs*7 variants and >0.9999 for all other variants.
Exact p values for b are <0.0001 for the control and the R553H, R328* and Q390Vfs*7 variants, 0.024 for the P416T variant, and >0.9999 for all
other variants. Exact p values for c are <0.0001 for the control and the R553H, R328* and Q390Vfs*7 variants, 0.088 for the N597H variant, and >0.9999
for all other variants. d Fluorescence micrographs of HEK293 cells transfected with YFP-fusions of the FOXP2 variants p.R553H, p.R328* and p.Q390Vfs*7,
together with wild-type FOXP2 fused to mCherry. Nuclei were stained with Hoechst 33342
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interaction between CTBP1 and FOXP2 (Fig. 3a,b). The
difference in the magnitude of the BRET signal may reflect
subcellular localization differences between the CTBPs:
CTBP2 is wholly nuclear and therefore shows a large de-
gree of co-localization with wild-type FOXP2, whereas
CTBP1 is found in both the cytoplasm and nucleus, and
therefore has an overall lower degree of co-localization with
FOXP2 (Fig. 3c) [37, 38]. Strikingly, we found that CTBP1
and CTBP2 are also able to interact with FOXP1, but not
with FOXP4, in line with previously reported findings for
CTBP1 (Fig. 3a,b) [24]. The lack of interaction between
FOXP4 and CTBPs suggests that the FOXP proteins have
partially divergent mechanisms for transcriptional regula-
tion, which is particularly interesting given the ability of
FOXP2 to dimerize with FOXP4 (Fig. 2c).
We next evaluated the effects of rare variants in
FOXP2 on the interaction with CTBP1/2. The p.R553H
variant found in the KE family showed slightly reduced
interaction with CTBP2, but increased interaction with
CTBP1, when compared with wild-type FOXP2 (Fig. 3d,e).
Interestingly, the p.R553H variant displayed a mixed
nuclear and cytoplasmic localization when transfected
alone or with CTBP2, but became predominantly cyto-
plasmic in the presence of CTBP1 (Figs. 1e and 3f,g). In
contrast, the nuclear localization of wild-type FOXP2
was not affected by co-transfection with CTBP1 (Fig. 3c).
The cytoplasmic retention of the p.R553H variant, but not
of wild-type FOXP2, upon co-transfection with CTBP1
may be a consequence of the loss of DNA-binding
capacity in the p.R553H variant. These co-transfection
experiments indicate that the p.R553H variant shows
greater co-localization with CTBP1 but reduced co-
localization with CTBP2, compared with wild-type FOXP2,
consistent with the BRET data on interactions between
these proteins (Fig. 3d,e). Although altered interaction with
CTBP1/2 probably does not play a substantive role in the
speech/language pathology in the KE family, the retained
interaction between the p.R553H variant and CTBP1/2 is
notable because it indicates that DNA-binding activity is
not a prerequisite for interaction of FOXP2 with co-
repressors of the CTBP family. The four other missense
variants did not differ substantially from the wild-type
protein in their interaction with CTBP1/2 in the BRET
assay (Fig. 3d,e). These four variants thus have comparable
properties to wild-type FOXP2 in assays of subcellular
localization, transcriptional repression, protein dimerization,
and interaction with co-repressor proteins, suggesting that
all of these variants are benign rare polymorphisms (Table 2).
In particular, we do not find any support for the etio-
logical roles suggested previously for the p.M406T and
p.N597H variants [7, 15].
Interestingly, the p.R328* and p.Q390Vfs*7 variants
partially retained the ability to interact with CTBP1/2,
despite lacking a large proportion of the normal FOXP2
polypeptide (Fig. 3d,e). The interaction with CTBP1 in
particular was only mildly affected (Fig. 3d). Furthermore,
co-transfection of CTBP1 with the p.R328* and p.Q390Vfs*7
variants resulted in clear co-localization of CTBP1 with the
truncated variants within cytoplasmic aggregates (Fig. 3d,f).
The interaction with CTBP2 was more severely affected, but
co-localization of CTBP2 and the p.R328* variant
within aggregates was still readily apparent (Fig. 3e,g).
The interaction between these severely truncated FOXP2
variants and CTBP1/2 suggests that some key determi-
nants of CTBP binding lie near the N-terminus of FOXP2.
Characterization of the interaction between FOXP
proteins and CTBPs
The retention of CTBP binding by the severely truncated
p.R328* and p.Q390Vfs*7 variants (Fig. 3d,e) prompted us
to investigate further the interaction between FOXP2 and
CTBPs. The CTBP binding site in FOXP2 was previously
suggested to be a PLNLV motif at residues 422–426, due
to the similarity of this motif to the consensus CTBP-
binding motif PXDLS (Fig. 4a) [24, 36]. The PLNLV motif
is conserved in FOXP1 but not FOXP4, consistent with
the lack of interaction between CTBP1 and FOXP4 [24]
(Fig. 3a,b). However, the residual interaction of CTBPs
with the p.R328* and p.Q390Vfs*7 variants indicates that
the PLNLV motif is not essential for the interaction and
that the CTBP binding site is at least partially localized to
a more N-terminal region of FOXP2 (Fig. 3d,e). Further-
more, one of the yeast two-hybrid screens that identified
CTBP1 and CTBP2 as FOXP2 interactors employed a
fragment of FOXP2 encompassing residues 122–382, indi-
cating that this region, which lacks the PLNLV motif, is
sufficient for the interaction [34].
To map the region of FOXP2 involved in binding to
CTBP2, we performed a BRET assay using a series of
synthetic truncated versions of FOXP2 (Fig. 4a) [21].
Truncated protein variants lacking the endogenous
nuclear localization signals were targeted to the nu-
cleus by addition of an artificial localization signal to
the protein C-terminus (Fig. 4a,b). The efficacy of this
truncation series in mapping interaction domains was
demonstrated using a BRET assay for FOXP2 homodi-
merization (Fig. 4c). Truncation of FOXP2 after resi-
due 423 did not interfere with homodimerization,
whereas truncation after residue 329 dramatically re-
duced the interaction, reflecting the loss of the critical
leucine zipper domain (Fig. 4c) [24].
In a BRET assay for interaction with CTBP2, a FOXP2
variant truncated after residue 487 showed a similar level of
interaction to the full-length protein (Fig. 4d), indicating
that the C-terminal region of FOXP2 including the FOX
domain is not involved in the interaction with CTBPs.
More severely truncated forms of FOXP2 showed a pro-
gressive reduction in interaction with CTBP2. The
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Fig. 3 Interaction of rare FOXP2 variants with CTBP1/2. a, b BRET assays for interaction of FOXP proteins with CTBP1 and CTBP2. HEK293 cells
were transfected with FOXP1, FOXP2, or FOXP4 fused to Renilla luciferase (donor) and CTBP1 (a) or CTBP2 (b) fused to YFP (acceptor). The control
donor protein is a nuclear-targeted luciferase. Values are mean corrected BRET ratios ± S.D. (n= 3). Asterisks indicate significant differences compared to
control (p< 0.05, one-way ANOVA followed by Bonferroni post hoc correction). NS not significant. Exact p values for both a and b are <0.0001 for FOXP2
and FOXP1 and >0.9999 for FOXP4. c Fluorescence micrographs of HEK293 cells transfected with mCherry-CTBP1 or mCherry-CTBP2, together
with YFP-FOXP2. Nuclei were stained with Hoechst 33342. d, e BRET assays for interaction of rare FOXP2 variants with CTBP1 and CTBP2.
HEK293 cells were transfected with FOXP2 variants fused to Renilla luciferase (donor) and CTBP1 (d) or CTBP2 (e) fused to YFP (acceptor). The
control donor protein is a nuclear-targeted luciferase. Values are mean corrected BRET ratios ± S.D. (n= 3). Asterisks indicate significant differences compared
to wild-type (WT) FOXP2 (p< 0.05, one-way ANOVA followed by Bonferroni post hoc correction). NS not significant. Exact p values for d are <0.0001 for the
control and the R553H, R328* and Q390Vfs*7 variants, 0.221 for the M406T variant, and >0.9999 for all other variants. Exact p values for e are <0.0001 for
the control and the R553H, R328* and Q390Vfs*7 variants and >0.9999 for all other variants. f, g Fluorescence micrographs of HEK293 cells transfected with
YFP-FOXP2 and mCherry-CTBP1 (f) or mCherry-CTBP2 (g). Nuclei were stained with Hoechst 33342
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Table 2 Summary of functional characterization of rare FOXP2 variants in individuals with neurodevelopmental disorders
Varianta Localization Transcriptional repression Dimerization with FOXPs Interaction with CTBPs Role in disorderb
SV40 SRPX2 FOXP2 FOXP1 FOXP4 CTBP1 CTBP2
p.Q17L + + + + + + + + Incidental
p.M406T + + + + + + + + Incidental
p.P416T + + + + + + + + Incidental
p.R553H − − − − − − − − Causal
p.N597H + + + + + + + + Incidental
p.R328* − − − − − − − − Causal
P.Q390Vfs*7 − − − − − − − − Causal
+ Behaviour of the variant is comparable to that of the wild-type protein in this assay, − Behaviour of the variant differs from that of the wild-type protein in
this assay
aVariants are described in accordance with Human Genome Variation Society recommendations (www.hgvs.org/mutnomen, accessed June 2016) with reference to
the major transcript NM_014491.3 (ENST00000350908)
bProbable role of the variant in the disorder in the affected individual, based on the results of functional characterization
Fig. 4 Mapping of the CTBP binding site in FOXP2. a Schematic representation of synthetic truncated forms of FOXP2. The R328* and Q390Vfs*7
variants identified in patients are included for comparison. Known domains are labelled: glutamine-rich (Q-rich) region (hatched shading) including
polyglutamine tracts (solid shading), zinc finger (ZF), leucine zipper (LZ), and forkhead domain (FOX). The PLNLV motif is indicated with a green
bar. Nuclear localization signals are indicated with red bars. A synthetic nine-residue nuclear targeting sequence (hatched red bars) was appended
to the C-terminus of variants which lack one or both of the endogenous nuclear localization signals. b Fluorescence micrographs of HEK293 cells
transfected with synthetic truncated FOXP2 variants. Nuclei were stained with Hoechst 33342. c, d BRET assay for interaction of synthetic truncated
FOXP2 variants with full-length FOXP2 and CTBP2. HEK293 cells were transfected with truncated FOXP2 variants fused to Renilla luciferase (donor) and
FOXP2 (c) or CTBP2 (d) fused to YFP (acceptor). The control donor protein is a nuclear-targeted luciferase. Values are mean corrected BRET ratios ± S.D.
(n = 3). Asterisks indicate significant differences compared to control (p < 0.05, one-way ANOVA followed by Bonferroni post hoc correction). NS
not significant. Exact p values for c are 0.002 for FOXP2.330*, 0.025 for FOXP2.259* and <0.0001 for all other variants. Exact p values for d are
0.001 for FOXP2.423*, 0.012 for FOXP2.330*, 0.97 for FOXP2.259*, and <0.0001 for all other variants
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substantial retention of interaction between CTBP2 and
FOXP2 forms truncated after residue 422 or residue 329 in-
dicates that the PLNLV motif, zinc finger, and leucine zip-
per domains are not essential for interaction, although they
may enhance it, and furthermore, FOXP2 dimerization is
not necessary for CTBP2 binding (Fig. 4d). Only the short-
est FOXP2 variant, which is truncated after residue 258,
showed a complete or near-complete loss of interaction
(Fig. 4d). The protein region including residues 259–329
may therefore be sufficient for interaction with CTBP2.
The region of FOXP2 encompassing residues 259–329
corresponds to a single exon in which non-synonymous
nucleotide substitutions between different species are
relatively common in comparison to the exons encoding
highly conserved elements such as the FOX and leucine
zipper domains [39–41]. In particular, this exon includes
two non-synonymous nucleotide substitutions that oc-
curred after the split between the human and chimpanzee
lineages, but before the split between modern humans and
Neanderthals (Fig. 5a) [39, 42]. Mice carrying a ‘human-
ized’ version of Foxp2, containing these two recent amino
acid changes, exhibit altered neuronal morphology and
electrophysiology and subtle behavioural changes [43–45].
Strikingly, the morphological and electrophysiological
changes have a direction of effect opposite to that ob-
served in mice with only one functional copy of Foxp2,
suggesting that the changes might have been selected for
due to an enhancement of protein function [1, 46].
The molecular mechanisms underlying the neurobio-
logical changes observed in mice carrying humanized
Foxp2 are unknown, but might entail an alteration in
the strength of the interaction between Foxp2 and one
or more proteins involved in Foxp2-mediated transcrip-
tional regulation. Therefore, to test if the recent amino
acid changes affect interaction with CTBPs, we introduced
the ancestral amino acid residues, individually and in
combination, into human FOXP2 (Fig. 5a). Versions of
human FOXP2 carrying the ancestral amino acids were
compared with the natural human and mouse proteins in
functional assays. Introduction of the ancestral amino
acids did not result in any change in protein localization
or expression, and furthermore, the human and mouse
versions of the protein were indistinguishable in these
assays (Fig. 5b,c). Notably, the versions of FOXP2 car-
rying the ancestral amino acids also did not differ from
the natural human protein in assays of transcriptional
repression using the SV40 and SRPX2 promoters, and
there was no difference between the human and mouse
orthologues in these assays (Fig. 5d,e). Homodimerization
was also comparable for all variants tested (Fig. 5f). Finally,
the versions of FOXP2 carrying the ancestral amino acids
did not differ from the natural human protein in their inter-
action with CTBP1 and CTBP2 (Fig. 5g,h). Therefore, des-
pite the CTBP binding site in FOXP2 encompassing the
protein region that includes the recent amino acid changes,
it is unlikely that an alteration in the strength of the inter-
action between FOXP2 and CTBP1/2 is responsible for the
neurobiological differences observed in mice carrying a par-
tially humanized version of Foxp2.
The FOXP2 polyglutamine tract and neurodevelopmental
disorder
FOXP2 contains a large polyglutamine tract of 40 residues
(p.Q152-Q191) and a small tract of 10 residues (p.Q200-
Q209), separated by 8 residues of intervening polypeptide
(Fig. 6a). The tracts are located in the N-terminal portion
of the protein, within a larger glutamine-rich region
(Fig. 6a). Of note, the large tract in FOXP2 is the longest
polyglutamine tract in any human protein in healthy indi-
viduals [47]. Abnormal expansions of polyglutamine tracts
in at least nine different proteins result in neurodegenera-
tive diseases [48]. However, FOXP2 is not regarded as a
strong candidate for involvement in such disorders because
its large polyglutamine tract shows relatively little length
variation in the human population [47]. The mixture of
CAG and CAA codons without long pure CAG repeats
probably makes the tract less prone to expansion, and no
expansions were detected in a sample of 142 individ-
uals with progressive movement disorders [47, 49].
However, some rare variations in tract length have
been observed in individuals with neurodevelopmental
disorders (Additional file 4) [8, 11, 13, 14, 17, 18].
Most of the observed variants are deletions of 1–6 resi-
dues from the large tract (Additional file 4). Such deletions
have also been observed in the general population (Ex-
ome Aggregation Consortium (ExAC), Cambridge, MA
(http://exac.broadinstitute.org)), suggesting that they
are probably not high-penetrance causal variants in
cases of severe disorder, but might still represent risk
factors, or produce a milder phenotype.
The significance of the polyglutamine tracts to the
functions of the FOXP2 protein remains unknown.
Polyglutamine tracts may be critical to the function of
some proteins [50], and the absence of equivalent tracts
in human FOXP1 and FOXP4 (despite presence of
glutamine-rich regions) raises the possibility that tract
expansion in FOXP2 may have contributed to divergence
in FOXP protein function. To investigate the roles of the
polyglutamine tracts in FOXP2, we engineered versions of
the protein with reduced tract lengths reflecting the pre-
sumed ancestral protein sequence. The long tract in
FOXP2 underwent expansion early in tetrapod evolution
and has subsequently remained relatively stable: ray-finned
fish species have a cluster of only 3 glutamine residues in
place of the long tract in human FOXP2 [51, 52], whereas
the coelacanth, an evolutionary intermediate between
ray-finned fish and tetrapods, has a 25-residue tract,
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Fig. 5 (See legend on next page.)
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and tetrapod species typically have tracts of 35–41 resi-
dues (Additional file 5). We therefore reduced the length
of the long tract in human FOXP2 to 3 residues. Similarly,
the shorter tract was also reduced to 3 residues.
The two tract length reductions were engineered both
individually and together (Fig. 6a). The resulting synthetic
FOXP2 variants were assayed for a range of molecular
properties including subcellular localization (Fig. 6b),
expression level (Fig. 6c), transcriptional repression of
the SV40 and SRPX2 promoters (Fig. 6d,e), homodimeri-
zation (Fig. 6f), and interaction with CTBPs (Fig. 6g,h).
Across these assays, there were no large differences
between wild-type FOXP2 and versions of the protein
with reduced polyglutamine tracts. Versions of FOXP2
lacking either the large tract or both tracts showed a
small but statistically significant reduction in repressive
ability in the SV40 luciferase reporter assay and also a
small but statistically significant increase in homodimeri-
zation and CTBP1 interaction (Fig. 6e,f,g). However, these
effects were not consistently observed across independent
experiments and therefore may not represent genuine
biological differences. The lack of any substantial differ-
ences between the wild-type protein and variants with re-
duced polyglutamine tracts in our assays suggests that the
presence of the tracts may not have a marked impact on
fundamental aspects of FOXP2 biology.
Discussion
Our detailed functional characterization of rare FOXP2
variants reported in individuals with neurodevelopmental
disorders confirms the etiological role of the Q390Vfs*7
variant, which has similarly deleterious effects on protein
function to the two previously characterized pathogenic
variants, p.R553H and p.R328*, in our assays. The data
presented here point to potential diversity in molecular
mechanisms in FOXP2-related speech/language disorder.
Variants which abolish both transcriptional regulatory ac-
tivity and protein dimerization, such as the p.R328* and
p.Q390Vfs*7 variants, may act as null alleles, resulting in
haploinsufficiency of FOXP2. In contrast, variants which
show a loss of transcriptional regulatory activity but retain
the ability to dimerize, like the p.R553H variant, may
additionally interfere with the functioning of wild-type
protein, as has been suggested for comparable variants
in FOXP1 [31]. Variants producing these dominant-
negative effects might result in a more severe pheno-
type. However, it will be necessary to identify further
cases of FOXP2-related speech/language disorder result-
ing from missense variants in order to assess differences
in phenotypic outcome.
In our assays, the p.Q17L, p.M406T, p.P416T, or
p.N597H variants do not display any substantial effects
on the core functions of the FOXP2 protein, suggesting
that they may be incidental variants. Notably, the p.N597H
variant was previously described as a likely causal variant in
a child with CAS [7]. While we cannot rule out that the
p.N597H variant disrupts an aspect of FOXP2 function not
tested here, subtle effects on protein function are un-
likely to lead to a speech/language disorder of compar-
able severity to complete loss-of-function variants. This
case illustrates that, given the high level of rare coding
variation in the general population (The 1000 Genomes
Project Consortium, 2015), novel rare variants in known
disorder-related genes cannot automatically be regarded
(See figure on previous page.)
Fig. 5 Characterization of FOXP2 variants with ancestral amino acid substitutions. a Schematic representation of FOXP2 variants with ancestral amino acid
substitutions. The N303T, S325N and N303T/S325N constructs are synthetic variants of human FOXP2 carrying ancestral amino acid substitutions. The
chimpanzee and mouse orthologues of FOXP2 are included for comparison. Amino acid differences relative to human FOXP2 are indicated by
arrowheads: N303T (red), S325N (blue), D80E (green), glutamine insertion (+Q, black), and glutamine deletion (−Q, white). Known domains are
labelled: glutamine-rich (Q-rich) region (hatched shading) including polyglutamine tracts (solid shading), zinc finger (ZF), leucine zipper (LZ),
and forkhead domain (FOX). The minimal CTBP interaction region determined using the BRET assay is indicated by the grey-shaded box. b
Fluorescence micrographs of HEK293 cells transfected with FOXP2 variants with ancestral amino acid substitutions. Nuclei were stained with
Hoechst 33342. c Fluorescence-based measurement of the expression level of FOXP2 variants with ancestral amino acid substitutions. HEK293
cells were transfected with YFP-FOXP2, together with mCherry for normalization. Fluorescence intensity was measured 48 h post-transfection.
Values are mean YFP/mCherry fluorescence ratios ± S.D. (n= 3), relative to the value for human FOXP2. d, e Luciferase reporter assays for transcriptional
regulatory activity of FOXP2 variants with ancestral amino acid substitutions. HEK293 cells were transfected with a luciferase reporter vector containing the
SV40 promoter (d) or the human SRPX2 promoter (e), together with a Renilla luciferase normalization plasmid, and YFP-FOXP2 or YFP alone (control). Values
are mean relative luciferase activity ± S.D. (n = 3), expressed relative to the control. Asterisks indicate significant differences compared to human
FOXP2 (*p< 0.05, one-way ANOVA followed by Bonferroni post hoc correction). NS not significant. Exact p values for d are <0.0001 for the control, >0.9999
for the N303T, S325N, and N303T/S325N variants and 0.2730 for the mouse protein. Exact p values for e are <0.0001 for the control and >0.9999 for the
N303T, S325N, N303T/S325N and mouse variants. f–h BRET assays for protein-protein interactions of FOXP2 variants with ancestral amino acid substitutions.
HEK293 cells were transfected with FOXP2 variants with ancestral amino acid substitutions fused to Renilla luciferase (donor), together with YFP (acceptor)
fusions of the same FOXP2 variants (f), CTBP1 (g), or CTBP2 (h). The control donor protein is a nuclear-targeted luciferase and the control acceptor protein
is a nuclear-targeted YFP. Values are mean corrected BRET ratios ± S.D (n= 3). Asterisks indicate significant differences compared to wild-type (WT) FOXP2
(p< 0.05, one-way ANOVA followed by Bonferroni post hoc correction). NS not significant. Exact p values for f are <0.0001 for the control, >0.9999 for the
N303T, S325N, and N303T/S325N variants and 0.434 for the mouse protein. Exact p values for g are <0.0001 for the control and >0.9999 for the N303T,
S325N, N303T/S325N and mouse variants. Exact p values for h are <0.0001 for the control, >0.9999 for the N303T, S325N, and mouse variants and 0.10 for
the N303T/S325N variant
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Fig. 6 Characterization of synthetic FOXP2 variants with reduced polyglutamine tracts. a Schematic representation of synthetic FOXP2 variants
with reduced polyglutamine tracts. Known domains are labelled: glutamine-rich (Q-rich) region (hatched shading) including the long polyglutamine
tract (QL) and short polyglutamine tract (QS), zinc finger (ZF), leucine zipper (LZ), and forkhead domain (FOX). The ΔS variant has a short polyglutamine
tract reduced from 10 to 3 residues. The ΔL variant has a long polyglutamine tract reduced from 40 to 3 residues. The ΔS + L variant has shortened
versions of both tracts. b Fluorescence micrographs of HEK293 cells transfected with FOXP2 variants with reduced polyglutamine tracts. Nuclei were
stained with Hoechst 33342. c Fluorescence-based measurement of expression level for FOXP2 variants with reduced polyglutamine tracts. HEK293
cells were transfected with YFP-FOXP2 variants together with mCherry for normalization. Fluorescence intensity was measured 48 h post-transfection.
Values are mean YFP/mCherry fluorescence ratios ± S.D. (n = 3), expressed relative to the value for full-length FOXP2. d, e Luciferase reporter assays for
transcriptional regulatory activity of FOXP2 variants with reduced polyglutamine tracts. Cells were transfected with a luciferase reporter vector
containing the SV40 promoter (d) or the human SRPX2 promoter (e), together with a Renilla luciferase normalization plasmid, and YFP-FOXP2
or YFP alone (control). Values are mean relative luciferase activity ± S.D. (n = 3), expressed relative to the control. Asterisks indicate significant
differences compared to full-length FOXP2 (p < 0.05, one-way ANOVA followed by Bonferroni post hoc correction). NS not significant. Exact p
values for d are <0.0001 for the control, 0.4892 for ΔS, 0.0003 for ΔL, and 0.0010 for ΔS + L. Exact p values for e are <0.0001 for the control,
0.0768 for ΔS, 0.0633 for ΔL, and 0.1506 for ΔS+ L. f–h BRET assays for protein-protein interactions of FOXP2 variants with reduced polyglutamine tracts.
HEK293 cells were transfected with FOXP2 variants with reduced polyglutamine tracts fused to Renilla luciferase (donor) and YFP (acceptor) fusions of the
same variants (f), CTBP1 (g) or CTBP2 (h). The control donor protein is a nuclear-targeted luciferase and the control acceptor protein is a nuclear-targeted
YFP. Values are mean corrected BRET ratios ± S.D. (n= 3). Asterisks indicate significant differences compared to wild-type (WT) FOXP2 (p< 0.05, one-way
ANOVA followed by Bonferroni post hoc correction). NS not significant. Exact p values for f are <0.0001 for the control, ΔL and ΔS+ L, and >0.9999 for ΔS.
Exact p values for g are <0.0001 for the control, >0.9999 for ΔS, 0.038 for ΔL, and 0.024 for ΔS+ L. Exact p values for h are <0.0001 for the control, 0.4 for
ΔS, and >0.9999 for ΔL and ΔS+ L
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as causal. This is particularly true if it is not possible to
establish segregation of the variant with disorder (or de
novo occurrence of a variant in sporadic disorder) or if
the disorder is genetically heterogeneous and many gen-
etic risk factors remain unknown, as is the situation for
CAS. Functional characterization of novel rare FOXP2
variants is therefore essential to provide a concrete diag-
nosis of FOXP2-related disorder and to shed light on the
aspects of protein function that are disrupted. Our experi-
ments provide a framework for the characterization of
novel FOXP2 variants uncovered through future genetic
analyses of individuals with speech/language disorder.
Concurrent with the present study, two further cases
of probable FOXP2-related speech/language disorder were
added to the DECIPHER database (patient IDs 271859 and
271246) [53]. One DECIPHER case presented with delayed
speech and language development, dysarthria, and pul-
monic stenosis and carries a de novo p.R553H variant
identical to that observed in the KE family. The probability
of recurrence for this particular variant is elevated because
it involves mutation of a CpG site. Indeed, pathological
mutation events have been observed at the equivalent CpG
site in the FOX proteins FOXC2, FOXE1, FOXF1, FOXL2,
and FOXP1 [31, 54–57]. The second probable new case of
FOXP2-related speech/language disorder in DECIPHER
presented with delayed speech and language development,
delayed fine motor development, strabismus and tall stature
and carries a novel de novo stop-gain variant, p.R564*,
truncating the FOXP2 protein within the FOX domain.
These two new DECIPHER cases underline the charac-
teristic manifestation of heterozygous FOXP2 disrup-
tion as a motor speech disorder. In addition, fine motor
delays have now been reported in connection with two
FOXP2 variants (p.R564* and p.Q390Vfs*7), suggesting
that the effects of FOXP2 disruption on motor coordination
may in some cases extend beyond the orofacial movements
required for speech, consistent with the broader motor skill
learning deficits observed in mice with heterozygous
FOXP2 disruption [1, 9].
Very recently, while the current manuscript was under
review, eight further families with potential FOXP2-related
speech/language disorder have been newly described, based
on sequencing data [58]. Although functional characteriza-
tions were not carried out in that study, the new cases sug-
gest that there is some variation in the nature and severity
of the speech and language deficits resulting from FOXP2
disruption and that there may also be variable cognitive
impairments and behavioural anomalies in affected individ-
uals. Of particular note, the newly described cohort in-
cluded two novel missense variants in the FOX domain of
FOXP2, but unlike the p.R553H variant found in the KE
family, these missense variants do not occur in the DNA-
binding helix of the domain. Future functional analyses of
these newly identified variants would therefore be valuable
to reveal how they might interfere with protein function
and to confirm that these variants play a causal role in the
disorder. The description of these eight new families
represents a step towards a ‘genotype-first’ approach to
the characterization of the FOXP2-related phenotype
[59]. However, sequencing of FOXP2 in much larger co-
horts of language-impaired individuals, preferably coupled
to functional analyses, will be necessary to obtain a
complete picture of the clinical spectrum associated
with FOXP2-related disorder and to gain further in-
sights into the role of FOXP2 in neurodevelopment.
In addition to assessing the effects of rare variants on
FOXP2 protein function, we performed the first detailed
characterization of the interactions between FOXP2 and
the transcriptional co-repressors CTBP1 and CTBP2, find-
ing that these interactions are independent of FOXP2
homodimerization and DNA binding. Our results point to
an extended CTBP binding site in FOXP2 within residues
258–487, possibly encompassing multiple subsites. Previous
yeast two-hybrid screens identified residues 122–382 in
FOXP2 as sufficient for interaction with CTBPs [34]. We
propose a narrower critical region of 71 residues, from
residue 259 to 329. This minimal region contains both
of the amino acid substitutions that have occurred
since the divergence of the human and chimpanzee lin-
eages. However, we did not find any effect of these sub-
stitutions on CTBP interaction, and the human and
mouse versions of FOXP2 exhibit comparable levels of
interaction with CTBPs. Changes in CTBP interaction
do not therefore appear to underlie the neurobiological
changes observed in mice carrying a partially humanized
version of Foxp2. The amino acid changes on the human
lineage may instead result in altered interaction with as
yet unidentified protein interaction partners or in changes
to post-translational modifications. In addition, we con-
firmed that the FOXP2 paralog FOXP1 also interacts
with CTBPs, whereas FOXP4 does not, pointing to a di-
vergence in mechanisms of transcriptional regulation
within the FOXP subfamily.
The CTBPs are conserved vertebrate proteins that
interact with several different transcription factors and
mediate transcriptional repression primarily through re-
cruitment of the histone deacetylases HDAC1/2 [36].
The CTBPs are widely expressed during embryonic de-
velopment and have essential and partially overlapping
roles in the development of multiple organs [35, 36].
They are expressed in the brain from a very early stage,
although their specific roles in neurodevelopment have
not been extensively investigated [35, 36]. CTBPs may
therefore be key players in FOXP2- and FOXP1-mediated
transcriptional repression across multiple organs and
developmental stages, including in neurodevelopment.
In addition, CTBPs may play a role in the post-translational
modification of FOXP2. We and other groups have recently
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demonstrated that FOXP2 is post-translationally modified
by SUMOylation [21, 60, 61]. The essential SUMOylation
enzyme UBC9 is a core component of the protein complex
containing CTBP1, and CTBP1 has been suggested to func-
tion as a platform for protein SUMOylation [62]. Further-
more, the SUMO E3 ligase PIAS1, which promotes FOXP2
SUMOylation, is an auxilliary component of the CTBP1
complex [21, 62]. If CTBPs are among the key mediators of
FOXP-mediated transcriptional repression, variants in
FOXP2 or FOXP1 which disrupt the interaction with
CTBPs might have a similar impact on neurodevelopment
to variants which disrupt DNA binding, and an assessment
of the effects on CTBP binding should therefore be in-
cluded when characterizing novel, putatively pathogenic
variants in FOXP proteins.
Finally, we reported the first detailed analysis of the
role of the polyglutamine tracts in FOXP2 function. In
our experiments, shortening the polyglutamine tracts in
FOXP2 did not have a substantial impact on protein
expression, nuclear localization, homodimerization,
interaction with CTBPs, or transcriptional repression
activity. The tracts do not therefore appear to be essential
for core aspects of protein function in cellular assays. How-
ever, the tracts may have critical roles in vivo that are not
apparent in cell models, and the generation of mice carry-
ing a version of Foxp2 lacking the polyglutamine tracts
could therefore be informative. Deletion of the polygluta-
mine tracts in a small number of other proteins has been
found to affect behaviour in mouse models. For example,
deletion of the polyglutamine tract in mouse huntingtin
results in subtle behavioural changes relating to learn-
ing and memory and motor coordination [63]. Replace-
ment of mouse POU3F2 with a Xenopus orthologue
that lacks polyglutamine tracts and other homopolymer
amino acid repeats resulted in neurochemical changes
and a dramatic deterioration in pup retrieval behaviour
[64]. The polyglutamine tract in mouse SRY has important
roles in protein stabilization and transcriptional activation
that are essential for sex determination [65]. It is also pos-
sible that the polyglutamine tracts in FOXP2 do not have
critical roles in normal protein function. The tracts lie
within a glutamine-rich protein region that is conserved
in FOXP1 and FOXP4 and may be prone to developing
expanded stretches of glutamine residues. In FOXP1, a
different cluster of glutamine residues has undergone ex-
pansion in the rodent lineage to produce tracts of 37 resi-
dues in the mouse and 39 in rat, compared to 7 residues
in primates. Expansions of up to ~40 glutamine residues
within the glutamine-rich region of FOXP proteins may
therefore have negligible effect on protein function.
The failure to observe any substantial effects of poly-
glutamine tract reduction on core aspects of FOXP2
function makes it less likely that tract length reductions
contribute to risk for neurodevelopmental disorder.
However, one recent study suggested that a FOXP2 poly-
glutamine tract length variant tentatively associated with
speech sound disorder (p.Q172del) exhibits altered tran-
scriptional repression activity in a cell model [18, 66]. The
p.Q172del variant was reported to increase transcript levels
of the FOXP2 target gene CNTNAP2 in transfected cells,
whereas transcript levels were reduced in cells transfected
with wild-type protein [66]. Nonetheless, both the variant
and wild-type forms of FOXP2 produced increases in pro-
tein levels of CNTNAP2, with the variant having a stronger
effect [66]. It is therefore unclear what effect the p.Q172del
variant might have on transcriptional regulation in vivo, but
our experiments suggest that the effect of a single glutam-
ine deletion is likely to be extremely small. The p.Q172del
variant is observed in the general population with a minor
allele frequency of 0.6 % in the ExAC database (714 of
115484 chromosomes), and larger tract length reductions
are also present in the ExAC database at very low fre-
quency. Studies of larger numbers of individuals with
FOXP2 proteins with standard-length and reduced-length
tracts are therefore necessary to determine if tract length
reduction might confer an increased risk for neurodevelop-
mental disorder or a reduction in linguistic abilities.
Conclusions
By performing detailed functional characterization of
rare variants in FOXP2 found in individuals with neuro-
developmental disorders, we confirm the causal role of
one recently reported uncharacterized variant and provide
further characterization of two further causal variants. In
addition, we highlight two variants which had been sug-
gested to contribute to the neurodevelopmental disorders
in the affected individuals, but which do not have detri-
mental effects on protein function, suggesting that they are
in fact incidental. These findings underline the importance
of performing functional characterization of novel vari-
ants identified in individuals with neurodevelopmental
disorders, even when the affected gene has previously
been implicated in disorder. The provision of accurate
molecular diagnoses in cases of neurodevelopmental
disorder will require consideration of protein function
data together with detailed clinical observations and
genetic characterization of affected individuals and
their parents on a genome-wide scale.
Our research also provides important new insights
into the biology of the FOXP2 protein, expanding our
knowledge of the molecular functions of this key neural
transcription factor. Our characterization of the inter-
action of FOXP2 with co-repressor proteins of the CTBP
family provides additional mechanistic insight into
FOXP2-mediated repression of transcription. We also
report the first detailed examination of the role of the
polyglutamine tracts in FOXP2. We find that these tracts
are not essential to the core molecular functions of the
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FOXP2 protein, suggesting that variations in tract length
are unlikely to be a highly penetrant cause of neurodeve-
lopmental disorder.
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N E D E R L A N D S E SA M E N VAT T I N G
Taal is een onderscheidende eigenschap van de mens. Taal gaat verder dan
enkel het overbrengen van simpele en praktische informatie zoals andere dier-
soorten doen, het geeft ons de mogelijkheid om gedachten uit te wisselen, gevoe-
lens uit te drukken en te praten over de meest abstracte zaken die we kunnen
bedenken. Ondanks de complexiteit van taal, is het iets dat ons van nature
gemakkelijk af gaat. Ons genoom bevat alle instructies voor het vormen van
hersenen die voorbereid zijn voor taal, waarin veel verschillende genen aan en
uit gezet worden om de hersencircuits te ontwikkelen die ervoor zorgen dat
we gesproken taal kunnen opnemen uit onze omgeving. Genen bevatten de in-
formatie om moleculen te vormen die bijna elke eigenschap in elke cel in ons
lichaam bepalen.
Om te ontrafelen welke genen bijdragen aan onze taalvaardigheden, kun-
nen onderzoekers kijken naar mutaties in het genoom van personen met een
taalstoornis. Op deze manier is FOXP2 geïdentificeerd als het eerste gen dat in
verband gebracht kon worden met een spraak- en taalstoornis. In een grote fam-
ilie van meerdere generaties (de KE familie) was de helft van de familieleden
gediagnostiseerd met een spraak- en taalprobleem. Alleen in de familieleden
met het spraak- en taalprobleem werd een mutatie in FOXP2 gevonden. On-
derzoek wees uit dat deze mutatie de functie van het FOXP2 eiwit aantastte.
Inmiddels zijn meer mutaties in FOXP2 ontdekt in mensen met een spraak- en
taalstoornis, hoewel in de meeste gevallen de oorzaak van een spraak- en taal-
stoornis nog niet gevonden kan worden. Studies naar de functie van FOXP2 in
cel- en diermodellen hebben tot op heden de meeste informatie verschaft over
de moleculaire mechanismen van taal.
Het FOXP2 gen komt tot expressie in specifieke hersengebieden en codeert
voor een transcriptiefactor, een type eiwit dat de activiteit van veel andere
genen reguleert. Als de functie van FOXP2 verstoord is, kan het niet langer
genexpressie reguleren. FOXP2 is onderdeel van de FOXP familie van eiwit-
ten, samen met FOXP1 en FOXP4, die ook in het centrale zenuwstelsel tot ex-
pressie komen en overlappende, maar ook afzonderlijke functies hebben tijdens
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de hersenontwikkeling. FOXP1 lijkt het meest op FOXP2 en is betrokken bij een
syndroom met verstandelijke beperking en taalproblemen
Om de biologische mechanismen van spraak en taal verder op te helderen,
is het grootste deel van dit proefschrift gewijd aan onderzoek naar de molecu-
laire functies van de FOXP familieleden. In hoofdstuk 2 tot en met 4 heb ik mij
gericht op de identificatie en karakterisatie van eiwitten die interacteren met
FOXPs. Het FOXP interactoom was nauwelijks in kaart gebracht en informatie
hierover zou waardevolle inzichten kunnen geven over hoe deze eiwitten de
hersen- en taalontwikkeling reguleren, en helpen om nieuwe taalgerelateerde
kandidaatgenen te identificeren.
In hoofdstuk 2 heb ik de interactie tussen FOXP2 en PIAS eiwitten onder-
zocht. PIAS eiwitten zijn enzymen die SUMOylatie van andere eiwitten reg-
uleren. SUMOylatie is een dynamische en omkeerbare vorm van posttransla-
tionele modificatie, waarin SUMO moleculen aan een eiwit bevestigd worden,
wat invloed kan hebben op de functie van het eiwit. Ik heb ontdekt dat PIAS1
met FOXP2 interacteert om de SUMOylatie van FOXP2 te reguleren, de eerste
en enige posttranslationele modificatie van FOXP2 die tot nu toe bekend is.
FOXP2 SUMOylatie vindt plaats op een specifieke plek in het eiwit die door
de evolutie heen niet veranderd is, wat suggereert dat deze posttranslationele
modificatie al vroeg in de evolutie een rol heeft gespeeld. FOXP1 en FOXP4
hebben eenzelfde SUMOylatie positie, en FOXP1 en FOXP4 interacteren ook
met SUMO moleculen en PIAS eiwitten, wat er op duidt dat FOXP1 en FOXP4
ook geSUMOyleerd worden. De etiologische mutatie in FOXP2, ontdekt in de
KE familie, zorgt voor een duidelijk verminderde SUMOylatie van het FOXP2
eiwit. In verschillende experimenten met celmodellen heb ik geen aanwijzingen
kunnen vinden dat SUMOylatie aspecten van de functie van het FOXP2 eiwit ve-
randert. Deze effecten zijn echter zo subtiel, dat ze wellicht alleen waargenomen
kunnen worden in de context van een ontwikkelend organisme.
In hoofdstuk 3 heb ik de gegevens van eerdere experimenten van onze on-
derzoeksgroep over potentiële FOXP2 eiwitinteracties opnieuw geëvalueerd, en
heb ik twee kandidaat FOXP2 interactoren, NONO en SFPQ, verder onderzocht.
NONO en SFPQ zijn twee transcriptiefactoren die tot expressie komen in het
centrale zenuwstelsel en met elkaar interacteren. De interactie tussen FOXP2 en
NONO/SFPQ kon echter niet worden aangetoond in verschillende eiwitinteractie-
experimenten. Deze resultaten suggereren dat deze eiwitten hoogstwaarschi-
jnlijk geen fysiologische FOXP2 interactiepartners zijn en dat de methodolo-
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gie van de eerdere experimenten gevoelig geweest zou kunnen zijn voor vals-
positieve resultaten.
Daarom heb ik in hoofdstuk 4 een nieuwe screening opgezet om eiwitinter-
acties van FOXP2, FOXP1 en FOXP4 te identificeren. Ik heb zeven nieuwe FOXP-
interacterende transcriptiefactoren ontdekt (NR2F1, NR2F2, SATB1, SATB2, SOX5,
YY1 en ZMYM2), waarvan van vijf bekend is dat ze een rol spelen in hersenon-
twikkeling. Deze transcriptiefactoren komen samen tot expressie met FoxP2 in
de hersenschors en het cerebellum, wat betekent dat ze daar mogelijk genex-
pressie reguleren in vivo. Een aantal van deze interacties worden ernstig ver-
stoord door etiologische mutaties in FOXP1 en FOXP2 die ontwikkelingsstoor-
nissen met spraak- en taalproblemen veroorzaken. Dit zouden nieuwe poten-
tiële moleculaire mechanismen kunnen zijn die deze ontwikkelingsstoornissen
veroorzaken.
De FOXPs zijn niet de enige genen die gelinkt zijn aan spraak en taal. De
genetische achtergrond van zulke eigenschappen is complex en veel meer an-
dere genen – de meeste nog onbekend – dragen ook bij aan spraak en taal. In
hoofdstuk 5 focus ik op een nieuw taal-gerelateerd gen, BCL11A. Mutaties in
dit gen veroorzaken een syndroom met een verstandelijke beperking en taal-
problemen. BCL11A is ook een transcriptiefactor en tot voor kort was de func-
tie van dit gen enkel onderzocht in het bloed. De functies van BCL11A in de
hersenen waren nog nauwelijks bestudeerd. De identificatie van BCL11A mu-
taties in kinderen met een ontwikkelingsstoornis belichtte de rol van dit gen in
de hersenontwikkeling. In hoofdstuk 5 heb ik de effecten van drie mutaties in
BCL11A op de functies van BCL11A in de cel onderzocht. Ik heb ontdekt dat
deze drie mutaties de lokalisatie van BCL11A in de cel ernstig verstoren, een
aantal BCL11A eiwitinteracties aantasten en de transcriptionele regulerende
activiteit beïnvloeden. Deze resultaten bevestigen de etiologische rol van deze
mutaties in ontwikkelingsstoornissen.
Het werk dat ik beschrijf in mijn proefschrift heeft de kennis vergroot over
hoe bepaalde genen de taal- en hersenontwikkeling reguleren. De karakterisatie
van nieuwe FOXP interactiepartners geeft nieuwe inzichten in de transcrip-
tieprocessen in de ontwikkelende hersenschors, en geeft een nieuwe kijk op de
moleculaire mechanismen die de FOXP functies reguleren in spraak- en taalon-
twikkeling. De functionele karakterisatie van de BCL11A mutaties bevestigt dat
dit gen betrokken is in een nieuwe monogene ontwikkelingsstoornis en wijst op
een mogelijke bijdrage van dit gen in de ontwikkeling van spraak en taal.

S U M M A RY
Language is a defining feature of the human condition. Human language goes
beyond transmitting simple and practical information like other species do, it
also enables us to share our thoughts, express our feelings and talk about even
the most abstract matters we can imagine. Given its high complexity, it is quite
extraordinary that language comes so naturally to us. The instructions to build
a language-ready brain are encoded in our genome, where a myriad of differ-
ent genes will be switched on and off in order to develop the brain circuits that
allow us to soak up language from our environment. Genes contain the informa-
tion to create the molecules that determine almost every single feature of each
cell in our body.
To decipher which genes contribute to our language abilities scientist can
look for mutations in the genomes of individuals with language impairment.
This is how FOXP2 was identified as the first gene implicated in human speech
and language. A mutation in FOXP2 was found only in the affected individu-
als of a large multigenerational family (the KE family) in which half of their
members presented speech and language difficulties. Following investigations
revealed that the mutation disrupted FOXP2 protein function. Since then multi-
ple other cases of FOXP2 mutations leading to speech and language impairment
have been discovered, although most cases of speech and language problems re-
mains unexplained. The study of FOXP2 function in cellular and animal models
has provided to date the vast majority of knowledge on the molecular mecha-
nisms underlying language function.
The FOXP2 gene is expressed in specific areas of the brain and encodes for
a transcription factor, a type of protein which regulates the switching on and
off of many genes. When disrupted, FOXP2 can no longer regulate gene expres-
sion. FOXP2 belongs to the FOXP family of proteins together with FOXP1 and
FOXP4, which are also expressed in the central nervous system and play over-
lapping yet distinct roles in brain development. FOXP1 is the most similar pro-
tein to FOXP2 and has been implicated in an intellectual disability syndrome
that includes language impairment.
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To shed light on the biological foundations of speech and language, the ma-
jor part of this dissertation further investigates the molecular function of the
FOXP family of proteins. In Chapters 2 to 4 I sought to identify and character-
ize which proteins interact with the FOXPs. The FOXP interactome had been
scarcely explored and promised to reveal valuable insights into how these pro-
teins function to regulate brain and language development, as well as to pin-
point novel language-related candidate genes.
In Chapter 2, I studied the interaction between FOXP2 and the PIAS family
of proteins, which are enzymes that mediate the SUMOylation of other proteins.
SUMOylation is a dynamic and reversible post-translational modification that
consists in the physical attachment of SUMO molecules to proteins in order to
finely modulate protein function. I discovered that PIAS1 interacts with FOXP2
to mediate its SUMOylation which is the first and only post-translational modi-
fication ever reported for FOXP2. I found that FOXP2 SUMOylation takes places
at a specific site of the protein that is evolutionarily conserved, suggesting an
ancient role for this post-translational modification. The SUMOylation site is
also present in FOXP1 and FOXP4, for which I found that they also interact
with SUMO molecules and PIAS proteins, suggesting that they are also sub-
ject to SUMOylation. Finally I observed that the etiological mutation in FOXP2
found in the KE family leads to substantially reduced SUMOylation of the en-
coded protein. Using a range of diverse cellular assays, I did not observe that
SUMOylation altered any aspect of FOXP2 protein function, however the effects
of SUMOylation are often so subtle that they may only detectable in the context
of a developing organism.
In Chapter 3, I re-evaluated a dataset of FOXP2 putative protein interactors
from prior experiments performed in our group and selected two promising-
candidate FOXP2 interactors, NONO and SFPQ for targeted investigation. NONO
and SFPQ are two neural transcription factors that interact with each other. The
interaction between FOXP2 and NONO/SFPQ was consistently not detected in
any of the several protein-protein interactions assays I employed. This suggests
that these proteins are unlikely to be true physiological FOXP2 interaction part-
ners and that the methodology used in the previous experiments may have been
vulnerable to false positive results.
Therefore, in Chapter 4, I set up fresh screens to identify protein-protein in-
teractions of FOXP2, FOXP1 and FOXP4. I discovered and characterized seven
novel FOXP-interacting transcription factors (NR2F1, NR2F2, SATB1, SATB2,
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SOX5, YY1 and ZMYM2), five of which have well-established roles in brain
development. I found that these transcription factors are co-expressed with
FoxP2 in the brain cortex and in the cerebellum, suggesting that they may reg-
ulate gene expression in vivo in these neural sites of co-expression. Several of
these interactions were severely disrupted by etiological mutations in FOXP1
and FOXP2 known to cause neurodevelopmental disorders that include speech
and language, which reveals novel putative molecular mechanisms underlying
these disorders.
The FOXPs are not the only genes implicated in speech and language. The
genetic architecture underlying these traits is complex and many other genes –
although most of them unkown – also contribute to this trait. In Chapter 5, I
focus on a novel candidate language-related gene, BCL11A, mutations in which
cause an intellectual disability syndrome that includes language impairment.
BCL11A is also a transcription factor and, until recently, it had been primarily
studied by its role in the blood. Its function in the brain had been rarely ex-
plored. The discovery of mutations in BCL11A in children with neurodevelop-
mental disorders highlighted a role for this gene in brain development. In Chap-
ter 5, I investigated how three mutations in BCL11A affect its cellular functions.
I discovered that the three mutations severely disrupt BCL11A localization in-
side the cell, some of its protein interactions and also its transcriptional regu-
latory activity, therefore confirming its etiological role in neurodevelopmental
disorder.
The work in this dissertation has expanded a bit more the knowledge on how
certain genes regulate language and brain development. The characterization
of novel FOXP-interactors revealed novel insights into the transcriptional archi-
tecture underlying cortical development and provided fresh understanding of
the molecular mechanisms that regulate FOXP function in language and speech
development. The functional characterization study of BCL11A mutations con-
firmed its involvement in a novel monogenic neurodevelopmental disorder and
highlighted its putative contributions to speech and language.
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